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FORWARD 
The Scientific Committee on Cosmetology was set up by Commission Decision 
78/45/EEC on 19 December 1977 (OJ N° L 13 of 17 January 1978, p. 24) in 
order to provide the Commission with informed opinions on any scientific and 
technical problems arising in connection with cosmetic products, and in 
particular on the substances used in their manufacture, on their composition 
and on the conditions for their use. 
The members of the Committee are independent scientists highly qualified in 
the fields of medicine, toxicology, biology, chemistry or other similar 
disciplines. 
The Committee is serviced by the Directorate-general for the environment, 
consumer protection and nuclear safety. 
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REPORT BY THE SCIENTIFIC COMMITTEE ON 
COSMETOLOGY CONCERNING CERTAIN PRESERVATIVES 
(Opinion expressed on 1 . Ju l y 1986) 
TERMS OF REFERENCE OF THE COMMITTEE 
To g ive i t s op in i on on the use , as p r e s e r v a t i v e s i n cosmetic p r o d u c t s , of 
t he substances L i s t e d in Par t 2 of Annex VI to D i r e c t i v e 76/768/EEC 
(Annex 1 ) . 
CONCLUSION 
Prese rva t i ves whose use i n cosmetic products can be pe rm i t t ed 
Formic ac id 
BronopoL (INN) 
T r i c l o s a n (INN) 
Po lyd-hexamethy Lenebiguanide hyd roch lo r i de ) 
Hexamethylenetetramine (methenamine) (INN) 
- n° 49 : 1-(4-Chlorophenoxy)-1-(imidazoL-1-yL)-3,3-dimethyLbutan-2-one 
- n° 50 : 1,3-Bis(hydroxymethyl)-5,5-dimethyl imidazol idine-2,4-dione 
- n° 57 : 1-Hydroxy-4-methyL-6(2,4,4-trimethyLpentyL) 2-pyridon and i t s 
monoethano I ami ne sa l t 
- n° 59 : 1,2-Dibromo-2,4-dicyanobutane 
Preservatives whose use in cosmetic products can be maintained for the time 
being, but concerning which the Committee would Like to obtain addi t ional 
data 
- n° 2 : Boric acid 
- n° 4 : 3-Acetyl-6-methylpyran-2,4(3H)-dione (Dehydroacetic acid) and its 
salts 
- n° 7 : Hexamidine (INN) and i t s sa l ts ( inc luding isethionate (INN) and 
4-hydroxybenzoate) 
- n° 8 : 3 /3'Dibromo-4,4'-hexamethylene-dioxydibenzamidine 
(Dibromohexamidine) and i t s sa l ts ( inc lud ing isethionate) 
- n° 
- n° 
- n° 
- n° 
- n° 
5 
19 
28 
42 
44 
- n° 13 : Undec-10-enoic acids : s a l t s , es ters , the amide, the mono- and 
bis(2-hydroxethyl) amides and t he i r suLphosuccinates 
- n° 15 : Hexetidine (INN) 
- n° 16 : Benzylformal (a 1:1 mixture of benzyloxymethanol and (benzyloxy-
methoxy) methanol) 
- n° 17 : Chlorofene (INN) 
- n° 18 : 5-Bromo-5-nitro-1,3 dioxane 
- n° 20 : 6,6-Dibromo-4,4-dichloro-2,2'-methylene-diphenol (Bromochlorophen) 
- n° 22 : 2-Chloroacetamide 
- n° 24 : 2,4-DichlorobenzyI alcohol 
- n° 25 : Triclocarban (INN) 
- n° 26 : 4-Chloro-a-cresol 
- n° 31 : Chlorhexidine (INN) and i t s digluconate, diacetate and 
dihydrochloride 
- n° 32 : 4-Chloro-3,5-xy lenol 
- n° 36 : 3 ,3 ' -B is (1-hydroxymethy l -2 ,5-d ioxo imidazo l id in -4-y l ) -1 ,1 ' -
methylenediurea ( " Imidazol id inyI urea") 
- n° 37 : 4-Isopropyl-m-cresol 
- n° 43 : 2-Phenoxyethanol 
- n° 45 : Mixture of 5-chloro-2-methyl- isothiasol-3(2H)one and 2-
methylisothiazol-3(2H)-one with magnesium chlor ide and magnesium 
n i t r a te 
- n° 48 : Methanamine 3-ch loroa l ly loch lor ide (INNM) 
- n° 50 : 1,3-Bis(hydroxymethyl)-5,5-dimethyl imidazol idine-2,4-dione 
- n° 51 : Benzyl alcohol 
- n° 52 : 1-DodecyIguanidinium acetate (Dodine - ISO) 
- n° 60 : 4,4-Dimethyl-1,3-oxazol idine 
Preservatives concerning which no opinion can be expressed because of a lack 
of data 
- n° 3 : Chlorphenesin (INN) 
- n° 6 : 4-Hydroxybenzoic acid benzyl ester 
- n° 9 : Dibromopropamidine (INN) and i t s sa l ts ( inc lud ing 
isethionate (INN)) 
- n° 12 : Esters of sorbic acid (Hexa-2 /4-dienoic acid) 
- n° 14 : 2,6-Diacety l -1,2,3,9b-tetrahydro-7,9-dihydroxy-8,9b-
dimethyldibenzolfuran-1,3-dione (usnic acid) and i t s sa l ts 
( inc luding the copper sa l t ) 
- n° 21 : Tetrabromo-o-cresol 
- n° 23 : 3,4-Dich lorobenzyl alcohol 
- n° 27 : Halocarban (INN) 
- n° 29 : Dichlorophen (INN) 
- n° 33 : 2,4-Dichloro-3,5-xylenol 
- n° 34 : Quino l in-8-o l and i t s sa l ts 
- n° 35 : 1,3,5-Tr is (2-hydroxyethyl)hexahydro-1,3,5-tr iasine 
- n° 38 : 2-Chloro-N-(hydroxymethyl) acetamide 
- n° 39 : 1-Hydroxymethyl-5,5-dimethyl-hydantoin 
- n° 46 : Pyr id in -2 -o l 1-oxide 
- n° 47 : Pyr i thione aluminium camsilate (INNM) 
- n° 55 : A lky l (C12-C22) trimethylammonium bromide and chlor ide ( inc luding 
Cetrimonium bromide) (INN) 
- n° 58 : 3-Hepty l -2- (3-hepty l -4-methy l -4- th iozo l in-2-y l idenemethy l ) -4-
methyLthiazolinium iodide 
Preservatives whose use in cosmetic products should not be permitted 
- n° 1 : 2,6-DimethyL-1,3-dioxan-4-yl acetate (Dimethoxane) 
- n° 10 : Thiomersal (INN), in eye make-up preparations and eye make-up 
remover, where no sa t is fac tory a l te rna t i ve ex is ts 
- n° 11 : Phenylmercuric sa l ts ( inc lud ing bora te) , in eye make-up 
preparations and eye make-up remover, where no sat is fac tory 
a l te rna t i ve ex is ts 
- n° 30 : N-(Trichloromethylthio)cyclohex-4-ene-1,2-dicarboximide 
(Captan - (ISO)) 
- n° 40 : Pyrithione sodium (INM) 
- n° 41 : 2,2'-Dithiobis(pyridine-1-oxide), addition product with magnesium 
sulphate trihydrate 
- n° 56 : 1-Phenoxypropan-2-ol 
Preservatives whose use in cosmetic products cannot be evaluated 
- n° 53 : Benzethonium chlor ide (INN) 
- n° 54 : Benzalkonium chlor ide (INN), 1-2-Benzisothiazol-3-(2H)-one 1,1 
d iox ide , i t s bromide and saccharinate 
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BACKGROUND 
1. In accordance with Article 5 of Council Directive 76/768/EEC on the 
approximation of the laws of the Member States relating to cosmetic 
products, as last amended by Directive 86/199/EEC, Member States must 
allow the marketing of cosmetic products containing the preservatives 
listed in Part 2 of Annex VI, within the limits and under the conditions 
referred to, until 31 December 1985. 
2. On 1 January 1986 these preservatives will have to be : 
- either definitively permitted; 
- or definitively prohibited; 
- or maintained for a specified period; 
- or deleted from all the Annexes. 
3. The Committee is therefore requested to express an opinion on the use in 
cosmetic products of the preservatives listed in Part 2 of Annex VI of 
Directive 76/768/EEC (Annex 1). 
DISCUSSION 
N° 1 2 , 6 - d i m e t h y l - 1 , 3 - d i o x a n - 4 - y l ace ta te (Dimethoxane) 
C8H14°4 
MW : 174.20 
CAS N° 828-00-2 
M i s c i b l e w i t h water and organic s o l v e n t s . 
Dimethoxane i s used i n cosmetics at dose l e v e l s of 0.2%. 
The p u r i t y of t he compound i s not known. 
The substance possesses low acute t o x i c i t y upon o r a l , dermal and i n h a l a t i o n 
exposure. 
No sensitization could be detected in human volunteers and guinea pigs. 
10% Dimethoxane is well tolerated in the rabbit eye. Higher concentrations 
induce, after a single application, moderate irritation of the conjunctivae. 
Repeated application of a 10% solution was required to induce slight 
irritation of the guinea pig skin. 
1% did not cause iritation in humans. 
In a 13-week toxicity study dimethoxane was subcutaneously administered to 
dogs at dose levels up to 1.0 mg/kg/day. No effects were noted. 
In a 90-day subcutaneous rat study the substance was administered at dose 
levels of 3,10, and 30 mg/kg/day; no clear effects were noted. It would 
have been preferable to have had a cutaneous study as well; and the top dose 
level chosen should have been high enough to give a definite effect. 
A study in male rats lasting 88 weeks showed that oral administration at a 
concentration of 1% in drinking water gave rise to the formation of 
malignant tumours, especially hepatomas. 
Studies into the metabolism, mutagenicity and reproduction are Lacking. 
In view of the carcinogenicity in rats, the Committee recommended that the 
use of dimethoxane in cosmetic products should be suspended, subject to 
revision in the light of ongoing new N.C.I, studies. 
Information : - Data sheet Council of Europe 
- IARC - Monograph Vol 15(1977) 177 
- Tox Tips June 1981, p. 61.11 
- Colipa dossier, January 28, 1983 
6 -
N° 2 Boric acid 
See Report EUR 7297 and Report EUR 8634, 
N° 3 Chlorophenesin 
OH 
0 - CH2 - CH - CH^ OH 
C9H1(|CL03 
MW : 202.64 
CAS N° 104-29-0 
Synonyms : - 3(p-ch lorophenoxy) p r o p a n e - 1 , 2 - d i o l 
- p -ch lo ropheny l -gLyce ro l e ther 
S l i g h t l y so lub le i n water (0 .6%), moderately so lub le i n g l y c e r o l (9.5%) and 
a l coho l (15%). 
Used i n cosmetics up to 0.2%. 
LD s n values ( i n mg/kg) are : o r a l i n r a t s > 1400, in mice 1060, i n guinea 
p igs 820 , i . p . i n ra t s 520, i n mice 675 and 9 1 1 ; i n guinea p igs 425, s . c . i n 
mice 930. 
A sk in i r r i t a t i o n t e s t i n r a b b i t s was nega t i ve (no d e t a i l s ) . 
In repeated i n s u l t patch t e s t s w i t h 18 humans, a p p l i c a t i o n of 0.05 ml of 
0.2% in hand cream, sk in l o t i o n and sk i n soo th ing m i l k on 5 successive days 
was n e g a t i v e , or produced s l i g h t erythema i n some cases. 
An eye i r r i t a t i o n t e s t i n r a b b i t s w i t h 1% i n g l y c e r i n e , d i d not provoke 
cornea l i r r i t a t i o n . 
In a repeated in t ramuscu la r i n j e c t i o n t e s t i n mice , w i t h 0.5 ml of a 0.6% 
aqueous s o l u t i o n d a i l y f o r 40 days the re were no observable e f f e c t s on 
growth or on the s t a t e of the organs. 
In an oral 13-week study in rats given doses of 50, 100 or 200 mg/kg 
b.w./day by gavage, no effect on mortality, growth rate or food intake was 
observed. 
Examination of vaginal smears provided no evidence of interference with 
oestrus. No gross changes were observed at autopsy (no report available). 
Chlorphenesin possesses immunosuppressive properties. It is one of the 
glycerol ethers which are known to cause paralysis and to act as 
anti convulsants. 
Dogs given 75 or 150 mg/kg/day (route not specified), 5 days a week for 18 
weeks, did not show any significant changes in behaviour or growth, in 
haematology or clinical chemistry, and in urine composition (summary report 
only). 
An oral dose of the labeled compound given to rats was rapidly absorbed and 
reached a peak concentration in the blood in 30 min. The half life in serum 
was 140 min. More than half of an oral dose was excreted in the urine in 
4 hr, partly as the unchanged compound. Four metabolites have been 
identified : 3-p-chlorophenoxylactic acid, p-chlorophenoxyacetic acid, a 
conjugate of chlorophenol, and a conjugate of chlorphenesin. 
Although sub-chronic oral studies have been conducted the target organ and a 
no effect level cannot be established. There is no information on 
mutagenicity or teratogenicity. The Committee requests further details 
about those tests which have been incompletely reported, and information on 
possible immuno-suppressant action at doses used in cosmetics. 
No opinion can be expressed because of a lack of data. 
Information : Colipa dossier, September 1983 
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N° 4 3-Acetyl-6-methy lpyran-2,4(3H)-dione (Dehydroacetic acid) and its 
salts 
CH, *V 
CO - CH, 
C8H8°4 
MW : 168.15 
CAS N° 520-45-6 
Insoluble in water, soluble in organic solvents; the sodium salt is soluble 
in water. 
Dehydroacetic acid and its sodium salts are used in cosmetics up to a level 
of 0.6%. 
These compounds show moderate acute toxicity. The LD,-n of the sodium salt 
for the dog is probably under 400 mg/kg b.w. irrespective of the route of 
administration. 
They are neither primary irritants nor sensitizers in rabbits. These 
observations were confirmed in man by patch testing using occlusion. 
Repeated oral administration of 0.3 g/kg b.w. to rats and monkeys caused 
decreased body weight, ataxia, convulsions and death. 
Long-term studies involving administration of 0.1% of the acid in the diet 
of rats demonstrated no toxic phenomena. 
In dogs 60 mg/kg b.w./day caused an uncompensated metabolic acidosis, but 50 
mg/kg b.w./day did not. 
- 10 -
Reproduction data were not available. 
Mutagenicity tests were negative. 
It is rapidly and apparently completely absorbed, following oral 
administration to man, monkey, dog and rat. It appears that 80% of 
dehydroacetic acid is metabolised in the body; urinay excretion accounts for 
less than 20%. 
These compounds are detected in the plasma for as long as 2-3 weeks after 
the cessation of administration. 
The use of dehydroacetic acid as a preservative in cosmetic products can be 
allowed owing to the absence of carcinogenicity and systemic toxicity in 
animals. Nevertheless the Committee wishes to obtain information on 
reproduction data upon oral administration. 
Information : - Data sheet Council of Europe 
- Colipa Partial Submission I, September 1983 
- 11 
N° 5 Formic ac id 
/ 
CH 
CH202 CAS N° 64-18-6 
MW : 46.02 
M i s c i b l e w i t h water , e ther and g l y c e r o l . 
Formic ac id i s used i n cosmetic products at a maximum l e v e l of 0.5%. 
I t has a moderate acute o r a l t o x i c i t y . L D „ : 700-1200 mg/kg b.w. i n r a t s 
and mice. 
Formic ac id i s a severe i r r i t a n t of the sk in and eyes i n animals and 
acc idents have been repor ted i n man due to i t s caus t i c a c t i o n on the s k i n , 
the eyes and the mucous membranes. No data were submi t ted concerning any 
i r r i t a n t p r o p e r t i e s at the concen t ra t i on used i n cosmet ics . 
A sub-chronic i n h a l a t i o n study i n r a t s and guinea p igs has shown t ha t fo rmic 
ac id a f f e c t s the l i v e r and the k idneys . Marg ina l e f f e c t l e v e l : 
5 mg/m . 
In a 5 -genera t ion rep roduc t ion study w i t h ra t s 0.2 - 1% calc ium formate d i d 
not show embryo tox i c i t y or t e r a t o g e n i c i t y . 
I t s sodium s a l t d i d not prove mutagenic i n two b a c t e r i a l i n v i t r o t e s t s . 
The formate i on i s a normal i n te rmed ia ry of human metabol ism; 3 to 14% of an 
admin is tered dose i s found i n the u r i n e , the p ropo r t i ons va r y i ng w i t h the 
spec ies . 
- 12 
The formate ion is only sLigthLy toxic and in spite of the caustic action of 
formic acid on the skin and the mucous membranes, the Committee sees no 
objection to maintaining the use of this substance in a concentration of 
0.5%. 
Information : - WHO 1974 Food Add. Series N° 5 
- Z. Ernährungswiss. 9(1969)332 
- Data Sheet Counci l of Europe 
13 
N° 6 4-Hydroxybenzoic acid benzyl ester 
._/~V ,..-!-/"> 
H 
C 1 4H 1 20 3 CAS N° 99-96-7 
MW 228.25 
Synonym : Benzyl-pa råben 
Poorly soluble in water, soluble in propylene glycol, highly soluble in 
ethanol. 
Used in cosmetics in combination with other paraben esters up to 0.1% (as 
acid). 
The oral LD_n in mice was y 10 g/kg, in rats > 5 g/kg. 
From a skin irritation test in rabbits with 500 mg undiluted substance 
(applied on a gauze patch moistened with isotonic NaCl solution for 4 hours) 
it was concluded that the substance is not an irritant. A second test in 
rabbits with 500 mg applied for 4 hours did not produce irritation. 
An eye irritation test in rabbits with 0.1 g of the test substance was 
negative. 
Patch tests have been conducted in different countries with thousands of 
eczema patients using a mixture of benzyl, butyl, propyl, ethyl and methyl 
paraben, 3% of each, total 15% in vaseline. The incidence of sensitized 
patients varied from c. 1.0% to c. 4.0%, though in one year in a Canadian 
hospital the incidence was 6.7% in 405 patients. 
Among 2000 patients tested in a hospital in one year, 4 were found sensitive 
to parabens. These 4 were tested with each of the 5 paraben esters and 2 
were found to react to benzyl paraben. 
- 14 -
Short-term (19-day) oral administration of 1 g/day to guinea pigs did not 
produce adverse effects (only a summary report is available). 
Short-term (5-day) oral administration of 2 g/day to 1 male and 1 female 
human subjects did not induce toxic effects or clinical abnormalities 
(summary report only). 
An adequate short-term oral test and information on genotoxicity is needed 
to evaluate this compound. Depending on the results, information on dermal 
absorption may be required. 
No opinion can be expressed because of a lack of data. 
Information : Colipa dossier, Submission I, September 14, 1984 
" II, September 7, 1984 
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N° 7 Hexamidine (INN) and i t s salts (including isethionate (INN) and 
4-hydroxybenzoate) 
H2N 
- 0 - (CH2)6 - 0 - <v /) - C 
m'' ' V V ^ " N H , 2(OH, CH2-CH2-S03H) 
C^nH_,N.0o CAS N° 3811-75-4 
¿U ¿o 4 ¿ 
MW : 354.45 
Synonym : 1,6-di(4-amidinophenoxy)-n-hexane and i t s salts including d i -
isethionate and di(p-hydroxybenzoate) 
Soluble in water. Insoluble in organic solvents. 
Hexamidine is used in cosmetics at a maximum dose level of 0.1%. 
The acute tox ic i ty of hexamidine administered by the cutaneous route is very 
low in rats. In rabbits no dermal LD,-n value was 
in rats, mice and rabbits is 500 - 750 mg/kg b.w. 
 determined. The oral LD„ 
In a concentration of 0.1%, this substance has only a very sl ight i r r i t an t 
effect on the skin and eye (sl ight reversible opacity of the cornea). 
Hexamidine is not a photosensitizing compound. 
A subacute (28-day) dermal toxic i ty study in rabbits showed that solutions 
up to 2% were only very s l ight ly i r r i t an t and revealed no systemic tox ic i ty . 
No sensitization was observed in guinea pig studies. 
A 90-day dermal study in rabbits revealed no systemic tox ic i ty at dose 
levels up to 4 ml/kg b.w. of a 0.4% aqueous solution (16 mg/kg b.w.). This 
presupposes very low absorption by the skin and/or test doses which are too 
low to give effects. 
16 -
In a 90-day oral study in male rats, daily doses of 400 and 800 mg/kg by 
gavage induced mortality, growth depression, signs of anaemia increased 
liver weight and decreased liver- and kidney function. The lower dose of 
200 mg/kg was not a clear no-effect level. 
The Committee is of the opinion that the use of hexamidine as a preservative 
in cosmetics at a concentration of 0.1% may be continued for the present. 
It wishes to obtain data on : 
1. a 90-day study using the oral route to establish the no-effect level; 
2. mutagenicity studies; 
3. if there is substantial dermal absorption, a teratogenicity study. 
Thereafter the Committee will reevaluate the toxicity of hexamidine and 
consider if a study on long-term toxicity including carcinogenicity will be 
necessary. 
Information : - Data sheet Council of Europe 
- Data sheet National Institute of Public Health, 
the Netherlands, based on Colipa file 
- Additional submission from Colipa, 27 September 1982 
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N° 8 3 /3 ,Dibromo-4 /4 ,-hexamethyLene-dioxydibenzamidine 
(Dibromohexamidine) and i t s sa l ts ( inc luding isethionate) 
\ 
H2N / = = \ / = = = \ /H2 
C <v /> - 0 - ( C H 2 ) 6 - 0 — (K Ù Cv> 
/ 
/ \ 2 6 \ / \ 
M' \ (/ \ /J NH, 2(H0-CH2 -CH2 -S03H) 
C24H36Br2N4°10S2 
MW : 764.2 
Synonym : 1,6-di(4-amidino-2-bromophenoxy)-n-hexane and i t s sa l ts inc luding 
isethionate 
Soluble in water, a lcoho l , g lycer ine. Insoluble in benzene. 
Dibromohexamidine isethionate is used in cosmetics at a maximum level of 
0.1%. 
This substance proved to be only s l i g h t l y toxic in acute t o x i c i t y studies in 
the case of the ora l and cutaneous routes (LD,-n > 4000 mg/kg) but highly 
tox ic in the case of the in t raper i tonea l route (LD 71 mg/kg). 
I t is s l i g h t l y i r r i t a n t to the skin of rats and rabbi ts under severe 
conditions of skin abrasion (0.5 g / r a b b i t ) . Reddened conjunctivae were 
observed a f te r i n s t i l l a t i o n of 0.25% in the eyes of rabb i ts . No 
sens i t iza t ion reaction has been observed. 
A sub-chronic (90-day) o ra l study in rats with the isethionate sa l t 
administered by gavage as suspension in 1% aqueous methyIcellulose at levels 
of 0, 4 , 20 and 100 mg tes t substance/kg/day did not reveal treatment-
related ef fects other than increased sa l i va t ion fo l lowing dosing in a l l 
treatment groups and increased water consumption in the top-dose group. 
18 -
In a 90-day dermal toxicity study in rabbits the maximum dose was only 
2.5 mg/kg b.w.. The micro-abscesses in the Lungs observed in 2/5 of the 
rabbits of this group were not considered significant. 
Metabolic studies in rabbits showed only slight intestinal absorption of 
dibromohexamidine. 
An Ames test conducted with the isothionate salt was negative both with and 
without metabolic activation. 
The data available indicate relatively high toxicity, but low absorption 
from the gut. The Committee wants to obtain information on dermal 
absorption. If this is considerable a short-term dermal study at 
appropriate dose levels would be indicated. However, the Committee sees no 
objection to maintaining the use of this substance as preservative in 
cosmetic products for the time being at a maximum level of 0.1%. 
Information : - Data sheet Council of Europe 
- National Institute of Public Health, the Netherlands, 
based on Coli pa file 
- Additional submission from Colipa, 27 September 1982 
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N° 9 Dibromopropamidine (INN) and i t s salts ( i n c l u d i n g i s e t h i o n a t e (INN)) 
H2N \J \ S 
HN 
0 - ( C H ^ - 0 r\p C .2H0CH-,CH-,S0-H 
\ 2 2 ^ 
NH 
C 2 l H 3 0 Br 2 N 4 0 1 0 S 2 
MW 470.19 
Synonym : 1,3-d i (4-amidino-2-bromophenoxy)propane d i -2 -hydroxye thane 
su l f ona te 
Solub le i n water and e t h a n o l , p r a c t i c a l l y i n s o l u b l e i n e ther and c h l o r o f o r m . 
Used at l e v e l s up to 0 . 1 % . 
The o r a l LD™ in mice was > 1000 mg/kg; the i . p . LD-» i n mice was 78 mg/kg. 
From a subacute (5-day) o r a l study i n which mice rece ived d a i l y d i f f e r e n t 
o r a l doses, a cumulat ive LDÇ„ of 840 mg/kg/day was c a l c u l a t e d . 
A s k i n i r r i t a t i o n t e s t i n r a b b i t s w i t h an aqueous s o l u t i o n of 0.15% was 
nega t i ve . 
An eye i r r i t a t i o n t e s t i n r a b b i t s w i t h 0.15% i n water induced on ly redness 
of the con junc t i vae i n 1/6 an ima ls . 
A maximizat ion t e s t i n guinea p igs w i t h 1% i n d i s t i l l e d water (and us ing 
Freund's a d j u v a n t , sodium l a u r y I s u l f a t e , and microscopic examinat ion of the 
sk i n ) d i d not p rov ide i n d i c a t i o n s of s e n s i t i z a t i o n . 
In a 90-day o r a l s t u d y , ra t s were t r e a t e d w i t h 0 , 3 , 30 and 300 mg/kg 
b .w. /day by gavage. Increased s a l i v a t i o n was observed i n each t reatment 
group a f t e r dos ing . In the top-dose group the re was occas iona l p i l o -
e r e c t i o n d u r i n g the f i r s t 30 days, and one female d i e d . In t h i s group 
changes were observed i n the stomach both g ross l y and m i c r o s c o p i c a l l y . The 
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changes consisted of thickening of the Limiting ridge of the stomach 
accompanied by acanthosis. No changes were observed in body weight, food 
intake, haematology, blood chemistry, urinalysis or organ weights. 
Rabbits treated dermally with 3 mg/kg as a 0.15% aqueous solution each day 
for 90 days showed lack of hair growth from the 10th week. No other gross 
changes were observed (no control group). 
An Ames test with up to 5 ug/plate was negative. 
There is no information on reproduction or teratogenicity. The similarity 
to stilbamidine (used in trypanosomiasis) was noted. The substance may be 
bound to protein. The effects on the stomach are typical of bromides. The 
substance is used therapeutically for treating surface infections, e.g. in 
burns and skin grafting. Information is needed on dermal absorption. 
Genotoxicity tests required are in vitro gene mutation and chromosomal 
aberration in mammalian cells. The necessity for further tests would be 
considered when the above information was available. 
No opinion can be expressed because of lack of data. 
Information : - Data sheet provided by National Institute of Public Health, 
the Netherlands (based on Colipa dossier 14th July 1979) 
- Colipa dossier. Submission II, April 1984 
- Colipa dossier, Submission III, September 1984 
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N° 10 Thiomersal ( INN) 
COONa 
V^ 
S - Hg - CH2 - CH3 
C9H9Hg02S Na 
MW : 404.84 
CAS N° 54-64-8 
Synonyms : - [(o-carboxyphenoD-thioJethyImercury sodium sal t 
- sodium ethyl mercurithiosal icyLate 
- Merthiolate 
- Thi me rosai 
Soluble in water and ethyl alcohol. Insoluble in ether and benzene. The 
use of sodium ethyl mercurithiosalicylate is restricted to eye make-up and 
eye make-up remover at a maximum concentration of 0.007% (expressed as Hg). 
The LD s n values vary from 15 to 100 mg/kg, according to the route of 
administration and the animal species used. Up to 500 mg has been 
repeatedly given intravenously to man with no ill-effects. 
No quantitative data are available concerning skin irritation in animals or 
man. 
Eye irritation did not occur in rabbits treated daily for seven days with 2 
drops of 1.0% aqueous solutions. Nevertheless it is recognized that eye 
irritation in man may be produced by contact lenses sterilised with 
merthiolate. 
Various epidemiological studies in man have shown that the frequency of 
contact allergy due to merthiolate is 2 to 7%. Sensitization may occur when 
either the epidermal or the intradermal route is used, and cases of cross-
sensi tization are observed with a few organic mercury derivatives. 
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A subacute toxicity study carried out with dogs, involving intravenous 
injection of merthiolate in doses of 2 mg/kg b.w. every three days for 
36 days, showed no pathological changes. 
A carcinogenicity study in rats with twice-weekly subcutaneous 
administration of 0.03, 0.1, 0.3 and 1 mg/kg b.w. of merthiolate for one 
year and terminated after 18 months revealed no systemic carcinogenicity. 
Nevertheless, a high incidence of bronchopneumonia related to the injected 
dose and numerous indurations at the injection site were observed. This 
study is of limited value as regards the prediction of possible 
carcinogenicity. 
An Ames test with up to 1 mg/plate both with and without metabolic 
activation was negative. However, in a DNA repair test by the E.coli DNA 
polymerase A-assay, genetic toxicity was observed when the assay was 
conducted in the light but not when conducted in the dark. 
In a teratogenicity study, groups of 10 pregnant rats received daily i.p. 
injections of 1 ml of either 0.2 or 2.0% thiomersal solution from day 6 
through 18 of pregnancy. Although deaths, abortion and resorption of 
foetuses were increased, malformations did not occur. 
Treatment of seven pregnant rabbits with 2 drops of 2% thiomersal in 0.9% 
saline in both eyes from day 6 - 18 of pregnancy (8 times on day six and 4 
times daily thereafter) failed to induce congenital malformations in the 
foetuses. A relatively high level of Hg was found in the blood and in 
tissues after application to the eye. 
The Committee noted that 
1. The data available did not permit a full toxicological assessment. 
2. Absorption of thiomersal through the mucous membrane of the eye takes 
place. 
3. There is evidence of accumulation of mercury in the tissues. 
On the basis of toxicological information and the desirability to restrict 
the use of Hg containing compounds, thiomersal must be banned for general 
use. However, in the absence of effective alternative substances to prevent 
eye infections, its inclusion in eye make up preparations and eye make up 
removers can be permitted for the time being, where no satisfactory 
alternative exists, at a maximum concentration of 0.007% expressed as Hg. 
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Information : - Data sheets of the Council of Europe 
- C l i n i ca l Toxicology 4 , 185-204 (1971) 
- Am. J . Ophthalmology 78, 98-105 (1974) 
- Data sheet of the I n s t i t u t d'Hygiène et d'Epidemiologie, 
Brussels 
- Colipa submission I , Nov. 1983 
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N° 11 Phenylmercuric salts (including borate) 
■Hg - 0 - CO - CH, 
^ 
C8H8Hg02 
MW 336,74 
CAS N° 102-98-7 
(62-38-4) 
Sparingly soluble in water. Soluble in alcohol, benzene and acetone. The 
use of phenylmercuric acetate (PMA) is restricted to eye make-up and eye 
make-up remover at a maximum concentration of 0.007% (expressed as Hg). 
The oral LDç_ varies from 22 to 60 mg/kg according to the species of animal 
used. In mice values of 8, 18 and 37 mg/kg are reported for respectively 
the intraperitoneal, intravenous and subcutaneous LD,-n. 
When given in a dose of 50 ¿ig, PMA severely irritates the rabbit eye. 
In man, it can be considered a severe skin irritant when given in a dose of 
100 ug. At a concentration of 0.1% and above it is an irritant and a 
sensitizer. Sensitization does not occur at 0.001%, but a dose-related 
increase in incidence of sensitized subjects occurred at higher 
concentrations. In a commercial make-up product, 0.003% was not sensitizing 
in a maximization test in guinea pigs. 
It is a poor skin penetrant; at concentrations of 1% to 0.06% the 
penetration through stripped human stratum corneum was about 1 ng/cm /hr. 
Nevertheless mercury levels above normal have been reported in urine, blood 
or hair of chronic users of mercurial bleach creams. In a few cases the 
urinary levels of mercury were in the range of values reported for mercury 
intoxication. 
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PMA is metabolized in vivo, reLeasing Hg which is partly excreted by the 
kidneys upon administration by different routes to various animal species. 
Accumulation of mercury was found in several tissues (kidneys, central 
nervous system, liver, muscle, hair). 
In various subacute and subchronic oral studies in rats, dose-related 
changes in enzyme activity were found in the liver and blood. Brain enzymes 
showed changes which were related to the length of exposure. Inhalation 
exposure of rats to 0.012 mg/m of PMA caused changes in the blood picture, 
which were irreversible. 
In a chronic oral rat study with dietary levels of 0.1 - 160 ppm only the 
highest dose caused mortality. Growth depression occurred with 10 ppm and 
more, kidney damage with 0.5 ppm (as Hg) and above. The no-toxic effect 
level was <C 0-1 ppm because tissue storage of mercury was found even at this 
low feeding level. 
PMA proved to be genotoxic for Baci llus subtilis and to produce chromosomal 
aberrations in human leucocytes. 
It is embryotoxic and teratogenic in hamsters, rats and rabbits when 
administered by gastric intubation from the 5th to the 12th day of gestation 
in doses ranging from 1/6 to 1/2 of the LDsr). 
Teratogenic effects were also observed in hamsters as a result of 
intraperitoneal injection of a 7500 ¿ig/kg dose on the 8th day of gestation. 
When 600/jg/day was administered to hens subcutaneously, in the course of a 
study lasting several months, gradual inhibition of egg-laying was observed. 
After 20 days, approximately 30% of the daily injected dose was detected in 
the yolk. 
In man, epidemiological studies revealed cases of irritative and allergic 
dermatiti s. 
The chronic intoxication syndrome due to organic mercury compounds is 
characterized by insidious onset, long-continued clinical sequelae and a 
guarded prognosis as to complete recovery, and is confined to the CNS, in 
particular the visuosensory cortex and the cerebellum. Ingestion of this 
substance during pregnancy can have highly detrimental effects on the foetal 
CNS. 
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The j o i n t FAO/WHO Expert Committee on Pesticides did not establ ish an ADI 
because of the very Low no tox ic e f fec t Level and because i t considered any 
increase in the use of mercury as undesirable. 
Because the t o x i c i t y of t h i s compound w i l l be determined pr imar i l y by the 
mercury i t conta ins, i t is assumed that the other sa l ts have s imi la r tox ic 
proper t ies . 
This substance is highly t o x i c , mutagenic and teratogenic , and must be 
banned for general use. However, in the absence of e f fec t i ve a l te rna t i ve 
substances to prevent eye i n fec t i ons , i t s inc lusion in eye make-up 
preparations and eye make-up removers can be permitted for the time being, when 
no sa t i s fac to ry a l t e rna t i ve ex is ts at a maximum concentration of 0.007% 
expressed as Hg. 
Information : - TOXLINE 
- Data sheet of the Council of Europe 
- Data sheet of the I n s t i t u t d'Hygiène et d'Epidemiologie, 
Brussels 
- WHO/Food add./67.32 p. 188 
- Marzul l i and Brown, J . Soc. Cosmet. Chem. 23 (1972) 875-886 
- Co l ipa submission I , Sept. 1983 
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N° 12 Esters of sorbic acid 
CH,CH = CHCH = CHCOOH 
r Ho0, CAS N° 110-44-1 
6 8 2 
MW : 112.12 
Synonyms : - 2,4-Hexadienoic ac id 
- Sorbic acid 
- Sorbistat 
The esters cannot be evaluated because of Lack of information. But the 
esters are no Longer used as preservatives in cosmetic products. 
Information : - data sheet Council of Europe 
- data sheet of the Free University of Brussels 
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N° 13 Undec-10-enoic acids : salts, esters, the amide, the mono- and 
bis(2-hydroxethyI) amides and their suLphosuccinates 
CH- = CH - (CH2)g - C02H 
C„,H.,nCs CAS N° 112-28-9 
11 20 2 
MW : 184.28 
Synonyms : - 10-undecenoic acid 
- undecylenic acid 
Practically insoluble in water. Soluble in alcohols, chloroform and ether. 
Used in cosmetics at dose levels of 0.2%. 
The acute oral toxicity (LD,-n) varied from 2.5 to 10 g/kg in rats, and from 
2.3 to 8.5 g/kg in mice. Mice treated orally with 0.14 to 0.29 g showed 
hyperirritability. Upon necropsy, engorgement of the stomach and the small 
intestine, accompanied by petechial haemorrhages were observed. With 
intraperitoneal administration, the LD_n was 0.96 g/kg in mice; with dermal 
application in rabbits, it exceeded 5 g/kg. 
When applied as such to the intact or abraded skin of rabbits for 24 hours 
under occlusion, undecenoic acid proved to be extremely irritating. A 
concentration of 30% in ethanol was mildly irritating. The substance was 
well tolerated by human skin in an open epidermal test at concentrations of 
up to 60% for 21 days and in a test under occlusion at 4% for 48 hours. 
No allergic sensitization reactions were observed in a maximization test 
performed with a 4% solution in vaseline on 25 human volunteers. 
In a sub acute (eight weeks) oral toxicity test in rats, weight loss 
followed by a gradual recovery was observed with a 2.5% concentration of 
undecenoic acid in the diet. 
A subchronic (six months) oral toxicity study in rats revealed no sign of 
toxicity at concentrations of 0.1, 0.2 and 0.4 g/kg b.w./day. 
In the same study, no teratogenic effect was noted when the same dosages 
were given over nine months. 
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The Committee wishes to obtain information concerning mutagenicity. There 
is doubt concerning the use and the efficacy of this substance in cosmetics. 
NB : The above assessment applies to undecenoic acid only. 
Information : - Opdyke, Food Cosmet.Toxicol. 16 (suppl 1) 883-884 (1978) 
- BLAISE 
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N° 14 2,6-Diacety l -1,2,3,9b- tet rahydro-7,9-d ihydroxy-8,9b-
dimethyLdibenzoLfuran-1,3-dione (usnic acid) and i t s sa l ts 
( inc luding the copper s a l t ) 
COCH 
COCH-, 
C 1 8 H 1 6 ° 7 
MW 344.32 
CAS N° 125-46-2 
Very sparingly soluble in water, acetone and e thy l a lcohol . 
Soluble in f u r f u r a l and f a t s . 
Usnic acid is used in cosmetics at dose levels of 0.2%. I t appears that i t 
is seldom used in cosmetic products because of i t s i n s o l u b i l i t y . I t i s 
probably used in the form of double sa l ts of copper and tr iethanolamine. 
The o r a l , subcutaneous, and in t raper i tonea l LD values in mice are 515, 700 
and 47,3 mg/kg b.w. respect ive ly . The intravenous LD_Q fo r mice, rats and 
dogs was 25,30, 30 and 40 mg/kg b.w. respect ive ly . 
No teratogenic studies have been reported. Freese et a l . (1979), regard i t 
as a suspect teratogen based on i t s physico-chemical propert ies and i t s 
i nh i b i t o r y e f fects on growth of human and bac ter ia l ce l l s in v i t r o . 
No opinion can be expressed because of a lack of data. But t h i s substance 
is no longer used as preservative in cosmetic products. 
Information - Data sheet of the Council of Europe 
- Freese e t a l . , Teratology 20(1979) 413-440 
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N° 15 Hexet id ine (INN) 
CH, 
CH, - CH(CH-,),(CH, / 2 j Z 3 5 
C2H5 
N CH2 CH(CH2)3CH3 
C2H5 
C2 1H4 5N3 
MW : 339.60 
CAS N° 141-94-6 
Synonyms : - 5 -Amino -1 ,3 -d i - (2 -e thyLhexyL) -hexahydro -5 -methy lpy r im id ine 
- S t e r i s o l 
A v iscous o i l w i th a dens i t y of 0.87 g / m l . 
P r a c t i c a l l y i n s o l u b l e i n wa te r , e a s i l y so lub le i n e t h a n o l , acetone and o ther 
organic s o l v e n t s . 
Used up t o 0.2% i n cosmet ics. 
LDs r )values are : o r a l i n r a t s 1.43 g / k g ; i n t r a p e r i t o n e a l i n mice 0.030 
0.085 g / k g ; dermal i n ra t s 1.86 m l / k g , and i n r a b b i t s 4 .0 m l / k g . 
In t ravenous a d m i n i s t r a t i o n of 5 mg/kg was l e t h a l f o r c a t s . 
No sk i n i r r i t a t i o n or s e n s i t i z a t i o n was observed i n 200 vo lun tee rs examined 
f o r pr imary i r r i t a t i o n w i t h 1% i n an o in tmen t . A repeated i n s u l t t e s t i n 50 
humans w i t h 1% i n o i l caused m i l d i r r i t a t i o n ; 10 and 5% i n o i l caused s t rong 
pr imary i r r i t a t i o n but no s e n s i t i z a t i o n . 
Very s l i g h t eye i r r i t a t i o n was seen i n r a b b i t s w i t h 0 .1% o in tmen t , moderate 
i r r i t a t i o n w i t h 4% aqueous d i s p e r s i o n , and w i t h the u n d i l u t e d substance, and 
severe i r r i t a t i o n w i t h 25% ointment and 50% d i s p e r s i o n . 
A 0 .1% aqueous s o l u t i o n used tw ice d a i l y as a mouth wash by 200 vo lun tee rs 
f o r 3 months d i d not induce c l i n i c a l s i g n s , pr imary i r r i t a t i o n or 
s e n s i t i z a t i o n . 
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In a study in 327 pat ients with cervicovaginal in fec t ions 0.1% as a get and 
0.5% so lu t ion did not induce i r r i t a t i o n , sens i t i za t ion or systemic t o x i c i t y . 
In a skin sens i t i za t ion test in guinea p igs , induct ion with 10 intradermal 
in jec t ions of 0 .001, 0.005 and 0.01% in acidic sa l i ne , fol lowed by one 
intradermal i n j ec t i on of 0.001% and top ica l app l icat ion of a 25% in absolute 
ethanol a f te r 14 days, no signs of sens i t i za t ion occurred. Repeating the 
challenge treatment a f te r one week, and also a f te r 2 weeks, was l ikewise 
negative. 
In a 3-wk ora l tes t in rats with 20, 50, 100 and 200 mg/kg/day, the top dose 
caused m o r t a l i t y ; with 100 mg/kg there was reduced erythropoies is . No 
changes were seen at lower leve ls . 
In a one year study, rats received 0.02, 0.05 or 0.1% in the d i e t . Growth 
re tardat ion and decreased food consumption were seen in the top dose group. 
No treatment-related changes were found upon microscopic examination (Only 
summary report i s ava i lab le ) . 
Daily dermal appl icat ion of 50, 100, 200 or 500 mlg.kg to rats for 3 weeks 
(5 days/week) caused mor ta l i t y in the top-dose group. No changes occurred 
at lower leve ls . 
Dermal treatment of rabbi ts with 0.0625 up to 4.0 ml/kg/day for 90 days 
caused mor ta l i t y and growth retardat ion with 0.25 ml/kg and above. No 
ef fects on haemopoietic and ur inogeni ta l systems were seen at any treatment 
level (Summary reports on l y ) . 
In a sub-chronic (90-day) ora l study, rats received 0, 100, 300 or 1000 ppm 
in the d i e t . There were no deaths or c l i n i c a l signs of t o x i c i t y . Growth 
depression, decreased intake of food and water, changes in biochemical blood 
parameters and increased organ-to-body weight ra t ios for several organs, 
occurred in the top-dose group. Microscopical ly , the top dose rats showed 
signs of systemic l i p i d o s i s . No deta i led report of the pathological 
f ind ings was ava i lab le . I t is stated that 300 ppm was a no-effect level (or 
27 mg/kg b.w.) . 
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An Ames t e s t w i th 5 s t r a i n s of S. typhimur ium and dose l e v e l s up to 
5 mg/plate was nega t i ve . 
14 An o r a l dose of C-hexet id ine i n r a t s (20 mg/kg) and dogs (10 mg/kg) was 
r a p i d l y e x c r e t e d . A f t e r 72 hours 60-70% was recovered i n the faeces and 
20-25% i n the u r i n e , wh i l e 1-2% was found i n the l i v e r and k idneys . 
Exact data on dermal absorp t ion are l ack i ng but acute and subacute dermal 
t o x i c i t y s tud ies suggest cons iderab le dermal a b s o r p t i o n . There i s no 
i n f o r m a t i o n on reproduc t ion or t e r a t o g e n i c i t y . A negat ive Ames t e s t i s the 
on ly i n f o r m a t i o n on g e n o t o x i c i t y . 
I n f o rma t i on on t e r a t o g e n i c i t y and r e s u l t s of a chromosomal a b e r r a t i o n t e s t 
should be p r o v i d e d . 
However, the Committee sees no o b j e c t i o n t o ma in ta i n i ng the use of t h i s 
substance as p r e s e r v a t i v e i n cosmetic products f o r the t ime b e i n g , but on 
the basis of t he e x i s t i n g i n f o r m a t i o n 0.2% i s too h igh f o r non r i nsed o f f 
cosmet ics . 
I n fo rma t i on : - Data Sheet Counci l of Europe 
- Environmental Safety Labo ra to ry , Un i l eve r Research, 
Colworth House, England. 
Dossier Safety Eva lua t ion of Hexe t i d i ne . V o l . I and I I 
Document : D 83 /037, August 1983 
- T0XLINE 1974-1984, MEDLARS 1981-1984 and RTECS have been 
searched. 
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N° 16 Benzylformal 
CH2 — (0CH2)x0H 
x = 1:50 % 
x = 2:50 % 
Synonym : Preventol D_ 
Soluble in organic solvents; solubility in water 25 g/l. 
Used up to 0.2% in all types of cosmetics. 
The oral LD 5 Q in rats was 1700 mg/kg; the i.V. LD_Q in rats was 153 mg/kg. 
The animals showed sedation, loss of consciousness, paralysis. The dermal 
LD,.- in rats was > 1000 mg/kg. 
A skin irritation test in rabbits with 500 mg undiluted substance applied to 
the intact skin of the ear for 8 hours induced redness and oedema; when 
applied for only 2 hours, slight redness was observed. A 0.2% aqueous 
solution applied for 24 hours did not induce any changes. 
In an eye irritation test in rabbits 50 mg undiluted substance caused 
erythema and oedema and an opaque cornea. A 0.2% aqueous dilution only 
produced erythema. 
A sensitization test by the Landsteiner-Draize method with 0.1% of the test 
substance in saline both for the induction and for the challenge treatment 
did not reveal signs of sensitization. 
A sub-chronic (90-day) dermal study was conducted in groups of 10 
rabbits/sex which received 0, 1, 4 or 16 mg/kg b.w. daily, 5 days/week. 
With 4 and 16 mg, the skin showed dose-related changes at the site of 
application. In the top dose group, growth depression occurred in females 
and decreased cholesterol values in both sexes. The weight of the pituitary 
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was decreased in males of the intermediate- and high-dose group, however, no 
treatment related pathological changes were found in the internal organs. 
One mg/kg was a clear no-effect level in this well conducted dermal study. 
An Ames test with up to 500 jjg/plate was positive for S. typhimurium TA 100. 
This result is attributed to the presence of 29.7% formaldehyde in the 
product. In a micronucleus test, male and female mice received 2 x 
250 mg/kg, or 2 x 500 mg/kg with an interval of 24 hours. No increase in 
the incidence of micronuclei was observed. 
There is no information on short- or long-term oral toxicity, reproduction, 
teratogenicity or dermal absorption. 
The substance liberates formaldehyde. According to Dr Crisp (UK Laboratory 
Governmental Chemists) this is 0.004% maximum (under test conditions). 
In the body, benzylformal may be broken down (initially) to benzyl alcohol 
and formaldehyde. 
Information is required on : 1. Dermal absorption 
2. The fate of the substance in the body 
3. The effect of the substance and/or its 
breakdown products in the body, in a short-
term, oral toxicity study. 
However, the Committee sees no objection to maintaining the use of this 
substance as preservative in cosmetic products for the time being at a 
maximum level of 0.2%. 
Information : - Data sheet Council of Europe 
- Colipa dossier, April 1984 
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N° 17 ch lo ro fene (INN) 
OH 
_ C H , _ ^ N 
V*"' 
CL 
Cj jH^CLO 
MW 218.69 
CAS N° 120-32-1 
Synonyms : - 2-BenzyL-4-ch lorophenol 
- Prevented BP 
- Santophen 1 
Used in cosmetics up to 0.2%. 
Insoluble in water, soluble in ethanol, isopropanol, propylene glycol. 
Oral LD_n values in rats are > 5 g/kg, and 2.8 g/kg. 
The dermal LD,.« in male and female rats was > 2.5 g/kg. 
Skin irritation in rabbits was found to be moderate (3.1/8). 
An eye irritation test in rabbits showed moderate irritation (37.3/100). 
A patch test in humans with a 1% solution, followed by a second patch test 
with the same solution 10 days later did not reveal signs of sensitizing 
properties. However, a soap containing 3.125% Santophen was sensitizing. 
Short-term dermal toxicity was examined in a detailed study with 4 groups of 
5 rabbits/sex treated with 0, 10, 40 and 160 mg/kg b.w./day in polyethylene 
glycol 400 on 5 days/week. There was no mortality. Changes in behaviour, 
growth rate, or food intake were not observed. In the two higher dose 
groups the treated skin showed erythema, oedema, acanthosis, keratosis, 
subepidermal round cell infiltration and hyperplasia of sebaceous glands. 
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The skin changes were reversible. There were no changes in haematoLogy. 
The top-dose group showed slight liver changes consisting of decreases in 
weight, in activity of alkaline phosphatase and in glycogen content of 
hepatocytes. 
A teratogenicity study was conducted with groups of 24 pregnant rabbits, 
treated by gavage (with Santophen 1) at dose levels of 40, 80 and 160 
mg/kg/day on days 7-19 of gestation. Mortality in the high-dose group 
(10/24) was high, which resulted in only 7 litters available for 
examination. Weight loss occurred in each of the test groups during the 
treatment period. Implantation data, weight, length and ossification of 
foetuses were not affected by treatment. Litters of the test groups 
contained more males than females. External-, and skeletal malformations 
were significantly increased only in the mid-dose group. At 160 mg/kg 
maternal toxicity occurred. The authors concluded that there were no 
indications of embryotoxicity or teratogenicity. 
A second teratogenicity study was conducted with groups of 25 mated female 
rats, treated daily (with Preventol BP Technical) by gavage at dose levels 
of 0, 15, 75 and 375 mg/kg b.w./day. 
In the dop-dose group there was mortality (3/24), reduced food intake and 
body weight gain of the dams, and decreased weight of the foetuses. An 
increased incidence of skeletal abnormalities in the top-dose group was 
attributed to the retarded development in this group. These findings 
indicate maternal toxicity with 375 mg/kg and a no-effect level of 75 mg/kg. 
Preliminary mutagenicity data from the U.S. National Toxicology Program 
(NTP) did not indicate mutagenic properties, either in the Ames test at dose 
levels up to 100 /ug/plate, or in a chromosomal aberration test and a sister 
chromatid exchange test with CHO-cells at concentrations between 16 JJQ and 
0.05 /ug/ml. 
The available studies indicate that the substance is of low or moderate 
systemic toxicity. Irritative and sensitizing properties have been observed 
and need to be further examined at use levels. Moreover information should 
be provided on the purity of the technical product and on the possible level 
of contamination with TCDD. 
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However, the Committee sees no objection to maintaining the use of this 
substance as preservative in cosmetic products for the time being at a 
maximum level of 0.2%. 
Information : - Colipa dossier, Submission I, October 1985 
- Data sheet Mme Dorlet 20-022 F. 139 
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N° 18 5-Bromo-5-nitro-1,3-dioxane 
C.H.BrNO. CAS N° 30007-47-7 
H O 4 
MW : 212.02 
Synonym : Bronidox 
Poorly soluble in water; soluble in ethanol and propylene g l y c o l . 
Bronidox is authorized in rinsed o f f cosmetics up to a level of 0.1%. 
Oral LD_n values are 455 mg/kg in the rat and 590 mg/kg in the mouse. 
In t raper i tonea l l y in the mouse the f igure is 31.5 mg/kg. On rabbit s k i n , 
500 mg/kg in o l i ve o i l caused death in 24 hours. 100 mg/kg caused severe 
skin i r r i t a t i o n . 
A skin i r r i t a t i o n test in rabbits with 0.5% in o l i ve o i l was negative. 
0.1% was negative in hai r less mice, but with 0.5% i r r i t a t i o n and necrosis 
occurred. In rabbi ts 0.5% produced desquamation. 
In an eye i r r i t a t i o n tes t in rabbits 0.1% and 0.5% caused i r r i t a t i o n , which 
was severe at the higher concentrat ion, but the ef fects were revers ib le . 
0.05% was n o n - i r r i t a n t . Daily app l icat ion of 50/JI of a 0.05% solut ion to 
the eye of rabbi ts fo r 10 days without r ins ing did not induce any 
deleter ious e f f ec t . 
Tests in guinea pigs showed no evidence of sens i t i za t i on , but the studies 
were unsat is factory in some respects. There was no evidence of 
photosensi t izat ion in a test in hair less mice treated with concentrations 
varying from 0.05 to 0.5%. 
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Patch testing in man with 0.25% daily with occlusion for 21 days showed that 
this concentration became progressively more irritant after about 6-8 
applications. Slight changes at 0.1% were of dubious significance. 
In man, use of 0.1% in shampoos or foam baths for 6 weeks (at least weekly, 
but not more often than daily) elicited one report (in 118 subjects) of 
slight irritation of dubious significance. 0.05% in a cream formulation 
applied daily for 21 days caused no irritation. 
In the rat, a six-week study by gavage was carried out with 0, 10, 50 and 
100 mg/kg/day; at the end of the period of dosing, the animals were observed 
for a further 9 weeks. No abnormalities were observed up to 50 mg/kg. 
In a 14 week study in rats, 0, 10, 50 and 100 mg/kg/day were given by gavage 
on 5 days/week. After seven weeks, the dose in the top-dose group was 
increased to 200 mg/kg, but this part of the experiment was terminated after 
some of this group died. At the low dose some minor changes were found in 
the gastric mucosa, perhaps related to the mode of administration. At 
higher doses, eosinophilic and round cell infiltration in the heart was 
found, and at the top dose hypoxic myocardial changes were found as well. 
In the 10 and 50 mg/kg group there was slight growth depression and 
decreased kidney function. 
The compound has been shown to be well-absorbed from the gut and the 
peritoneal cavity in animals. When applied to the skin, absorption is 
considerable in rats, rabbits and man (10-40%). Three metabolites have been 
identified. 
In an oral teratogenicity study, dose levels of 0, 5, 15 and 45 mg/kg were 
administered to groups of 30 rats. All treated groups showed clinical signs 
of intoxication and enlarged livers. One of the dams in the mid dose group, 
and four in the high dose group died. Foetuses did not show signs of 
teratogenic properties of the compound. 
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The Ames test was inconclusive. The micronucleus test was negative. 
In view of its structure, it is Likely that this compound could give rise to 
nitrosamine formation under certain conditions. The no-toxic effect level 
is less than 5 mg/kg. Percutaneous penetration is considerable in animals 
and man. Its continued use may be justified only, if a no effect level is 
firmly established, and if a gene mutation test turns out to be negative. 
However, the Committee sees no objection to maintaining the use of this 
substance as preservative in cosmetic products for the time being but only 
for rinsed off products and not more than 0.1%. 
Information : - Colipa dossier. Submission I Oct. 15, 1980 
Submission II, January 28, 1983 
Submission III, September 26, 1984 
- Data sheet National Institute of Public Health (the 
Netherlands), June 1981 
- J. Soc. Cosmet. Chem 28, (1977) 427 
- Data sheet Council of Europe 
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N° 19 BronopoL (INN) 
N02 
HO - CH2 - C - CH2 - OH 
Br 
C,H,BrN0. CAS N° 52-51-7 
3 6 4 
MW : 169.97 
Synonym : 2-bromo-2-nitropropane-1,3-diol 
Soluble in water and ethanol, 50%. Poorly soluble in non-polar solvents. 
Bronopol is used at dose levels up to 0.2%. 
The acute t o x i c i t y is moderate to h igh ; LD5Q in rats and mice (mg/kg) was 
about 300-350 ( o r a l ) , 200 (subcutaneous, mouse), 20-30 i n t rape r i t onea l l y , 
60-160 dermally ( in acetone, mouse). 
In the dog by gavage, a l l doses in excess of 40 mg/kg caused gastr ic 
i r r i t a t i o n and pyrex ia ; one of two dogs died at 250 mg/kg. 
In the rabb i t , a 10% aqueous so lu t ion was highly i r r i t a t i n g to the eyes. 
Up to 0.5% was not i r r i t a n t . 
In the guinea-pig, 0.1% to the shaved skin was n o n - i r r i t a n t ; 1% caused 
s l i gh t i r r i t a t i o n . 
I r r i t a t i o n of the skin was found at concentrations varying from 0.5% to 2% 
depending on the solvents. 
In dermal tests in man, the threshold of i r r i t a t i o n varied from 0.5% to 2% 
in d i f f e ren t experiments. In 149 eczematous pa t ien ts , a 24 hr patch test 
with 0.25% showed 4 pos i t i ve react ions. 
In the guinea-p ig, the substance was found not to be a sens i t i z ing agent. 
In man, 2% was found not to be sens i t i z i ng . 
In the r abb i t , a 9-day study showed gast r ic i r r i t a t i o n and pulmonary e f fec ts 
(perhaps due to asp i ra t ion) a f te r various doses by gavage; 3.3 mg/kg/day was 
wel l t o l e ra ted . 
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In a 13-week study, up to 20 mg/kg/day were given to dogs by gavage. The 
probable NEL was 4 mg/kg/day; higher doses induced increased relative 
weights of liver and spleen, and some leukopenia. 
In a 14 days intubation study in the rat, 4 of 5 animals died at 
300 mg/kg/day; 100 mg/kg/day was tolerated. In a six week study, rats were 
treated with 80 (later 300) and 160 mg/kg/day in drinking water. At both 
levels there was an increased relative kidney weight; 2 M died at 
300 mg/kg/day. In a 12 week study in the rat, 100 and 1000 ppm was given in 
the diet. No abnormalities were found. In a 13 week study, also in the 
rat, groups of 40 animals were given 20, 80 and 160 mg/kg/day by gavage. 
There were severe symptoms and mortality at the top dose; at 20 mg/kg one 
animal showed transitory respiratory distress, but apart from this no 
abnormalities were noted at this dose. 
In a two-year rat study, groups of 60 M and 60 F received 10, 40 and 
160 mg/kg/day in drinking water. All treatment groups showed a reduction in 
water intake, attributed to unpalatability. The top dose group showed clear 
signs of toxicity including mortality. There was a dose related increase in 
the incidence of squamous metaplasia of the salivary glands. No significant 
changes at the low dose by comparison with the controls. 
Repeated dermal applications of 90% acetone solutions at various 
concentrations were made to the shaven skin of mice for 4 weeks. The top 
dose animals (4% and 2%) were sacrificed after 1 week in view of severe 
toxic effects; concentrations up to 0.5% were well tolerated. 
In rats, 0.5% in an aqueous medium with occlusion caused a severe local 
reaction. A similar study was carried out over 80 weeks, but due to high 
mortality, full evaluation is not possible. 
Using radioactive substance in aqueous solution, rats and rabbits absorb the 
substance relatively slowly from the skin - about 11% in 24 hrs. Use of 
acetone as a solvent leads to somewhat more rapid and greater absorption. 
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Dominant lethal test, host-mediated assay, and Ames test were negative. 
Administration of 20 and 40 mg/kg/day to dams from day 15 of pregnancy to 
the end of lactation had no adverse effect on offspring in the rat. The 
same dose to male rats for 63 days before mating, and to female rats from 14 
days before mating to day 12 of pregnancy, and also to weaning, did not 
affect the offspring adversely. 
Teratogenicity : tests with up to 100 mg/kg/day orally in rat and rabbit 
were negative. In a dermal study in rats up to 20 mg/kg/day did not cause 
any teratogenic effects. 
It should be mentioned that Bronopol, as well as other preservatives, may 
act as a nitrosating agent. 
The use of this substance as preservative in cosmetic products at a maximum 
level of 0.2% can be permitted. 
Information : - Data sheet Council of Europe 
- Data sheet National Institute of Public Health, 
the Netherlands, based on Colipa file 
- J. environmental Pathology and Toxicology, 4(4) 47-61 (1980) 
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N° 20 6 , 6 - D i b r o m o - 4 , 4 - d i c h l o r o - 2 , 2 ' - m e t h y l e n e - d i p h e n o l (Bromochlorophen) 
C^HoBr -CUO, CAS N° 15435-29-7 
13 8 2 2 2 
MW : 426.95 
Synonyms : - 3,3,-dibromo-5,5'-dichLoro-2x2,-dihydroxyphenylmethane 
- Bromophen 
Poorly soluble in water ( < 0.6%), moderately soluble in ethanol (9.5%). 
Used up to 0.1% in non rinsed off products. 
Oral LD-p-values in rats are 3.7 g/kg and 8.15 g/kg, in mice 1.55 g/kg. 
The intraperitoneal LD in rats was 580 mg/kg; the dermal LD_n in rats was 
found to be > 1 0 g/kg. 
In a primary skin irritation study in rabbits, a 50% suspension in water 
produced very slight erythema in 2/6 animals. The substance was classified 
"mildly irritating". 
A 50% suspension in water was not irritant to the eye of the rabbit. 
A guinea pig maximization test with 0.3% for induction, and 3% for the 
challenge treatment did not reveal any indication of sensitizing properties. 
In a phototoxicity test, 5 human subjects were treated once on the forearm 
skin with 0.05 ml of a 2% concentration in ethanol on two spots, one of 
which was UV-irradiated. No signs of phototoxicity were observed. After 10 
days rest the treatment was repeated with the test substance in paraffin 
oil. Again 10 days'later a third treatment was given using 8% soap solution 
as a vehicle. There were no signs of photosensitization. 
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Sub-chronic (13-wk) toxicity was examined in an oraL study in rats with dose 
Levels of 0, 250, 500 or 1000 mg/kg/day. ALL treatment groups showed 
diarrhoea, caecaL enlargement, and increased Liver weight. Mortality, 
growth depression and signs of anaemia occurred in the top-dose group. 
In an oral embryotoxicity/teratogenicity study in pregnant rats with dose-
Levels of 20, 100 and 500 mg/kg, no indications of teratogenicity were 
observed. In the two higher dose groups, the weight of the foetuses was 
decreased. Delayed ossification and an increased incidence of lumbar 
vertebrae were found in the top-dose group. 
In a sub-acute inhalation study in rats with a bromophen aerosol, a 
concentration of 220 mg/m did not induce any detrimental effects u\ 
applied 2 hours/day, seven times weekly, for 4 weeks. 
An Ames test with the Salmonella strains and with E. coli up to 10 jug/plate 
was negative. 
14 A metabolism study with the C-labelled compound was conducted in rats by 
oral, intravenous and dermal application. The substance is poorly 
metabolized and mainly excreted with the faeces after conjugation in the 
liver. Only 2% of an oral dose and 4% of an intravenous dose is excreted by 
the kidneys. Blood plasma contains only a relatively small amount of 
metabolites. The pattern of metabolites after different routes of 
administration is very similar. An oral dose is absorbed only slowly and 
results in a maximum blood level only after 8 hours. A dermal dose of the 
radiolabelled compound showed 2% absorption after 2 hours and 8 to 10% after 
24 hours. 
The Committee noted the structural similarity between this compound and 
hexachlorophene and drew attention to the known deleterious effects of the 
latter compound at high concentrations to brains of neonates in man and 
non-human primates. A no effect level in a short-term oral toxicity study 
should be established. A chromosomal aberration test and an adequate Ames 
test are required. However, the Committee sees no objection to maintaining 
the use of this substance as preservative in cosmetic products at a 
maximum level of 0.1%. 
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Information : - Colipa dossier, December 1984 
- Data sheet Council of Europe 
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N° 21 Tetrabromo-o-cresol 
OH 
B r -
Br — 
— CH, 
— Br 
Br 
C-.H.BT.0 
( 4 H 
MW : 423.77 
CAS N° 576-55-6 
Practically insoluble in water; soluble in alcohol, ether and alkali 
hydroxides. 
Used in cosmetics up to 0.3%. 
The oral LD,-n in mice was 0.8 g/kg. 
The undiluted substance is irritating to the skin and the mucous membranes. 
A 2% solution was not irritating to the skin of guinea pigs, nor to the eye 
of rabbits. Four out of one hundred human volunteers reacted positively to 
solutions of 0.25 - 2.0%. 
No opinion can be expressed because of a lack of data, but the substance is 
no longer used as preservative in cosmetic products. 
Information : Data sheet Council of Europe 
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N° 22 2-Chloroacetamide 
H 
I 
CL -•— C "C NH 2 
C E C I N O CAS N° 79-07-2 
MW : 93.52 
Moderately so lub le i n water (5%); e a s i l y s o l u b l e i n e t h a n o l . The product 
manufactured i n the EEC i s 99.5 - 99.8% pure ( i m p u r i t i e s are ammonium-
c h l o r i d e 0.1 - 0.2%, and monochloroacet ic ac id 0.03%). 
Used mainly as a mix tu re of ch loroacetamide and sodiumbenzoate ( 7 0 : 3 0 ) , i n 
r insed o f f products 0.15%, i n non- r insed o f f products 0.3%. 
The o r a l LD-,. of a 70:30 mix ture of ch loroacetamide and sodium benzoate was 
0.37 g/kg i n r a t s and 0.15 g/kg i n mice. The i n t r a p e r i t o n e a l LD of 
ch loroacetamide was 50 mg/kg; hydrop ic degenerat ion of the l i v e r of r a t s 
occurs w i t h i n 3 hours f o l l o w i n g an i . p . dose of 75 mg/kg. 
A 1% s o l u t i o n was not i r r i t a t i n g to the s k i n of guinea p i g s . 
S ing le patch t e s t i n g of 209 dermal p a t i e n t s w i t h 0.5% of the 70:30 mix tu re 
( con ta i n i ng 99% pure ch lo roace tamide , so lven t not mentioned) d i d not r e s u l t 
i n any sk in r e a c t i o n , even a f t e r exposure of seve ra l persons t o s u n l i g h t . 
In another s i n g l e patch t e s t w i t h 0 .1% aqueous s o l u t i o n of a s i m i l a r m ix tu re 
in 200 dermal p a t i e n t s , no sk i n reac t i ons were seen. Repeated a p p l i c a t i o n 
of t h e same s o l u t i o n d a i l y f o r 14 days to 10 hea l thy persons and t o 15 
persons w i t h a l l e r g y f o r benzoic a c i d , p-hydroxybenzoic ac id e s t e r , or 
Peruvian balsam, d i d not induce i r r i t a t i o n . 
Single patch t e s t i n g of 296 eczema p a t i e n t s w i t h 0.2% aqueous 
ch loroacetamide (99% pure) induced s k i n r eac t i ons i n 7 p a t i e n t s (2 .3%) . 
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Single patch tests with the 70:30 mixture of chloroacetamide (99% pure) and 
sodium benzoate did not induce irritation in 14 humans treated with 1%, in 
10 humans treated with 0.5% or in 102 humans treated with 1%. Daily patch 
testing of 25 subjects with 0.1 or 0.2% in formulations was likewise 
negative. 
A 5% aqueous dilution of the 70:30 mixture applied to the rabbit eye was 
found to be non irritating. 
A single application of a 10% solution/suspension to the rabbit eye induced 
redness of the conjunctivae in 1/4 animals. Slight redness was observed 
upon daily application of 1% in an ointment for 12 days. 
A similar response, however, occurred in controls treated with the ointment 
only. 
A 0.2% preparation was well tolerated in the eye of 5 humans. 
In a sensitization test by a modified Buehler method with the mixture of 
chloroacetamide (99% pure) and Na-benzoate (70:30) guinea pigs received 
topical induction treatments with 0.5 ml 0.3% in water, once a week, for 
3 weeks. After a 14-day rest period, a challenge treatment with 0.3% in 
water, did not induce any sign of sensitization. 
In a second sensitization test, a 1% aqeous solution of the mixture 
(containing the 99% pure compound) was painted on the skin of guinea pigs 
nine times every other day. After a 14-day rest period the same solution 
applied as a challenge treatment did not induce any positive response. 
A third test was conducted with 0.1% of the mixture in a skin cleaning 
formulation, by rubbing it into the intact and scarified skin of guinea pigs 
in an amount of 0.1 ml, three times weekly for three weeks. This induction 
treatment caused erythema and oedema. Since the challenge treatment with 
0.1 ml, 0.1% solution after 14 days did not produce more severe changes, the 
test substance was not considered a sensitizer. 
A fourth test conducted in a similar way, however, with a 1.0% (instead of a 
0.1) solution, also induced erythema and oedema. These findings were not 
considered the result of sensitizing properties. 
In a fifth test, guinea pigs were treated daily for 4 weeks with 1% and 3% 
of the pure compound in an aqueous mixture. The challenge treatment with 
0.2% after 10 days rest did not produce sensitization. 
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In a maximization test in guinea pigs with the 99% pure compound (using for 
induction a 9% aqueous concentration intradermally and a concentration of 9% 
in vaseline topically) a challenge treatment with 3, 1 and 0.3% in distilled 
water given after 14 days rest did not produce sensitization. 
A sensitization study was conducted in 147 humans by topical application of 
a 0.5% aqueous solution of chloroacetamide of unknown purity, on every other 
day for 3 weeks. The challenge, also with 0.5% after 14 days, consisting of 
two consecutive patch applications for 48 hours each (on the same site, but 
away from the induction site) resulted in a high incidence of sensitized 
subjects, viz. 19/33 females and 28/114 males. 
In another study in humans with 1.25% in a cream base used both for 
induction and challenge treatment, 35/205 subjects showed a positive 
response. 
Posit ive reactions were obtained with 2/18 humans treated with 0.18% in a 
cream. A pos i t i ve resul t was obtained also with 0.18% in water. In another 
patch test on 200 humans with 0.18% in a cream no pos i t i ve reactions 
occurred. 
In a 13-wk feeding study in rats with levels providing 12.5 and 50.0 mg/kg 
b.w./day, marked tes t i cu la r atrophy occurred at each dose l eve l . Increased 
weight of the thyro id was also observed (no fu r ther de ta i l s provided). A 
recent 90-day ora l study in rats was conducted with a 99.7% pure substance 
at levels of 0. 20, 100 and 500 mg/kg d i e t . The top-dose induced growth 
depression, increased leucocyte counts, reduced weights of t e s t i c l e and 
l i v e r , suppression of spermiogenesis and p r o l i f e r a t i o n of Leydig c e l l s . No 
treatment-related changes occurred with 20 and 100 mg/kg d i e t . 
Dermal treatment of rats with 12.5 and 50.0 mg/kg b.w. fo r 13 weeks did not 
induce gross or microscopical changes (no fur ther de ta i l s provided). 
Rats treated with an in t raper i tonea l dose of 20 mg/kg on day 7 of gestat ion 
or on day 11 and day 12 showed no signs of t o x i c i t y to the mothers or the 
foetuses (no fur ther de ta i l s were provided). 
Single administrat ion (route ?) of 50 mg/kg to pregnant rats did not a f fec t 
f oe ta l development (no fur ther de ta i l s were provided). 
Mutagenicity tests were conducted with the 70:30 mixture of chloroacetamide 
and Na-benzoate. An Ames test with up to 1000 ¿ig/plate was negative. 
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Chinese hamsters treated with up to 50 mg/kg intraperitoneally did not show 
chromosomal aberrations or an increased incidence of micronucleated 
erythrocytes. 
A dominant Lethal test in male mice treated intraperitoneally with 114 and 
123 mg/kg was Likewise negative. 
Chloroacetamide has shown considerable sensitizing potency in humans at 
concentrations in the range of those present in cosmetics. This property 
might be due to a contaminant in certain batches of the substance. 
However the Committee sees no objection to maintaining the use of this 
substance as a preservative in cosmetic products for the time being at a 
maximum level of 0.3%. 
Information : - Data sheet Council of Europe 
- Colipa dossier, Submission I, November 1984 
Submission II, June 20, 1985 
Submission III, September 13, 1985 
Submission IV, February 1986 
- Toxicol, appi. Pharmacol. 55 (1980) 273-280 
- Dermatologica (Basel) 144 (1972) 108 
- Contact Dermatitis 1 (1975) 265 
- Contact Dermatitis 7 (1981) 51 
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N° 23 3,4-Dichlorobenzyl alcohol 
Not used as preservative in cosmetic products. 
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N° 24 2,4-Dichlorobenzyl alcohol 
CH20H 
Cl 
C7H6C120 
MW : 177.04 
CAS N° 1777-82-8 
Synonym : Dybenal 
Poorly soluble in water (0.2%), soluble in organic solvents. 
used at levels up to 0.15%. 
The oral LD-« in rats was 3 g/kg; in male mice 2.3 g/kg. The subcutaneous 
LD,.- in mice was 1.7 g/kg. 
Preliminary studies in rabbits showed no eye irritation at 0.08% in aqueous 
solution, or 0.1% in propylene glycol (PG). Skin irritation studies carried 
out in a limited number of guinea pigs showed irritation with 5% and above 
in PG, but not with 1%. In preliminary rabbit studies repeated dermal 
application of 0.5% caused very slight erythema. On human skin (numbers of 
subjects not specified) no irritation occurred with 2.5% in a cream 
formulation on 8 successive days, although a stinging sensation was noticed 
if damaged skin was treated. 
Sensitization in guinea pigs was not induced with 2% in acetone, 0.1% in 
water or 2.5% in a cream formulation. 
A short-term (3-wk) oral study in rats with dose levels of up to 500 mg/kg 
b.w., and an incomplete, sub-chronic (13-wk) study with 0.36 and 0.72 mg/kg 
b.w. were negative. A short-term (4-wk) oral study in guinea pigs treated 
with 1.2 mg/kg bw/day for 4 weeks was likewise negative. 
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No mutagenic properties were found in tests with 5 strains of S.typhi muriurn 
and E. coli. 
A teratogenicity study in rabbits treated orally with 20 mg/kg/day was 
negative. 
Dermal absorption and excretion in rats was rapid, particularly when 
formulated in non-polar vehicles. Nearly 90% of the dermal dose applied was 
excreted in the urine over 96 hours. 
It was noted that mutagenicity tests had been made with the substance in a 
drug, containing other mutagenic agents. 
The Committee drew attention to the inadequate doses used in two oral 
studies and recommended that an oral study and a teratogenicity study be 
made at doses sufficiently high to demonstrate a possible effect. 
However the Committee sees no objection to maintaining the use of this 
substance as a preservative in cosmetic products for the time being at a 
maximum level of 0.15%. 
Information : Colipa dossiers. Submission I : October 1980 
Submission II : June 1982 
Submission III : April 1984 
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N° 25 Triclocarban (INN) 
,J V NHCONH 
C,,HoCl,N_0 CAS N° 101-20-2 
13 9 3 2 
MW : 315.59 
Synonym : 3,4,4'-Trichlorocarbanilide 
Poorly soluble in water, soluble in acetone. Used at levels up to 0.2%. 
The oral LD_n in rats was > 34.6 g/kg b.w. when given in corn oil and 
23.1 g/kg b.w. when given as a 5% soap solution. 
No skin- or eye-irritation was observed in rabbits with solutions of 2% in 
dimethylphthalate, or of 0.2% in soap. 
A sensitization test and a photosensitization test in guinea pigs, with 
0.05 ml of a 0.1% solution in oil was negative and no cross-sensitization 
with tetrachlorosalicylanilide was observed. 
An oral dose is excreted mainly in the faeces. Metabolism has been 
extensively studied in man and other species : o_ - hydroxysulfates and N and 
N' - glucuronides are formed. Blood levels of TCC and metabolites remained 
low in rats and humans, even upon rigourous oral or dermal exposure. 
Absorption through human skin in vitro was very low. 
Sub-chronic (90-day) toxicity studies did not reveal toxic effects upon 
daily oral treatment of monkeys with dose levels up to 300 mg/kg b.w., or 
upon dermal treatment of rats with dose levels up to 200 mg/kg. 
Two year feeding of rats revealed testicular atrophy at dietary levels of 
1.0 and 0.3%, but not at 0.1%. 
- 57 
In a reproduction study in rats 250 mg TCC/kg and more caused degenerative 
testicular changes, while 500 mg/kg and more also induced reduction of 
implantation sites. No changes were seen at 125 mg/kg. 
No teratogenic properties were found upon oral administration of 500 and 
1000 mg/kg in rats, and of 30 and 100 mg/kg in rabbits. Dermal treatment of 
rats and rabbits with 40 and 200 mg/kg was likewise negative. 
No dominant lethal changes were induced in mice treated intraperitoneally 
with levels up to 300 mg/kg. 
The available information does not suggest that the substance presents a 
considerable risk to humans. Since, however, trichloroazobenzene and 
trichloroaniline may be present as contaminants, information is desirable on 
the purity of the substance and on the identity of impurities. 
However the Committee sees no objection to maintaining the use of this 
substance as a preservative in cosmetic products for the time being. 
Information : - Data sheet by National Institute of Public Health, the 
Netherlands 
- British Library automated information service (BLAISE) 
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N° 26 4-Chloro-m-cresol 
OH 
CL 
CH, 
C7H?CLO 
MW : 142.59 
CAS N° 59-50-7 
Synonyms : - 4-Chloro-3-methyIphenoL 
- ChLorocresoL 
Poorly soluble in water (0.4%), f ree ly soluble in organic solvents. 
Use level up to 0.2% in a l l types of cosmetics except those for contact with 
mucous membranes. 
Oral LD,-n values fo r rats are ( in mg/kg) : 1830 and 5129 ( for males) and 
3636 ( for females). The s.c. LD_n fo r rats was 400 mg/kg. For mice the 
s.c. LD_n was 360 mg/kg, the i .V . LD_0 70 mg/kg. 
The substance was i r r i t a t i n g to the skin of rabbits when tested at 0.2 -
0.8% in aqueous so lu t i on . 
In an eye i r r i t a t i o n test in rabbi ts 0.1% was severely i r r i t a t i n g ; 0.05% 
produced s l i gh t changes. 
In an open epicutaneous'test (Klecak) in guinea pigs induct ion with 1 , 3 , 10 
and 30% in a polyethylene g lyco l (Lu t ro l ) and challenging with d i l u ted and 
pure substance did not reveal sens i t i za t ion react ions. 
However, when tested in the maximization test 25% was strongly sens i t i z ing 
and 1% was weakly sens i t i z i ng . 
In 252 normal human subjects, 10 induct ion treatments with 5, 10 and 20% and 
challenging a f te r 2 weeks with 5% in petrolatum did not produce 
sens i t i za t i on . 
- 59 -
In another test with 31 normal humans no positive reaction was seen after 
induction and challenging with a 5% concentration. 
From a Large number of observations in dermatological patients 0.3 - 0.6% 
showed positive sensitization reactions. 
Cases of cross sensitization with chloroxylenol have been reported. 
In a short-term (90-day) feeding study in rats with 0, 150, 500 or 1500 ppm 
in the diet slight growth retardation occurred with 500 and 1500 ppm. 
Haematology, clinical chemistry, organ weights and gross- and microscopic 
pathology showed no treatment-related changes. Therefore, 150 ppm was 
considered a no-toxic effect Level. 
In a short-term (3 weeks) dermal study 10 rabbits/sex/group received 15 skin 
applications at levels of 10, 40 and 160 mg/kg/day. Apart from gross and 
microscopic skin changes, there was no evidence of treatment-related 
systemic effects (only a summary report is available). 
An Ames test with up to 12.5 mg/plate was negative. 
In a micronucleus test in mice, 2 oral doses of 200 and 500 mg/kg b.w. given 
at an interval of 24 hours no changes were detected in the incidence of 
micronucleated erythrocytes. 
Upon oral administration (300 mg/kg b.w. of rats) the substance is rapidly 
absorbed and excreted mainly (54 - 95%) in the urine as unchanged compound 
within 24 hours. Two highly polar urinary metabolites were detected but not 
identified. No residues were detected in the liver during a 13-week feeding 
study, but very small amounts (up to 3 ¿ig/g) were found in fatty tissues. 
The substance is a severe eye irritant and possesses sensitizing properties 
in maximization tests in guinea pigs but is not significantly sensitizing in 
humans. It showed little systemic toxicity upon oral administration. No 
systemic effects were found when relatively high levels were applied 
derma ILy. 
The substance is used medicinally in multidose aqueous injection solutions 
at a Level of 0.1% without apparent ilL-effects. Mutagenicity tests were 
negative. Studies on possible effects on reproduction, or teratogenic 
properties are lacking, but the percutaneous absorption seems to be low. 
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However, the Committee sees no objection to maintaining the use of this 
substance as a preservative in cosmetic products for the time being at a 
maximum level of 0.2%. 
Information : - Data sheet Council of Europe 
- NIOSH data 
- Colipa dossier, September 1983 
- Data sheet National Institute of Public Health, the 
Netherlands 
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N° 27 Halocarban (INN) 
C,.HoCl,F:.N-0 CAS N° 369-77-7 
14 9 2 3 2 
MW : 349.15 
Synonyms : - 4 ,4 ' - d i ch lo ro -3 - ( t r i f l uo rme thy l ) carbani l ide 
- Clofucarban 
- Irgasan CF3 
Insoluble in water, soluble in organic solvents. 
Used in cosmetics up to a level of 0.3%. 
The acute, oral LD_0 in rats is > 5 g/kg. The i.v. LD50 in rats is 29 
mg/kg. 
No skin irritation was observed in rabbits, and eye irritation was slight. 
No sensitization or Local effects were seen in guinea pigs upon repeated, 
dermal application of 0.1% suspensions. 
Repeated application (12 weeks, 5 times/week) of 0.1 - 0.5% solutions to the 
skin of rats did not cause irritation, and no microscopical changes of the 
internal organs were found. 
A metabolic study has been reported : the metabolite found was glucuronide. 
On the basis of the above information an evaluation is not possible, but the 
substance is no longer used as preservative in cosmetic products. 
Information : Data sheets Council of Europe 
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N° 28 Triclosan (INN) 
,-f V.-/ V . 
'CL OH 
C 1 2 H ? C L 3 0 2 CAS N° 3380-34-5 
MW : 289.55 
Synonyms : - 2,4,4 '-Tr iehLoro-2 ,-hydroxy-diphenylether 
- Irgasan DP 300 
PoorLy soluble in water; readi ly soLubLe in organic solvents. 
Use level : 0.5%. 
The acute oraL and dermaL t o x i c i t y is Low (LD > 4 g/kg in severaL 
species). However, the acute intravenous LD_Q in rats and mice is 29 and 19 
mg/kg respectiveLy. The dermaL LD_Q in rabbi ts is 9.3 g/kg. 
The substance possesses considerabLe i r r i t a t i n g potency for the skin and 
mucous membranes at concentrations above the use LeveL of 0.5%. SoLutions 
of 0.3 - 0.5% in aLcohoL have been found to cause dermat i t is in man on 
repeated app l i ca t ion . 
No sens i t i z ing or photosensi t iz ing propert ies were observed in guinea pigs 
or humans. 
Absorption through the skin and the i n t e s t i n a l waLL is considerabe in 
severaL animaL species. Up to 10% dermaL absorption was found in man. The 
absorbed substance is excreted pa r t l y as glucuronide. 
Sub-chronic o ra l studies revealed l i ve r changes at exposure Levels higher 
than 125 mg/kg in rats and 25 mg/kg in dogs, but no tox ic ef fects were seen 
in other studies in r a t s , dogs, rabbits or monkeys at dose Levels of 
respect ively 160, 25, 138 and 3 mg/kg b.w. 
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Upon chronic dermal treatment of mice with c. 0.5 - 1.0 mg/mouse 3 
times/week the incidence of certain tumours was slightly higher in test 
animals than in controls. This finding was not considered significant. 
Teratogenicity studies in mice, rats and rabbits with oral dose levels up to 
100 mg/kg were negative. This level was negative also in a one generation 
reproduction study in rats. 
No mutagenic properties were detected with 1500 mg/kg in a dominant lethal 
assay in mice in screening tests for chromosome abnormalities in Chinese 
hamster cells, or in the in vivo test for somatic mutations (spot test) in 
mice treated i.p. 
The use of this substance as preservative in cosmetic products at a maximum 
level of 0.3% can be permitted. 
Information : - Data sheet National Institute of Public Health, 
the Netherlands 
- T0XLINE (HEEP and IPA) 
- Data sheet Council of Europe 
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N° 29 Dichlorophen (INN) 
CH. 
C13H10C L2°2 
MW : 269.12 
CAS N° 1215-74-3 
Synonym : 5 , 5 ' - D i c h l o r o - 2 , 2 ' - d i h y d r o x y d i p h e n y l m e t h a n e 
Poor ly s o l u b l e i n w a t e r , r e a d i l y s o l u b l e i n e thano l and e t h e r . 
Use i n cosmetics up to a l e v e l of 0.5%. 
The acute o r a l t o x i c i t y (g /kg ) i n r a t s was 2 . 6 9 , i n mice 1 .0 , i n dogs 2 .0 
and i n guinea p igs 1.25. The in t ravenous L D „ i n r a t s was 17 mg/kg. 
Skin i r r i t a t i o n i n r a b b i t s was m i l d by app ly ing 0.5 g , but eye i r r i t a t i o n 
was severe w i t h 0.05 mg. 
S e n s i t i z i n g p r o p e r t i e s have been r e p o r t e d , as w e l l as cross s e n s i t i z a t i o n 
w i t h hexachlorophene. 
Rad ioac t i ve s t u d i e s i n the ra t showed 75% absorp t i on over two days f o l l o w i n g 
o r a l a d m i n i s t r a t i o n , w i t h ex tens i ve me tabo l i t e con juga t i on as g lucuron ide 
and s u l p h a t e . 
Eva lua t ion i s not p o s s i b l e on t he bas is of the a v a i l a b l e i n f o r m a t i o n , but 
the substance i s no longer used as p r e s e r v a t i v e i n cosmetic p roduc t s . 
I n f o rma t i on : - Data sheet Counc i l o f Europe 
- R e g i s t r y of Toxic E f f e c t s of Chemical Substances 1978 
- CBAC 
65 
N° 30 N-(Trichloromethylthio)cyclohex-4-one-1,2-dicarboximide (Captan-ISO) 
N-S-CCL. 
C9HgCL3N02S 
MW 300.57 
CAS N° 133-06-2 
Synonyms : - Captan 
- Vanei de 89 
Practically insoluble in water, sparingly soluble (0.2 - 0.3%) in ethanol 
and other solvents. 
The technical grade product (Vancide 89) is used as an agricultural 
fungicide, the purified product (Vancide 89 RE) as preservative in cosmetics 
and topical pharmaceuticals. 
Used in cosmetics up to 0.06%. Not used for products in contact with mucous 
membranes. 
Oral LD5_ values for rats are 2.65, 9.0 and 12.5 g/kg; for mice 6.5 and 7.0 
g/kg, for rabbits 2.0 g/kg. Intraperitoneal LD^- values for rats are 
between 25 and 100 mg/kg, and for mice 462 mg/kg. 
A skin irritation test in rabbits with a formulation (containing captan 
0.25 g, propylparaben 0.50 g, distilled water 10.0 g and Tween 20 89.25 g) 
was negative. Daily application of this mixture to the skin (2 ml/kg) b.w. 
for 90 days did not induce dermal changes. 
In an eye irritation test in rabbits the same formulation was slightly 
i rritating. 
A maximization test in guinea pigs with this formulation did not provide 
evidence of sensitization. 
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A photosensitization test in guinea pigs with the formulation by the method 
of Vinson and Borsetti was negative. 
Sub-acute (21-day) dermal treatment of rabbits with the formutation in an 2 amount of 12 mg/cm over an area of 15 x 20 cm dai ty on 5 days a week did 
not adversely affect body weights/ food intake, haematology or urine 
parameters. Mild erythema occurred at the treated skin sites. No 
pathological changes were observed. 
An oral dose is well absorbed from the intestinal tract and rapidly 
metabolized and eliminated, mainly in the urine. Several degradation 
products have been identified, e.g. thiophosgene. 
14 Dermal absorption in rats treated with 0.5 or 5 mg of the C-tabelted 
compound in aqueous medium varied between 6.4 and 9.0% within 2 - 4 hours 
after application. There were no significant differences in mean percent 
absorption between doses. 
In a multigeneration study in rats technical captan was fed in the diet at 
levels providing 0, 25, 100, 250 or 500 mg/kg b.w./day. Pregnancy rate and 
pup survival were reduced at 250 and 500 mg. Growth depression and 
reduction of litter size and pup weight occurred at all dose levels. This 
study did not provide a no-effect level. 
A teratogenicity study (conducted with the third litter of the F ..-parent 
animals of the above reproduction study) failed to reveal any effect on 
incidence of foetuses or litters with malformations. 
Inhalation exposure of mice to 488 mg/m during 4 hr/day, from day 6 - 13 of 
gestation, did not induce malformed foetuses. Similarly no teratogenicity 
was observed in mice treated orally with 100 mg/kg b.w./day. 
Hamsters treated orally with 50, 100, 200, 300 or 400 mg/kg b.w. showed 
growth depression at 300 and 400 mg/kg but no teratogenicity or other signs 
of maternal or embryonic toxicity. 
In another oral hamster study with 50, 200 or 400 mg/kg b.w./day of the 
technical product, the top-dose group showed maternal weight loss, reduced 
litter size and foetal weight, and an increase in resorptions. With 200 
mg/kg maternal weight gain and foetal weight were depressed. A slight 
increase in a foetal rib abnormality was dose related. 
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An oral teratogenicity study in rabbits with 6, 12, 25 or 60 mg/kg of the 
technical substance showed signs of maternal toxicity at 12 mg/kg and above. 
There were no indications of embryonic toxicity or teratogenicity. In a 
second rabbit teratogenicity study dose Levels of 18.75, 37.5 and 75.0 mg/kg 
body weight were administered orally by gelatin capsule. No signs of 
teratogenicity were seen even at dose levels showing maternal and foetal 
toxicity (I.B.T.-study). 
Groups of at least 7 Rhesus monkeys were orally treated with 10, 25 or 75 
mg/kg from day 21 - 34 of pregnancy. There were no signs of maternal or 
foetal toxicity or of teratogenicity (I.B.T.-study). 
Pregnant beagle dogs received captan in the diet throughout the gestation 
period at levels providing 30 or 60 mg/kg b.w. No deleterious or 
teratogenic effects were observed (I.B.T.-study). 
An oral carcinogenicity study was conducted in mice which received 215 mg/kg 
b.w. daily from an age of 7 day until weaning, and then 560 ppm in the diet 
for 18 months. No significant increases in tumour incidence was seen (IARC 
1983). 
A second mouse carcinogenicity study with dose levels of 8000 and 16000 ppm 
in the diet for 80 weeks showed a small, though dose related and 
statistically significant increase in duodenal adenocarcinoma (IARC 1983). 
A chroçnic feeding study in rats with 4000 and 8000 ppm in the diet (later 
changed to 2000 and 4000 ppm, and in the final 33 - 34 weeks of the study to 
diets not containing the test substance) revealed slight increases in 
adenomas of the thyroid and adrenals which were considered unrelated to 
treatment (IARC 1983). The results of the latter carcinogenicity studies in 
mice and rats have been confirmed in other studies with a different strain 
of rats and mice (Lowy, 1985). 
A large number of mutagenicity studies has been performed. The results have 
been summarized by IARC (1983) as follows : 
"Captan was mutagenic to bacteria and yeast. Both positive and 
negative results were obtained in the host-mediated assay in mice. 
Weak or negative effects were observed in Drosophila melanogaster. 
Captan induced chromosomal aberrations, sister chromatid exchange and 
mutations at several loci, but not unscheduled DNA synthesis in 
cultured mammalian calls. No increase in micronucleated erythrocytes 
or chromosomal aberrations was detected in treated mice or rats; 
positive results obtained in dominant lethal tests in mice and rats 
were not confirmed by other studies. Thus, there is sufficient 
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evidence to establish the mutagenicity of captan in cellular systems, 
but the data were insufficient to establish its mutagenicity in 
mammals". 
The ADI for Captan as a pesticide residue in foods has been set at 
0.1 mg/kg b.w./day. The use of the substance in cosmetics, even at the 
reduced maximum level of 0.06%, could Lead to a human exposure, considerably 
higher than the maximum considered acceptable from its use in agricultural 
crops. In addition to the possible carcinogenicity this substance was 
rejected on other toxicological characteristics. 
Information : - Colipa dossier, September 1984 
- Colipa submission II, September 1985 
- FA0/WH0, Pesticide residues in food : 1982 evaluations 
- IARC Monograph 30 (1983) 
- WHO Pesticide Residues Series No. 3 (1974) 
- R. Lowy, C.S.C/477/85, Nov. 1985 
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N° 31 Chlorhexidine (INN) and i ts digluconate, diacetate and 
di hydrochloride 
CI (' V —NH-C-NH-C-NH(CH2)6-NH-C-NH-C-NH— (/ X) c l 
II II ¿ ° II II 
NH NH NH NH 
C 22 H 30 C L 2 N 10 CAS N° 5 5 ~ 5 6 " 1 
MW : 505.48 
Synonym : 1,6-di-(N-p-chlorophenyl-N'-diguanide)-n-hexane 
Poorly soluble in water, insoluble in organic solvents and fats. 
Use level : 0.5%. 
The oral LD,-n in rats and mice is relatively high (c. 2 g/kg), but the i.V. 
LDcn is much lower (c. 25 mg/kg). Values for the acetate and the gluconate 
were comparable. 
Eye injury was found by EM examination of rabbit eyes treated with aqueous 
solutions of the gluconate at concentrations of 0.1% and higher. 
Despite extensive use in man, sensitization has not been a problem. 
A sub-chronic (90-day) oral study in rats with levels up to 0.3% 
chlorohexidine gluconate in drinking water revealed infiltration of 
lymphocytes and vacuolation in several organs, and giant cells in testicles 
and lymphnodes. 
Similar changes were seen in a rat study with the acetate. The no-effect 
level was 50 mg/kg b.w. 
A sub-chronic (90-day) dermal study in monkeys, bathed daily with a skin 
cleanser containing twice the normal level of Chlorhexidine gluconate and 
subsequently rinsed with water, was negative. After 8 weeks of treatment no 
Chlorhexidine was found in the blood (11 µg/l) which may indicate very low 
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dermal absorption. Trace amounts were, however, present in some organs and 
in faeces which might be due to grooming. Microscopy of selected organs 
revealed no changes attributed to treatment. 
In a one-generation reproduction study in rats, 44 mg/kg b.w. (in drinking 
water as the gluconate) induced growth retardation and increased pup 
mortality; 5 mg/kg was without effect. No teratogenic potency was observed 
with dose levels of Chlorhexidine (as base) up to 50 mg/kg by gavage, but 
oral absorption is very poor. 
A chronic oral rat study with the gluconate in the drinking water, revealed 
histiocytes in mesenteric lymphnodes at all dose levels (5, 25 and 
50 mg/kg b.w.) 
Mutagenic properties of Chlorhexidine were established in an Ames test. A 
positive effect was found also in a DNA-repair test with E. coli. 
However, in a micronucleus test in mice two intravenous applications of up 
to 2 x 30 mg/kg (the maximal tolerated dose) did not increase the number of 
polychromatic erythrocytes containing a micronucleus. 
There is only a small margin between potential dermal exposure of humans and 
the lowest oral exposure that induced lymphatic histiocytosis in the chronic 
rat study. For this reason information on dermal absorption in man is 
urgently required. 
In view of the positive results obtained in two mutagenicity tests in 
microbial systems, a chromosomal aberration test on mammalian cells in vitro 
is requested. 
However, the Committee sees no objection to maintaining the use of this 
substance as a preservative in cosmetic products for the time being at a 
maximum level of 0.3%. 
Information : - Data sheet National Institute of Public Health, 
the Netherlands 
- Toxicol, appi. Pharmacol. 52 (1980) 255-261 
- Co li pa dossier January 24, 1984 
- BLAISE and T0XLINE 
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N° 32 4-chLoro-3 /5-xyLenoL 
CgHçCLO 
MW : 156.61 
CAS N° 88-04-0 
Synonym : p-Chloro-m-xyLenoL (PCMX) 
Poor ly so lub le i n water (0 .05%) , s o l u b l e i n e t h a n o l . 
Readi ly so lub le i n o ther organ ic s o l v e n t s . 
Use l e v e l : 0.5%. 
The o r a l LD_0 i n r a t s and mice i s c . 3 g / k g . The dermal LD5Q i s 3 g / k g . 
Recovery has occurred a f t e r i n g e s t i o n of 15 g i n man. 
Marked eye i r r i t a t i o n occurred i n r a b b i t s t r e a t e d w i t h a 30% s o l u t i o n i n 
propylene g l y c o l , and moderate eye i r r i t a t i o n was n o t i c e d w i t h 2% i n a 
shampoo. A 2% e thano l s o l u t i o n p a t c h - t e s t e d i n humans n e i t h e r caused s k i n 
i r r i t a t i o n nor s e n s i t i z a t i o n . 
Shor t - te rm (21 day and 90-day) dermal t o x i c i t y was examined i n r a b b i t s by 
d a i l y a p p l i c a t i o n of 1.0 ml 1.8% or 18% in propylene g l y c o l t o the abraded 
sk in f o r 21 days, or t o the i n t a c t sk i n f o r 90 days. Skin i r r i t a t i o n was 
s l i g h t i n t h e low-dose animals and cons ide rab ly more marked i n the h igh dose 
an imals . In t h i s respect no d i f f e r e n c e between i n t a c t and abraded sk i n was 
n o t i c e d . There were no t r e a t m e n t - r e l a t e d d i f f e r e n c e s between groups i n 
growth r a t e , haematology, u r i n e composi t ion or i n gross or microscopic 
pa tho logy . 
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In a sub-chronic (13-week) oral toxicity study in rats, 0, 1.2, 60 or 
120 mg/kg b.w. were applied daily as an aqueous emulsion. Salivation 
occurred upon dosing. There was transient growth retardation in the mid-
and top-dose groups. The top-dose group showed various haematological 
changes, impaired renal function, and increased weights of the liver and 
kidneys, not associated with microscopical changes. Increased kidney 
weights occurred also in the mid-dose group (summary report only). 
The same Levels as used in the 13-week rat study were administered by gavage 
in a 13 week dog study. There were no deleterious effects on body weights, 
haematology, or clinical chemistry. Total reducing substance in the urine 
was increased at the two high dose levels. Increased liver weights not 
accompanied by histological changes, occurred in all dose groups (summary 
report only). 
When applied to the skin of humans the substance is absorbed, and shows 
prolonged circulation in the blood at a low level, of generally 
<C\ mg/100 ml. 
An Ames test with only LO^g/plate was negative. 
The summarized reports of the 13-week oral studies in rats and dogs suggest 
that the no-toxic effect level may be around 1 mg/kg b.w. However, 
considerably higher doses (18 mg/kg) did not induce overt signs of toxicity 
upon dermal administration to rabbits for 13 weeks. The Committee wishes to 
examine the detailed reports of the 13-week oral studies and also to see the 
results of an Ames test carried out with higher doses. 
However, the Committee sees no objection to maintaining the use of this 
substance as a preservative in cosmetic products for the time being at a 
maximum level of 0.5%. 
Information : - Data sheet Council of Europe 
- Co Li pa dossier, September 1983 
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N° 33 2,4-Dichloro-3,5-xylenol 
C8H8CL2° 
MW : 191.06 
CAS N° 133-53-9 
Poorly soluble in water, soluble in organic solvents. 
Use in cosmetics up to a level of 0.1%. 
The only toxicological information available is an oral LD_n in rats 
(3.94 g/kg) and in mice (6.0 g/kg). 
No opinion can be expressed because of a lack of data, but the substance is 
no longer used as preservative in cosmetic products. 
Information : Data sheet Council of Europe. 
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N° 34 Qu ino l i n -8 -oL and i t s s a l t s 
OH 
y^-N^ 
C9H7N0 
MW 145.15 
CAS N° 148-24-3 
Synonyms : - 8 -Hydroxyqu ino l ine 
- OxychinoLine 
- Oxine 
Hydroxyquinoline is insoluble in water and ether, slightly soluble in other 
organic solvents; the sulphate dissolves well in water. 
Used in cosmetics at dose levels of 0.3%. 
LD50 values reported are : oral in rats 1200 mg/kg, in guinea pigs 
^ 1 . 2 g/kg for the free base; i.V. in mice 50 mg/kg, in rabbits 65 mg/kg 
for the free base; s.c. in mice 25 mg/kg, in rats 200 mg/kg for the 
sulphate; i.p. in mice 43 mg/kg. 
Sensitizing properties have been reported from studies in man. 
Oral administration to dogs resulted in rapid intestinal absorption and 
renal excretion and slow excretion with the bile. 
Intravenous treatment of rabbits with a single dose of 8-hydroxyquinoline in 
amounts of 10 - 50 mg/kg resulted in destruction of the ß-cells in the 
pancreas and increased blood glucose levels. Pancreatic damage was observed 
also in several other species upon i.v. administration. 
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Feeding rats 400 mg/kg b.w. for 16 weeks caused hemosiderosis in the liver 
and spleen. In another rat feeding study hepatotoxicity and renal toxicity 
occurred on diets providing 100-250 mg/kg b.w. for 30-40 days. 
In 1977 IARC examined several carcinogenicity studies in mice and rats 
conducted by oral, subcutaneous and intravaginal administration, and in mice 
by skin application and bladder implantation. These studies were considered 
of limited value for various reasons and no evaluation could be made of the 
carcinogenicity of this substance. Meanwhile further longterm studies were 
conducted and reported recently by NTP (1985). Groups of 50 rats/sex and of 
50 mice/sex were fed diets containing 0, 1500 and 3000 ppm of the test 
substance. The top-dose groups showed relatively low body weights. No 
significant differences in mortality occurred between groups in either 
species. Extensive gross and microsopic pathology did not reveal 
treatment-related changes and there was no evidence of carcinogenic 
properties. Haematological and clinical examinations were not conducted. 
The substance showed mutagenic properties in the Ames test. A test on 
induction of aneuploidy in Neurospora crassa was equivocal. Chromosome 
aberrations were observed in root tips of Vicia faba, and in bone marrow 
cells of mice after i.p. injection of 40 mg/kg b.w. Equivocal or 
inconclusive results were obtained in a variety of other short-term tests 
such as a Drosophila test, a micronucleus test in mice and a chromosome 
aberration test in human leucocytes in vitro. 
No information is available on skin or eye irritation, on dermal toxicity or 
on dermal absorption. Information on reproductive effects or teratogenicity 
is also absent. The substance seems to be relatively harmless because 
1500 ppm in the diet of rats (75 mg/kg b.w.) and in the diet of mice 
(150 mg/kg b.w.) was a no effect Level. These substances are no longer used as 
preservatives in cosmetic products. 
Information : - Data sheet National Institute of Public Health, 
the Netherlands 
- IARC Monograph 13 (1977) 101-112 
- NTP Technical Report series No. 276, April 1985 
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N° 35 1 ,3 ,5 -Tr is (2 -hydroxyethy l )hexa-hydro-1 ,3 ,5 - t r ias ine 
CH2-CH2-OH 
HO-CH2-CH2-Nv^ ^N-CH 2 -CH 2 -OH 
C9H2 1N303 
MW : 219.28 
CAS N° 4719-04-4 
Synonyms : - Tr i - (ß-hydroxyethyl ) -hexahydrotr iaz ine 
- Grotan BK 
Easi ly soluble in water; soluble in e thanol , acetone, chloroform. 
Used in cosmetics at dose levels of 0.3%. 
The ora l LDS_ was 0.37 ml/kg in mice. For rats ora l LD,-n values of 
0.46 ml /kg, 0.58 ml /kg , and 316 mg/kg are reported. The acute dermal LD 
was c. 0.5 ml/kg in the rabb i t . 
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The undiluted substance induced severe erythema and slight oedema of the 
skin of rabbits. Slight erythema and oedema were seen also with aqueous 
dilutions of 1.0 and 0.1%. No local effects were seen, however, in patch 
tests with 80 humans receiving 0.05 ml of concentrations varying from 0.05 
to 1.0%. 
Severe eye irritation occurred in rabbits with 0.1 ml of the undiluted 
substance. No deleterious effects were, however, observed if the eye was 
washed out 2, or 4 seconds after instillation of the test substance. 
No sensitization was observed in guinea pigs treated with 0.043 mg/day 
during the induction period and with 5 mg as the challenge dose. 
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Single dermal treatment of rabbits with 1 or 2 ml undiluted substance/kg 
body weight for 24 hours killed the animals. With 0.5 ml/kg damage of liver 
and lungs was observed. In a subsequent study in which rabbits received a 
single dermal treatment of 7 ml/kg of 0.1% or 1.0% dilution of the test 
substance either in water, in paraffin oil or in emulsions of oil in water 
or of water in oiI, there was no mortality and no systemic effects were 
seen. 
In a 90-day study in rats with various feeding levels up to 5400 ppm, high 
mortality occurred in all groups, but no significant treatment-related 
changes were observed. The study showed several deficiencies. 
No indications of mutagenic properties were obtained in a micronucleus test 
in rats treated by gavage, by dermal administration and by subcutaneous 
injection with various dose levels up to 960 mg/kg per 2 administrations. 
This substance shows considerable toxicity, irritant properties and dermal 
absorption. On the basis of available information evaluation is not 
possible. 
The Committee wishes to obtain additional data on short-term oral toxicity, 
and on eye irritation with dilutions below 1%. Information on 
teratogenicity is also requested. 
Information : - Data Sheet National Institute of Public Health, 
the Netherlands 
- Colipa dossier, Partial submission (1), September 1983 
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N° 36 S^'-Bisd-hydroxymethyl^^S-dioxoimidazol id in^-yU-l , ! ' -
methyLenediurea ("Imidazolidinyl urea") 
:OCH2-N : 
9N 
C - NH NH - i 
, C - C H - N H - C - N H - C H 2 - N H - C - N H - C H - C 
\ 
N - CH2OH,H20 
\ 
C11H16N8°8 
MW : 406 
CAS N° 39236-46-9 
Synonyms : - Germa LI 115 
- Euri II K 200 
Soluble in water, propylene glycol, glycerine 
Used in cosmetics at dose levels of 0.1 - 0.6%. 
The acute toxicity of the substance is low : the oral LD-,, in rats and mice 
is > 5 g/kg, the i.V. LD_n in rats and mice is c. 0.8 g/kg, the acute 
dermal toxicity in rabbits and guinea pigs > 2 g/kg. 
Skin irritation tests with aqueous solutions of 5% in rabbits, and 10% in 
humans were negative. No phototoxicity was observed with solutions up to 5% 
in guinea pigs. 
Intracutaneous injections of 0.1% saline solutions in guinea pigs did not 
provoke sensitization. Tests in man with concentrations up to 10% and with 
as many as 200 subjects provided little or no evidence of sensitization. No 
photoallergic sensitivity was observed in women after using formulations 
with 0.5% of the test substance daily for 4 weeks. 
Eye irritation was not observed in rabbits with aqueous solutions up to 20%. 
In the form of a fine white powder the substance produced mild transient 
conjunctival irritation. 
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Sub-acute (25-day) oral treatment of rats with 0.5% in drinking water 
produced no evidence of toxicity. 
Sub-acute dermal treatment of rabbits (6 h/day, 5 days/week, for 3 weeks) 
with dose levels up to 200 mg/kg/day of the undiluted substance only 
resulted in slight irritation. There was no effect on growth, haematology, 
urinalysis or gross pathology. 
Sub-chronic (90-day) dermal treatment of rabbits with 200 mg/kg/day of the 
compound as a 10% aqueous solution over 10% of the total body surface 
produced local skin changes (acanthosis, hyperkeratosis, and intradermal 
infiltration of inflammatory cells). There were no abnormalities in 
haematology, blood biochemistry, urinalysis, organ weights, or gross and 
microscopic pathology. 
Sub-chronic (90-day) feeding of the test substance in the diet of rats at 
levels providing 0, 6, 28, 130 or 600 mg/kg b.w./day, induced growth 
retardation of males in the 28, 130 and 600 mg/kg groups. Haematology, 
biochemistry, urinalysis and pathology revealed no toxicity. Similar 
results were obtained in a 90-day rat study with 0.5, 1.0 or 2.0% in the 
drinking water, but growth depression occurred in the top-dose group, which 
ingested 1300 mg/kg/day. 
A teratogenicity study in mice treated by gavage with 0, 30, 95 or 
300 mg/kg/day from day 6-15 of gestation increased the number of resorptions 
and/or fetal deaths but the number of abnormalities in either soft or 
skeletal tissue was not affected. 
An Ames test with up to 0.5 mg/plate with and without metabolic activation 
was negative (no detailed report is available). 
The available information suggests the substance to be of relatively low 
toxicity. Details of the Ames test carried out are required and a 
chromosome aberration test in mammalien cells in vitro. 
However, the Committee sees no objection to maintaining the use of this 
substance as a preservative in cosmetic products for the time being at a 
maximum level of 0.6%. 
Information : - Final report of the safety assessment of imidazolidinyl 
urea. J.Environm. Pathol. Toxicol. 4 (4) 1980, 133-146 
- Data sheet National Institute of Public Health, 
the Netherlands, March 1981 
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Colipa dossier, Submission I : 18.1.1981 
Colipa dossier, Submission II, March 1984 
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N° 37 4-Isopropyl-m-cresol 
OH 
I 
i 
HC. 
I 
CH, 
CH, 
C10H14° 
MW : 150 
CAS N° 3228-02-2 
Synonyms : - 3-MethyL-4- (1-methy le thyL)-phenoL 
- 4-isopropyl-3-methylphenol 
- O-cymen-5-oL 
Slightly soluble in water, and freely soluble in most organic solvents. 
Used in all types of cosmetics at dose levels up to 0.1%. 
Oral LD5_ values in mice are > 2.2, 2.25 and 1.1 g/kg, the i.p. LD 
mice was 0.47 g/kg. 50 
in 
Skin irritation in rabbits with 5% in polyethylene glycol was minimal, and 
with 1% in vaseline absent. In guinea pigs skin irritation with 10% in 
ethanol was minimal. No skin irritation was seen in a human patch test with 
0.5% in polyethylene glycol, or with 1% in vaseline. 
An eye irritation test in rabbits with 0.1% in propylene glycol produced 
slight effects only during the first few hours after treatment. With 1% in 
vaseline only very slight redness of the conjunctivae occurred. The eye 
irritating potential is very low. 
In a maximization test, guinea pigs received induction treatments with 20% 
in acetone. Upon the challenge treatment with 0.1, 1.0, 5.0 and 10% in 
acetone the incidence of positive reactions was 0/10, 0/10, 1/10 and 3/10 
respectively. It was concluded that the sensitizing potential was very low. 
A maximization test in 27 healthy humans with 5 induction exposures to a 1% 
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concentration and a challenge treatment with 0.1% in both vaseline and cream 
bases (after treating the test sites with 5% sodium lauryl sulphate) did not 
produce any positive reaction. 
Repeated intraperitoneal injections of mice with up to 300 mg/kg/day in an 
oil/water emulsion did not induce mortality. Higher levels caused asphyxia 
and death. 
Feeding the substance in the diet of mice at dose Levels up to 80 mg/animal 
for 30 days caused intoxication and mortality with 50 mg/animal and more. 
No toxicity was noted with 30 mg/animal or less ( ^ 1200 mg/kg b.w./day) 
(only a summary report is available). 
A 90-day feeding study was conducted in mice with 1, 10, 100 or 200 mg/100 g 
(it is not mentioned whether the levels are expressed per 100 g diet or per 
100 g body weight). The two highest levels caused growth retardation. It 
is stated that there were no changes in survival, haematology, biochemistry, 
urine composition, or in gross or microscopic pathology (Summary report 
only). 
No mutagenic properties were observed in an Ames test, or in a test with 
E.coli at levels of up to 800 ¿ig/plate. 
In a 6-month rat study with test groups of 4 animals, daily administration 
of 0.05, 01, 0.5 or 1.0 g/kg by gavage, was without effect (Summary report 
only). 
No detailed reports are available of the feeding studies, which were 
conducted around 1955 in Japan. 
A well-conducted, short-term, oral study in rats is desirable, as well as further 
information on mutagenicity. Information on percutaneous absorption is also 
sought. In the light of these data the necessity, if any, for further 
studies can be determined. 
However, the Committee sees no objection to maintaining the use of this 
substance as a preservative in cosmetic products for the time being at a 
maximum level of 0.1%. 
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Information : - Data sheet Council of Europe 
- Colipa dossier, September 1983 
- Colipa dossier, April 1985 
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N° 38 2 -Ch lo ro-N- (hydroxymethy l ) acetamide 
CLCH2 - C - NH - CH2OH 
C,H,CLN0o CAS N° 2832-19-1 
j o c 
MW : 123.54 
Synonyms : - N-Methy lo lch loroacetamide 
- Grötan HD2 
- Parmesol P 35 
A c l ea r c o l o u r l e s s l i q u i d . I t i s used i n concen t ra t i ons up to 0.4%. 
LD s n : o r a l : Mouse, 360 mg/kg 
Rat , 1.28 ml /kg (as 10% v / v aqueous s o l u t i o n ) 
dermal : R a b b i t , 2 .8 - 5.5 ml /kg as 10% aqueous v / v s o l u t i o n w i t h 
o c c l u s i o n f o r 24 h r s . M o r t a l i t y occurred i n th ree out of 
f ou r r a b b i t s t r e a t e d w i t h 5.5 m l / k g , but no deaths occur red 
w i t h 2 .8 mg/kg. Post-mortem gross and h i s t o l o g i c a l 
examinat ion showed dose - re l a ted changes i n s k i n o n l y ; L i v e r , 
k idney and hear t were normal . 
Patch t e s t s i n man were c a r r i e d out on 50 sub jec ts w i t h va r ious f o r m u l a t i o n s 
c o n t a i n i n g 0.2% of t he subs tance; these were n e g a t i v e . In another patch 
t e s t , w i t h o c c l u s i o n , c a r r i e d out i n 100 s u b j e c t s , 0.15% gave no r e a c t i o n i n 
99 ; one sub jec t showed a m i l d r e a c t i o n . In a s i m i l a r s t u d y , a lso on 100 
s u b j e c t s , t h e substance i n concen t ra t i ons of 0 . 0 8 , 0 . 1 2 , 0.05 ( s i c ) and 0 .1% 
had no adverse e f f e c t . 
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It is noted that 2-chloroacetamide is a relatively powerful skin sensitiser. 
Some of the N-substituted congeners are irritant to the skin and are 
absorbed by the percutaneous route. Systemically they have been noted to be 
toxic to the liver and kidney. They also exhibit central nervous system 
toxicity. 
No opinion can be expressed because of a lack of data, but this substance is 
no longer used as preservative in cosmetic products. 
Information : Data sheet Council of Europe 
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N° 39 1 -Hyd roxyme thy l -5 ,5 ' - d ime thy l -hydan to in 
CH20H 
3 V ' \^° 
H 3 C / \ 
0 
/ 
NH 
C6H10N2°3 C A S N ° 2 8 4 5 3 - 3 3 - 0 
MW : 158.16 
Synonym : Monomethy LoL—di met h y l - h y d a n t o i n 
Th is compound l i b e r a t e s fo rmo l at pH 6 , which ac ts as p r e s e r v a t i v e . On 
h e a t i n g , the formol combines w i t h the parent compound t o form a polymer 
which has p r o p e r t i e s s u i t a b l e f o r use as a h a i r lacquer . 
No data on animal exper iments have been p resen ted . 
In t he data p r o v i d e d , i t has been assumed t h a t the t o x i c i t y of the compound 
i s due on l y to f o r m o l . Formol i s s t a t e d t o be very i r r i t a n t , and a potent 
s e n s i t i s i n g agent . I t i s a p o t e n t i a l pulmonary carc inogen. 
S e n s i t i s a t i o n occurs i n about 5% of human sub jec ts when exposed to f o r m a l i n , 
an aqueous s o l u t i o n of 37% f o r m o l . I n sub jec ts a l ready s e n s i t i s e d t o 
f o r m o l , i r r i t a t i o n i s found w i t h s o l u t i o n s of f o r m a l i n of 0.01% t o 1.0% 
( e q u i v a l e n t t o an aqueous s o l u t i o n of fo rmol of 0.0037% t o 0.37%, or 
3 7 / j g / m l to 3.7 mg/ml ) . 
No op i n i on can be expressed because of a lack of d a t a , but t h i s substance i s 
no longer used as p r e s e r v a t i v e i n cosmetic p roduc t s . 
I n f o r m a t i o n : Data shee t , Counci l o f Europe 
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N° 40 Pyr i th ion sodium (INM) 
• " " % , 
S SNa 
I 
ONa 
= S 
C5H NOS.NA 
MW 127.18 
CAS N° 3811-73-2 
Synonyms : - Pyr id ine-1-oxide-2-thioL sodium sa l t 
- Sodium-pyridinethione 
- Sodiunromadine 
Soluble in water and methanol. 
Used in cosmetics at dose levels of 0.5%. 
The LD5Q (in mg/kg) is : oral in rats 660 - 900, in mice 870 - 1000; 
i.v. in mice 335; dermal in rabbits 300 in one study, and 2500 in another. 
Moderate erythema of the skin occurred in rabbits with 25 mg/kg applied as a 
40% paste in CMC. Death may occur with 100 mg/kg. In humans 500 mg of a 
0.5% ointment was not irritating. 
Slight eye irritation was seen in rabbits treated with aqueous 
concentrations of 0.2% and higher. 
Photosensitization tests with 2.0% aqueous solutions were positive in guinea 
pigs but not in humans. 
Sub-acute, oral studies have been conducted in several species. In rats 
toxic effects occurred in a 4-week study with 200 mg/kg b.w./day. In a 
4-week oral dog study eye damage and complete blindness were observed with 
10 - 20 mg/kg b.w./day. No eye damage occurred in monkeys treated orally 
with 25 mg/kg b.w./day for 5 days. With 20 ppm in the diet of chickens 
paralysis of the legs developed, while with 10 ppm there was only some 
growth depression. 
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Sub-acute dermal studies revealed intoxication in rabbits with 100 mg/kg/day 
for 9 days. Severe toxic effects occurred in rabbits with 300 mg/kg 
b.w./day for 14 days. In the monkey, nineteen daily applications of 0.75 ml 
of a 2.5% solution in PEG 300 (19 mg/monkey) produced effects only at the 
treated sites. 
Dermal absorption is considerable under various conditions and in different 
species. Abrasion of the skin enhanced absorption in rabbits. In rats the 
absorbed substance is largely metabolized to pyridine-N-oxide-2-sulfonic 
acid. 
Semi-chronic (15-week) oral studies in rats, dogs and monkeys with 50, 100 
and 300 mg/kg b.w. induced mortality and changes in the liver and kidneys 
with 100 and 200 mg/kg. 
In reproduction studies, reduced litter size occurred when males were 
treated orally with 50 mg/kg/day for a few weeks. When the same level was 
applied to females for 3 weeks before mating and during pregnancy, embryonic 
resorption was increased. 
In teratogenicity studies in rats 50 mg/kg/day, orally, caused increased 
embryonic resorptions. With lower dose levels embryonic survival was not 
affected, but a slightly increased incidence of rib deformities was seen 
with 7.5 mg/kg. The probable no-effect level was 3 mg/kg. 
Na-omadine is toxic and is rapidly absorbed through the skin. Blindness was 
oberseved in dogs treated orally with 10 - 20 mg/kg/day for 4 weeks. The 
substance is embryotoxic and teratogenic. The no-effect level has not been 
firmly established, but in rats it is lower than 50 mg/kg b.w. and probably 
even lower than 5 mg/kg b.w. 
This substance is no Longer used as a preservative in cosmetic 
products. 
Information : Data sheet National Institute of Public health, 
the Netherlands 
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N° 41 2,2'-Dithiobis(pyridine-1-oxide), addition product with magnesium 
sulphate trihydrate 
0...ngS0,, 3H-0...0 
î Î 
^ V^ 
CAS N° 43143-11-9 
MW : 426.3 
Synonyms : - Pyrithion-di sulphide + magnesium sulphate 
- Omadine MDS 
The adduct is better soluble in water and ethanol than pyrithione. 
Used in rinse-off cosmetics up to 0.27., but up to 1.0% rinse-off hair care 
products for other purposes than preservation. 
The oral LDsn values in rats varied from 1.1 to 1.35 g/kg. The dermal LD5Q 
in rabbits was 8 g/kg. 
A single oral or intraperitoneal dose of 20 mg/kg b.w. of mice did not 
induce abnormalities in behaviour or growth rate and no microscopic changes 
were detected in testicles and epididymides after 7 - 2 1 weeks. 
A single oral dose of 0.125, 0.250, 0.50 or 1.00 g/kg b.w. of rats was 
associated with decreased activity, decreased respiration and prostration in 
all dose groups, and 3/5 rats died in the top-dose group. 
A skin irritation test in rabbits with 0.5 g (undiluted substance) produced 
distinct dermal changes. Aqueous solutions up to 5% did not produce skin 
irritation in humans. 
No clear signs of phototoxicity were observed in guinea pigs treated 
topically with 0.1 ml of up to 5% suspensions in corn oil, followed by UV-A 
irradiation. 
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Distinct eye irritation occurred in rabbits with 0.1 ml of a 50% aqueous 
suspension (score 11/110). Severe eye irritation was induced in monkeys by 
applying 100 mg of the undiluted powder, but 0.1 ml of a 1% aqueous solution 
was negative. 
A sensitization test in guinea pigs with 0.1 ml of a 0.2% aqueous solution 
applied in the induction period and 0.05 ml of 0.1 and 0.5% aqueous solution 
as the challenge dose was negative. Negative results were obtained also 
when a 10% aqueous solution was applied in the induction period and as the 
challenge treatment. 
No photosensitizing properties were observed upon applying 0.1 ml of a 
5% suspension in corn oil and UV-A irradiation. 
A sub-chronic (90-day) oral study in rats was conducted with 1, 3, 10 and 
30 mg/kg b.w./day. Signs of intoxication (abdominal hypotension, kyphosis, 
and hind leg ataxia) occurred in all treatment groups. No microscopic 
changes were found in the pancreas but a report on the microscopy of other 
organs was not avai lable. 
In a 6 month oral study in monkeys 5, 15, or 50 mg/kg was administered daily 
by gavage. Decreased body weight and food intake occurred with 15 and 
50 mg/kg. The significance of mortality and .changes in organ weights which 
occurred in all treatment groups cannot be evaluated as a result of the 
small number of animals (4/sex/group). 
In a reproduction study, oral administration of 1.0, 3.0 or 7.5 mg/kg 
b.w./day to female rats from day 14 before mating through day 21 of the 
lactation period was associated with high mortality of females in the top-
dose group (14/20) and several other signs of intoxication. In the mid-dose 
group the dams showed decreased numbers of implantations and of viable pups 
and increased pre-implantation loss. The authors considered 1.0 mg/kg a 
no-effect level. 
In a peri- and postnatal study pregnant female rats were treated orally with 
1, 3 or 7.5 mg/kg b.w./day from day 15 of gestation up to day 20 of 
lactation. Dams of the high-dose group showed mortality and other signs of 
intoxication. In this group there was a decreased number of viable pups and 
decreased survival and growth rate of pups during lactation. 
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Teratogenicity has been examined in several studies. 
- In one oral rat study with 3, 10, 30 and 100 mg/kg maternal toxicity 
occurred at the two high-dose levels. In addition at these two levels 
there was an increased incidence of a major skeletal abnormality 
consisting of bifurcated ribs. 
- In a dermal rat study with dose levels of 1, 10 and 30 mg/kg skin changes 
occurred in the dams of all groups. Signs of embryotoxicity and growth 
depression of the dams were seen only in the high dose group. 
- In two dermal studies in swine (with dose levels of 30, 100 and 300 mg/kg 
in one study and of 10 and 30 mg/kg in the other) signs of maternal 
toxicity and skeletal anomalies occurred at all levels. The member of 
sows in each group (4-6) was too small to allow any definite conclusion. 
- An oral teratogenicity study in rabbits showed loss of body weight with 
5 mg/kg. With 3 and 5 mg/kg post-implantation losses were too high to 
allow any conclusion concerning teratogenic potential. No evidence of 
teratogenicity was found with 1 mg/kg. 
Mutagenic properties were observed in an Ames test when concentrations were 
used above the threshold of toxicity. At lower concentrations 
(1-100 jug/plate) the test was negative. One in vitro test with Chinese 
hamster lung cells indicated mutagenic properties, but the latter test was 
negative when repeated in a modified form. Increases in mutation frequency 
were obtained also with Chinese hamster ovary cells but the effects were not 
dose-related. No dominant lethal properties were observed in tests with 
mice and rats. The compound did not induce unscheduled DNA synthesis in 
hepatocytes of rats when tested at concentrations of 0.03 up to 30 jjg/ml. 
This finding indicates absence of DNA damage. 
In a dermal carcinogenicity study, mice were treated with 2 or 20 mg/kg, 
three times/week, for 18 months. The top-dose group showed increased 
mortality in both sexes, liver hypertrophy in males, a relatively high 
incidence of hepatocellular adenoma and carcinoma, and an increased 
incidence of malignant lymphoma. The authors considered the toxicological 
significance of the increased tumour incidences as unclear. 
Daily treatment of the skin of hairless mice with a 1% solution in 4.8% 
shampoo base for 20 minutes during 14 days did not affect proliferation of 
basal cells in the epidermis. 
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An ora l dose administered to rats is excreted mainly in the u r ine . The 
compound disappears from the blood in a rapid early phase (c . one hour) 
fol lowed by a slow phase (20 - 100 hours depending on the species). 
The main ur inary metabolite is the S-glucuronide of 2-mercapto-pyridine-N-
oxide. The predominant and persistent metabolite in blood is 2-methyl-
su l fony lpy r id ine . 
Dermal absorption occurs in animals and man. 
- In man, 3 - 15% of a dermal dose was recovered in the u r ine , when 4 , 12 
and 40 ¿jg/cm were applied in methanol, without occlusion. 
- In an in v i t r o study with abdominal skin of humans, exposure for 
1000 minutes without r i n s i ng , the amounts recovered were 14% in the horny 
layer , 0.6% in the epidermis, 1.0% in the corium and 1.0% in the 
penetrat ion chamber. 
- In an in v i t r o study with human scalp skin exposed fo r 10 minutes to an 
ointment containing 1%, the amounts recovered were 1.76% in horny layer , 
3.32% in epidermis, 1.32% in corium and 0.07% in penetration chamber 
- In rats dermal absorption was ¿C1% by applying shampoo solut ions 
(0.15 ml / ra t ) containing 0 .5 , 1.0 or 1.5%. 
- Rats t reated with a hair dressing formulat ion, containing 0.1% and applied 
to the back skin fo r 4 hours showed 4.45% of the dose applied in the urine 
and 0.31% in the faeces while the treated skin contained 2.55% at 48 hours 
a f te r app l i ca t ion . 
When evaluat ing the extensive information on th i s substance i t appears that 
t o x i c i t y occurs at low levels of exposure and that the no-effect level may 
wel l be lower than 1 mg/kg b.w./day. There is evidence of mutagenic and 
teratogenic proper t ies . 
Dermal absorption is l i k e l y to be considerably higher than 0.07%. 
Use levels up to 0.5% in cosmetics could resul t in dermal exposure of 1 
mg/kg in humans. I f 10% dermal absorption occurs the margin of safety is 
probably only a fac tor of 10. Industry proposed to decrease the use level 
as a preservat ive in rinsed o f f products to 0.2% and requested to allow up 
to 1.0% for other uses; 
However the Committee sees no object ion to maintaining the use of t h i s 
substance as a preservat ive in cosmetic products for the time being at a 
maximum level of 0.2% in rinsed o f f products. 
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Information : - Colipa dossiers - Submission I : May 11, 1982 
Submission II : February 15, 1984 
Submission III : November, 1984. 
Submission IV : June, 1985 
Submission V : September, 1985 
Submission VI : December, 1985 
- Data sheet Nat. Inst. Pubi. Health, the Netherlands, 1983 
- Toxicol, appi. Pharmacol. 43 ((1978) 373-379) 
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N° 42 Poly(1-hexamethyLenebiguanide hydrochloride) 
NH - C - NH - G - (CH-,), _ II || 2 6 Ì 
NH NH 
n.HCL, n = 3 - 6. 
(C0N.H..) (HCL) 8 4 16 n n 
Highly soluble in water and ethanol, poorly soluble in non-polar solvents. 
Commercial products contain c. 20% active ingredient. 
Used at levels up to 0.3%. 
Oral LD5Q values of formulations vary from about 135 to > 1000 mg/kg for 
în ■ 
These values are expressed as active ingredient. 
rats; a i.p. LD 5 Q value of 2.5 - 25 mg/kg was reported also for rats. 
A skin irritation test in rats treated on 3 alternate days with a 25% PHMB 
solution produced severe effects. Similarly, treating rats on 6 days with 
10% also caused severe irritation, but no effects were seen with 5% or less. 
Eye irritation in rabbits with a 25% solution was severe, but only slight 
inflammation occurred if the eye was washed after 5 seconds. 
No irritation was seen with a 5% solution. 
Moderate sensitization occurred in a maximization test in guinea pigs upon 
induction and challenge treatments with a 0.2% solution. A similar result 
was obtained in a Buehler test in guinea pigs after induction and a 
challenge treatment with a 2% solution. 
In a photosensitization test in 13 human volunteers treated with 0.4 ml 5% 
solution, 3 days a week for 4 weeks, and exposed to the sun for one hour, 
five volunteers showed slight signs of a positive effect. 
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Daily oral treatment by gavage for Less than 3 weeks caused mortality in 
mice with 50 mg/kg, and in rats with initially 500 mg/kg and subsequently 
125 mg/kg. 
In a 90-day study, rats fed 1250 ppm PHMB in the diet showed increased iron 
pigmentation and Kupffer cells in the liver. No changes occurred with 625 
ppm in the diet (30 mg/kg b.w./day). 
Dogs fed 500, 1500 or 4500 ppm in the diet showed growth depression and 
decreased food intake at the top-dose, and liver damage at the top-dose and 
intermediate dose. No changes occurred in the low-dose group (12.5 mg/kg 
b.w./day). 
Inhalation exposure of rats to 0.55 mg/m and above caused mortality in a 
3-week study. No significant changes were found at 0.005 mg/m 
A chronic feeding study with 0, 100, 200 and 1000 ppm PHMB in the diet was 
conducted in mice, which had been exposed already in utero. The top-dose 
caused decreases in growth rate, food intake and food efficiency, and liver 
enlargement. No toxi co logically important changes were found with 200 ppm 
(20 mg/kg b.w./day). There was no evidence of carcinogenicity. 
In a 2-year rat study dietary levels of 200, 1000 and 2000 ppm PHMB were 
used. Body weight and food intake showed dose-related decreases. At the 
two higher levels there were dose-related increases in the weight of the 
spleen and adrenals and some histiocytic conglomerates in the mesenteric 
lymph nodes. No evidence of carcinogenicity was found. The no-effect level 
was 200 ppm or 10 mg/kg b.w./day. 
An 80-week dermal study was conducted in mice with 0, 0.6, 6.0 or 30 mg 
PHMB/mouse/day, applied as an ethanolic solution on 5 days a week. The two 
higher dose groups showed growth depression and skin changes. In addition, 
the top-dose group showed exophthalmos, hepatitis and a relatively high 
incidence of liver tumours. The no-toxic effect level was 0.6 mg/mouse 
(12 mg/kg b.w./day). 
No evidence of mutagenicity was found in an Ames test, or in in vitro tests 
with hamster kidney fibroblasts, mouse lymphoma cells, or human lymphocytes. 
There were no adverse effects on reproduction with feeding levels up to 
1000 ppm PHMB in the diet of mice, or up to 1300 ppm in the diet of rats. 
A teratogenicity study in rats treated throughout gestation with 200, 1000 
or 2000 ppm in the diet showed an increased incidence of foetuses with extra 
ribs only in the high-dose group. In a similar study, mice treated with 10, 
20 or 40 mg/kg on days 6 - 15 of gestation showed changes of the skull in 
the two higher dose groups. The lowest dose was considered a no-effect 
level. No indication of teratogenicity were found in rabbits treated with 
dose levels up to 32 mg PHMB/kg b.w./day. 
In a metabolism study the radio-labeled compound was administered to rats by 
gavage in an amount of 20 mg/kg. More than 90% was excreted in the faeces 
and c. 5% in the urine within 48 hours. Very little was found in expired 
air. Metabolic change did not seem to occur. 
The substance has been extensively examined. Experience in use over 
16 years has produced no evidence of sensitization in man. The substance is 
heat-stable and non-volatile, so that inhalation exposure is unlikely to be 
a problem. 
The use of this substance as preservative in cosmetic products can be 
permitted. 
Information : - Data sheets national Institute of Public Health, 
the Netherlands 
- Reports ICI 
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N° 43 2-phenoxyethanol 
\ / 
0 - CH2 - CH20H 
C8H1002 CAS N° 122.99.6 
MW : 138.17 
Poorly soluble in water (2%); miscible with acetone, ethanol , g lycer ine ; 
soluble in f a t s . 
Use level : up to 1.0%. 
The acute toxicity studies indicate that in the rat phenoxyethanol is less 
toxic upon percutaneous administration (13 ml/kg b.w.) than upon oral 
administration (1,3 ml/kg b.w.). At lethal doses it affects the central 
nervous system. 
Intramuscular administration (of aqueous solutions of 0.4% and above, 
1 ml/kg b.w.) induced necrosis at the injection site in rats and rabbits. 
A 2% aqueous solution is mildly irritating on the skin and well tolerated by 
the mucous membranes of the eyes of rabbits. 
The substance is neither irritating nor sensitizing in guinea pigs or in 
man. 
A 90-day oral toxicity test in the rat showed that the no-effect level was 
80 mg/kg/day. The target organs at high levels were the liver, kidneys, 
lungs, testicles, thyroids and blood. 
The available information suggests that phenoxyethanol is relatively 
harmless. It is necessary, however, to obtain information on : 
- genotoxicity 
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- teratogenicity 
- the degree of purity; in particular the presence of any ethylene oxide 
residue resulting from the manufacturing process. 
The Committee sees no objection to maintaining the use of this substance as 
preservative in cosmetic products. 
Information : Data sheet National Institute of Public Health, 
the Netherlands 
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N° 44 Hexamethylenetetramine (Methenamine) 
C6H12N4 
MW : 140.19 
CAS N° 100-97-0 
Synonym : 1 , 3 , 5 , 7 - t e t r a a z a t r i c y c l o ( 3 - 3 - 1 - 1 ) - d e c a n e 
Eas i l y so lub le i n wa te r , moderately so lub le i n a l coho l and c h l o r o f o r m . 
Use l e v e l i n cosmetics up to 0.2%. 
The subcutaneous LD,-n i n r a t s was 200 mg/kg; an in t ravenous LD c n f o r r a t s of 50 
9200 mg/kg has been repor ted . 
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A skin irritation test in rabbits with a 0.2% aqueous solution produced 
slight erythema in 2/6 rabbits. The solution was classified slightly 
irritating. However, daily local application of 2 ml of the same dilution 
on 5 days per week for 6 weeks did not induce gross or microscopic changes 
of the skin; 
An eye irritation test in rabbits with 0.1 ml of a 0.2% aqueous solution did 
not induce any abnormalities. 
The same low concentration of 0.2% used both for the induction treatment and 
for the challenge treatment, did not provoke signs of sensitization in a 
maximization test in guinea pigs. 
In a 90-day oral study, rats were treated by gavage with 0.2 g or 
0.4 g/rat/day administered as a 40% aqueous solution. There were no 
abnormalities in behaviour or weight gain. A yellow discolouration of the 
fur was observed. 
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Administration of 0.4 g/rat/day by gavage to one group of 15 rats/sex for 
nearly one year did not cause growth depression, increased mortality or 
gross abnormalities of organs. The yellow discolouration of the fur was 
noticed already after a few days of treatment and slowly increased in 
intensity. It disappeared after a withdrawal period of 2-3 months. 
In a long-term study 16 males and 16 females, 2-months old rats werd fed 
0.16% in the diet until their natural death. Body weights, and muscular 
activity showed no significant differences with the controls. Mean life 
span was slightly decreased. Relative weights of the 4 organs weighed were 
comparable. Post mortem examinations revealed no treatment-related changes, 
apart from yellow coloured hair in a few test rats. 
In one mating cycle conducted with the test and control rats average litter 
size of the test rats was lower than in controls, though not significantly 
lower. Health, body weights and relative weights of organs of descendents 
showed no significant differences between test rats and controls. 
A carcinogenicity study was conducted in rats given 1% in the drinking water 
for 104 weeks. Then, treatment was discontinued and the rats were observed 
until week 156. One group was given 5% in the drinking water for only 2 
weeks because of high mortality. Treated rats showed yellow colouration of 
the fur which is attributed to a reaction between formaldehyde, present in 
contaminating urine, and kynurenine, a normal constituent of rat hair. 
Treated rats showed no increased incidence of tumours. 
Three strains of mice received 1% in the drinking water for 60 weeks. One 
of these strains received also 0.5% for 60 weeks, or 5% for 30 weeks. The 
animals were observed for 100 weeks. Slight reduction in growth rate and 
survival was observed with 5%. There were no indications of 
carcinogenicity. 
In a subcutaneous injection study, infant mice and rats were given 5 
injections of 5 g test substance/kg b.w. on alternate days. Then the 
animals were observed throughout their remaining life-span. No evidence of 
carcinogenicity was found. 
In a reproduction study in dogs the substance was fed in the diet at levels 
of 600 or 1250 ppm on day 4-56 after mating. Treatment did not affect 
pregnancy rate, weight gain of the pregnant animals, length of gestation or 
litter size. In the high-dose group there was a slightly increased 
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percentage of still-born pups and a slightly impaired weight gain and 
survival during the lactation period. Behaviours appearance, motility and 
muscular co-ordination were normal. This study did not reveal teratogenic 
properties. 
Rats fed 0, 400, 800 or 1600 ppm in the diet for 2 years were mated at the 
age of 20, 28 and 35 weeks. There were no effects on growth rate, survival, 
reproduction and viability of offspring. 
From a considerable number of studies, both short-term and long-term, it 
appears that the substance possesses a low degree of toxicity. Even 1% in 
the drinking water of rats and mice was well tolerated in long-term studies. 
No teratogenic, or carcinogenic properties have been reported. An ADI of 
0.15 mg/kg b.w. was established by JECFA. However, no information on 
mutagenic properties is available, and interaction with nitrite at pH 1-3 
might yield nitrosamines. The compound has been known to have been used as 
an urinary antiseptic in man with no adverse effects. 
The use of this substance as preservative in cosmetic products can be 
permitted. 
Information : - Colipa dossier. Submission I, September 1983 
- Data sheet Council of Europe 
- JECFA WHO Food Additive Series No. 5 (1974) 
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N° 45 Mix tu re of 5 - C h l o r o - 2 - m e t h y l - i s o t h i a z o l - 3 ( 2 H ) o n e and 2 -
m e t h y l i s o t h i a z o l - 3 ( 2 H ) - o n e w i t h magnesium c h l o r i d e and magnesium 
n i t r a t e 
Cl: 
= - 0 
S 
I and | I + flg(N0j 
H—CH, \ N - C H , * V y2 
/ 3 \ / 3 
CAS N° 26172-55-4 
MW : 148.5 MW : 114.0 
Synonyms : - M e t h y l c h l o r o i s o t h i a z o l i n o n e and me thy l t h i azo l i none 
- Kathon CG 
The r a t i o of ch lo romethy l t o methy l i s 3 : 1 . 
Trade names : "Ka thon" at va r i ous s t r e n g t h s , and fo rms , and w i t h d i f f e r e n t 
s t a b i l i s e r s . "Kathon CG" i s cosmetic grade and i s complexed w i t h magnesium 
n i t r a t e . I t con ta ins 1.5% t o t a l i s o t h i a z o l o n e s . 
Solub le i n wa te r , methano l , and e t h a n o l , pH 2 - 4 . 
Use l e v e l 0.05 t o 0.15% (0.00075% t o 0.00225% a . i . , or 7.5 t o 22.5 ppm 
a . i . ) i n a l l types of cosmet ics . 
Ora l LD5Q va lues are 50 mg/kg i n r a t s and 52 mg/kg i n male mice. The dermal 
LD_n i n r a b b i t s was > 75 mg/kg. The i n h a l a t i o n LC,-n f o r r a t s was 650 
3 3 
mg/m f o r a vapour and 200 - 300 mg/m f o r an a e r o s o l . 
In s k i n i r r i t a t i o n t e s t s i n r a b b i t s , aqueous s o l u t i o n s of 0.056%, 0.28% and 
0.56% of a . i . (or 560, 2800, or 5600 ppm) were r e s p e c t i v e l y n o n - i r r i t a t i n g , 
moderate ly i r r i t a t i n g and severe ly i r r i t a t i n g . In guinea p igs 1.5% was 
i r r i t a t i n g . In man (mod i f i ed Lauman-Maibach t e s t ) 0.02% was s l i g h t l y 
i r r i t a t i n g and 2.8% was severe ly i r r i t a t i n g . 
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In a maximization test, guinea pigs received induction treatment with 
0.0056% a.i. The challenge treatment with the same concentration after 2 
weeks did not induce sensitization reactions (IBL-study). 
A similar test using 0.0015% for injection and 0.3% on a patch as induction 
treatment showed positive reactions in 10/20 animals upon the challenge 
treatment by injection with 0.03%. A second challenge with 0.015% one week 
later was uniformly negative. 
A modified Buehler test in guinea pigs, using either 1.0% of the methyl 
compound or 0.2% of the mixture on covered patches for induction, showed 
positive effects in all animals when challenged with 0.2% Kathon, and in 
3/20 animals when 0.02% was used. Similar results were obtained with 1.6% 
of the methyl compound but not with lower concentrations. Only weak cross 
sensitization was observed between the product and the chlorocompound. 
In a repeated, occlusive insult patch test in 18 humans, 0.3 ml 0.0025% was 
applied for 24 hours, every 48 hours, 9 times. After a 2-week rest, the 
challenge dose (the same as the induction dose) induced irritation in one 
subject and sensitization in one subject. 
The sensitizing properties of the substance have been confirmed in several 
tests in humans under various conditions. In a threshold test with 9 
sensitized persons (verified with 100 ppm) one was found positive with 25 
ppm, five with 50 ppm and three not until 100 ppm. 
In an international patch testing programme using high concentrations (100-
300 ppm), 30 positive reactions were found in 7307 subjects tested (0.41%). 
In a photosensitization test, 0.15% was applied to the guinea pig skin on a 
patch, 4 times a week for 2 weeks, and half the animals were subjected to 
UV-irradiation. Ten to 14 days after the test insult exposure the animals 
were challenged with 0.3% a.i. No evidence of phototoxicity or 
photosensitization was found (IBL-study). 
Sub-acute (2-wk) oral studies with up to 224 ppm a.i. in the diet of rats, 
and up to 1550 ppm a.i. in the diet of dogs did not reveal any 
abnormalities. A 4-wk oral rabbit study with 0, 0.4, 1.3, 3.9 and 13.2 
mg/kg b.w. by gavage, 5 days/week, revealed gastro-intestinal irritation 
with haemorrhages at the two high dose levels and mortality (16/20) at the 
top dose. The no-effect level was 0.4 mg/kg b.w. 
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In a sub-chronic (90-day) study with groups of 15 ra ts /sex , fed d ie ts with 
the test compound at Levels providing 0 , 3, 10 and 30 mg/kg b.w., no 
t reatment-re lated changes were observed. 
In another 90-day rat study in which 25, 75 or 225 ppm a . i . was administered 
in the dr ink ing water (c . 2 , 6 , and 18 mg/kg b .w. ) , the top dose group 
showed decreased t o t a l prote in content of blood serum and enlarged l i ve rs 
and kidneys. The no-ef fect level was considered to be 75 ppm (or c. 6 mg/kg 
b.w.) . 
A 90-day study in dogs with 0, 84, 280 or 840 ppm a . i . in the d ie t (c . 2 . 1 , 
7.0 or 21 mg/kg b.w.) d id not reveal any abnormal i t ies. 
Inhalat ion of 30 jüg/I a i r by r a t s , 6 hrs/day on 5 days/week, induced 
m o r t a l i t y , respi ratory d i s t r ess , and weight loss. No changes were seen with 
10 and 3 p g / l ai r. 
A 13-wk inha la t ion study in rats with 0, 0.19, 1.62 and 6.33 p g / l d id not 
produce m o r t a l i t y . The no-effect level was considered to be 0.19 p g / l . 
In a sub-acute (3-wk) dermal study, groups of 10 rabbits/sex were treated 
with 0 , 5.6 or 28 mg/kg b.w., 5 times/week. Microscopic examination of the 
sk i n , l i ve r and kidneys was negat ive. 
A 13-wk dermal study with groups of 12 rabbits t reated with 100, 200 and 
400 ppm a . i . , on 5 days a week showed mor ta l i t y in the test groups (which 
was not considered t reatment - re la ted) , and local i r r i t a t i o n in the top-dose 
group. 
Dermal absorption is considerable in rats. Upon a single application of 
14 
C-"Kathon CG" about 50% seemed to be absorbed. Another dermal rat study 
indicated 40% absorption. At low exposure Levels a greater propertion seems 
to be held by the skin. 14 When 0.2 ml 2000 ppm of a.i. C-labelled, was applied to the skin of rats 
only once, some radioactivity was found in the testicle even at day 28. 
Multiple dermal treatment of rats with 0.2 ml, 500 or 1000 ppm labelled a.i. 
daily for 4 days resulted in 26% excretion in 24 hours. 14 I.V. administration of the C-labelled compound in a single dose of 0.8 
mg/kg b.w. of rats, was followed by fairly uniform distribution in the body, 
except that the blood levels were much higher than the plasma levels. The 
half life times (in hours) were : plasma 38 : whole blood 300, liver 98, 
kidney 90, testicles 120. 
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Effects on reproduction were studied by mating 9 or 10 male and female rats 
from each group at the end of one of the oral 90-day studies. No evidence 
of an adverse effect was noted upon observing the offspring. 
Teratogenic properties were examined in groups of 25 female rats dosed 
orally with 1.4, 4.3 and 14 mg a.i./kg b.w./day, from day 6 - 14 of 
pregnancy. No evidence of teratogenicity was found. 
Groups of 15 female rabbits were dosed orally with 0.23, 0.60 and 2.0 mg 
a.i./kg b.w./day during pregnancy. There was some embryotoxicity but no 
evidence of teratogenicity. 
Mutagenic properties have been extensively examined. 
In the Ames test, mutagenic potency was found with TA 100 in the absence of 
metabolic activation. Positive results were obtained also in the mouse 
lymphoma test in vitro. However, negative results were obtained in a gene 
mutation test in Drosophila, in a chromosomal aberration test in vitro, and 
in chromosomal aberration tests in vivo in mice and rats treated orally with 
15 mg/kg. A micronucleus test in mice treated orally with 3, 9, and 30 
mg/kg, and another micronucleus test in mice treated intraperitoneally with 
compounds 1 and 2 at 250 mg/kg, were all negative. Negative results were 
also obtained in a mitotic gene conversion test in yeast, an UDS-test in rat 
hepatocytes and a cell transformation test with C,Hir)T 1/2 cells. No 
binding of the compound with cell DNA could be established in spite of the 
positive results in certain tests. 
In a long-term, dermal carcinogenicity study in mice, groups of 40 males 
were skin painted, 3 times weekly, with 0.01 mg a.i. (or 0.2 mg/kg b.w.). 
Two test animals developed a tumour at the site of application. Two control 
mice treated with water also developed a tumour, but not at the application 
site. 
With 30 mg/kg b.w. administered in the diet of rats for 3 months, no changes 
were observed, although the oral LD_Q in the rat was only 50 mg/kg b.w. The 
no-effect level in different oral studies varied widely and indicated less 
toxicity when the compound was administered in the diet than when given by 
gavage or in drinking water. Information should, therefore, be provided on 
the stability of the compound under test conditions involving incorporation 
in the diet. 
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The Committee sees no objection to maintaining the use of this compound as 
preservative in cosmetic products. 
Information : - Colipa dossiers 
- Data sheet Bundesgesundheitsamt, Berlin 
- Evaluation Dr N. Loprieno, January 1984 
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N° 46 P y r i d i n - 2 - o l - 1 - o x i d e 
No op in ion can be expressed because of a Lack of d a t a . Bu t , t h i s substance 
i s no Longer used as p r e s e r v a t i v e i n cosmetic p r o d u c t s . 
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N° 47 Pyrithione aluminium camsiLate (INNM) 
C20 H23 N2°6 S3 A L 
MW : 510 
¿^N 
N' i 
0 
^ ^ 
^ ^ 
Synonym : Bis(N-oxopyridyl-2-thio)aLuminium camphosulphonate 
Poorly soluble (0.2%) in water and ethanol. 
Used at levels up to 0.2%. 
The oral LDcn in rats was 2.5 g/kg, in mice 1.9 g/kg. 
In a primary skin irritation test in rabbits with 0.5 ml of a 0.2% aqueous 
solution the substance was not irritating. Daily skin application of 2.5 ml 
of the 0.2% aqueous solutions for 30 days seemed to be well tolerated by 
rabbits but insufficient details of the results were reported. 
No eye irritation occurred in rabbits by applying 0.1 ml of a 0.2% aqueous 
solution. 
Guinea pigs treated in the induction period with aqueous solutions stated to 
contain 1% of the test substance and challenged with aqueous concentrations 
of 0.2 and 0.5% did not show any skin reaction; 
In sub-chronic (13-week) oral studies, mice and rats received 7.5 and 20 
mg/kg/day, 5 days/week, by stomach tube. In mice growth depression and 
increased activity and agressiveness occurred in both treatment groups. No 
gross or microscopic changes were reported. 
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In rats there was also growth depression, increased activity and 
agressiveness. Blood biochemistry showed increased contents of urea, 
Lipids, triglycerides, and cholesterol, which were, however, considered by 
the authors to be in the normal range. Some organs showed changes in 
weight, but no gross or microscopic abnormalities were reported. The 
reports on these studies show several deficiencies. 
A micronucleus test in mice treated twice intraperitoneal^ with dose levels 
between 300 and 500 mg/kg failed to reveal mutagenic activity. 
Information on dermal absorption or on systemic toxicity upon dermal 
application is not available. 
The oral 90-day studies suggest that the no-effect level for mice and rats 
is lower than 7.5 mg/kg. Because information on dermal absorption is not 
available, it is possible that the use of up to 0.2% in cosmetics is too 
high. In order to complete evaluation of this preservative information on 
dermal absorption is required; if this is substantial teratogenic tests 
should also be carried out. The mutagenic test already done is 
insufficient. 
No opinion can be expressed because a lack of data. The closely related 
compound Na-pyrithione shows considerable dermal absorption and is markedly 
toxic. The Committee believes it to be important that dermal studies 
(absorption and penetration) be carried out under comparable conditions in 
all pyrithiones listed in Annex IV. These compounds are known to be 
teratogenic and mutagenic and have a very high toxicity. 
Pyrithione aluminium camsilate is no longer used as preservative in cosmetic 
products. 
Information : Colipa dossier 
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N° 48 Methanamine 3-chloroallylochloride (INNM) 
CH 
• N. 
2 CH, "CH. 
,N-
N 
/ \ 
CH„ CH„ 
/ 2 ^ 
N 
•CH; 
-CH -CH=CH-C1 C l 
C 9H 1 6N 4CL 2 
MW : 251 
CAS N° 4080-31-3 
Synonyms : - 1-(3-chloroallyl)-3,5,7-triaza-1-azonia adamantane chloride 
(cis isomer) 
- Dowicil 200 
Highly soluble in water, soluble in propylene glycol and ethanol. 
Used up to 0.2% in rinsed off and non rinsed off products. 
Oral LDc« values for rats of 2.6 g/kg and 1.5 g/kg have been reported. The 
oral LD_0 for female rabbits was 78.5 mg/kg. 
Dermal LD,-n values for rabbits were 2.8 g/kg, 1.2 g/kg, 0.9 g/kg and 
0.6 g/kg. 
In a skin irritation test in rabbits with 0.5 g undiluted substance slight 
to moderate erythema and moderate oedema were seen (score 1.2). 
Eye irritation tests in rabbits with 0.1 g undiluted substance induced 
slight to moderate redness. 
In a sensitization test in guinea pigs (modified Maguire method) four 
applications of 0.1 ml 10% solution in 8 days, and a challenge after 14 days 
of rest, induced a positive response in 1 out of 10 animals; 
The compound was not considered to be a sensitizer. 
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A photosensitization test was conducted with groups of 25 male and 25 female 
volunteers by applying 1% in water or 0.1 to 0.75% in formulations, 25 
times, and irradiation for 30 seconds. The challenge dose, 18 days after 
induction, did not elicit any positive response. 
A sub-acute (30-day) dermal study in rabbits with 0, 25, 50 and 100 mg/kg 
showed growth depression with 100 mg, decreased liver weights with 50 and 
100 mg, and dose-related dermal changes. 
In a sub-chronic (90-day) dermal rabbit study 1.04, 10.5 and 31.3 mg/kg was 
applied daily, 5 days a week. No dermal or systemic effects were observed. 
In a teratogenicity study in rats with 100, 200 or 400 mg/kg b.w./day 
applied by gavage all dose levels induced maternal and foetal toxicity. In 
a second oral rat study with 5, 25 and 75 mg/kg, the two highest dose levels 
induced maternal toxicity, decreases in the weight and in the degree of 
ossification of the foetuses, and an increased incidence of microphthalmia. 
With 5 mg/kg there was neither maternal nor foetal toxicity. 
A tentative teratogenicity study was conducted in rabbits with oral doses of 
3, 10 or 20 mg/kg. The highest dose group showed maternal toxicity but no 
embryolethality or detrimental effects on reproductive parameters. 
A dermal teratogenicity study was conducted in rats with dose levels of 250 
and 500 mg/kg b.w. in a 50% aqueous solution. The reproductive parameters 
were not affected and there were no signs of fetotoxic or teratogenic 
properties. 
The metabolism was examined in rats by single administration of aqueous 
14 solutions of the C-labelled compound orally or dermally in amounts of 5 or 
75 mg/kg, and by intravenous administration of 5 mg/kg. Dermal absorption 
during 48 hrs was 1.5 to 2.0% of the applied dose at both dose levels. The 
percentage absorbed dermally was not dependent on the applied dose or 
concentration. Oral absorption was nearly complete. 
Following oral or i.v. administration, the compound was extensively 
metabolised and rapidly excreted, partly (30%) as CO-, in expired air. 
The urine contained 4 - 5 metabolites which have not been identified. The 
half life was c. 21 hrs for the 5 mg/kg dose and c. 29 hrs for the 75 mg 
dose. The pattern of urinary metabolites after dermal application was not 
the same as after oral dosing. 
An Ames test with up to 500/jg/plate was negative. A test for unscheduled 
DNA synthesis in hepatocytes with up to 0.2 mol/l was also negative. 
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The available data indicate that the substance is teratogenic in rats at 
oral dose levels of 25 mg/kg and above. Dermal absorption is low in rats but 
may be considerable in rabbits. Dermal application of 25 mg/kg did not show 
deleterious effects in this species. A short-term oral study with dose-
levels sufficiently high to induce a systemic effect, information on dermal 
absorption through human skin, and a chromosomal aberration test is needed 
to evaluate this substance. Information is also requested on the purity of 
the substance and on the presence of the trans-isomer. 
However, the Committee sees no objections to maintaining the use of this 
substance as preservative in cosmetic products. 
Information : - Colipa, Submission I, September 1983 
Submission II, September 26, 1984 
- Dossier The Dow Chemical Company 
- Data Sheet National Institute Public Health, 
the Netherlands, December 1983 
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N° 49 1 - ( 4 - C h l o r o p h e n o x y ) - 1 - ( i m i d a z o l - 1 - y l ) - 3 , 3 - d i m e t h y l b u t a n - 2 - o n e 
CH3 
CL — ( > O — CH — CO — C — CH, 
I I 3 
CH3 
C15H17CLN202 
MW : 292.8 
Synonym : Cl imbazole 
Poor ly so lub le i n wa te r , s o l u b l e i n e t h a n o l . 
Used at l eve l s up t o 0.5%. 
Ora l LD_n va lues ( i n mg/kg) are 400 i n r a t s , 664 i n mice , 250 i n r a b b i t s and 
250-500 i n dogs. 
Eye i r r i t a t i o n t e s t s i n r a b b i t s w i t h 0.5% i n i sop ropano l /wa te r showed marked 
to severe r e a c t i o n s , but v i r t u a l l y no reac t i ons occur red w i t h 0.5% i n 
p o l y e t h y l e n e g l y c o l . Eye i r r i t a t i o n a lso occur red when t es ted at a l e v e l of 
0.5% i n f o r m u l a t i o n s of h a i r l o t i o n s . 
No s e n s i t i z a t i o n was observed i n guinea p igs by i n d u c t i o n t rea tment w i t h 10% 
and cha l lenge t reatment w i t h 0 . 3 , 1.0 or 3.0%. 
In a sub-chron ic (13-week) o r a l s t u d y , r a t s rece ived d a i l y doses of 0 , 5 , 15 
or 45 mg/kg b.w. suspended i n 0.5% aqueous t y l o s e . The top-dose induced 
s l i g h t growth dep ress ion , decreased a l k a l i n e phosphatase and c r e a t i n i n e 
v a l u e s , and increased a c t i v i t y of n-demethylase. Increased l i v e r w e i g h t s , 
not accompanied by m ic roscop ica l changes, were seen i n the 15 , and 45 mg/kg 
g roup . 
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A sub-chronic (13-week) ora l study in dogs was conducted with dose-levels of 
0 , 5, 10 and 20 mg/kg, administered da i ly by gelat ine capsule. The only 
change was an increased n-demethylase a c t i v i t y in the top-dose group. 
In a sub-acute dermal study, rabbits received 2 ml 0.5% in polyethylene 
g lycol 400 or in isopropanol/water, da i l y fo r 21 days. In addi t ion to skin 
changes, the test rabbits showed a s l i g h t l y increased incidence of l i v e r 
changes ( d i l a t a t i o n , p r o l i f e r a t i o n and f i b r o s i s ) . 
In a te ra togen ic i t y study, pregnant rats were treated da i ly with 0 , 10, 30 
or 100 mg/kg in 0.5% aqueous ty lose by gavage. With 30 and 100 mg/kg growth 
depression occurred. C l i n i c a l signs of t o x i c i t y and an increased number of 
resorptions were observed only with 100 mg/kg. There were no indicat ions of 
teratogenic proper t ies . 
An Ames test with up to 2 mg/plate was negative. 
A micronucleus test in mice with the very high dose levels of 150 and 300 
mg/kg was also negative. 
Upon single ora l administrat ion of 50 mg/kg b.w. of r a t s , maximum blood 
levels of climbazole and i t s main metabolite were 5 and 6 jjg/ml 
respect ive ly . The hal f l i f e in rats was 3 - 4 hours. 
In the 90-day o ra l dog study the maximal blood levels of the compound and 
the main metabolite in the top-dose group (20 mg/kg) were respectively 0.4 
and 1.3 ^ig/ml. 
Upon repeated dermal appl icat ion of 1 ml 0.5% solut ion to rabbit skin peak 
blood levels were 0.013 and 0.010 jug/ml. 
Human volunteers, a f te r single or repeated exposure to hair lo t ion with 0.5% 
or shampoo with 2% showed maximum plasma levels of 10 ng/ml. 
The substance is moderately tox ic upon acute and sub-acute ora l exposure. 
The no-effect level in short- term ora l studies in rats and dogs is around 
10 mg/kg b.w. Dermal absorption has been observed in animals and man. Upon 
rigourous dermal exposure of humans to formulations with 0.5 or 2% 
climbazole the maximum blood levels of the compound and i t s main metabolite 
( ^ 3 5 ng/ml) were considerably lower than the blood Levels found in those 
rats and dogs (1000 - 10.000 ng/ml) showing s l i gh t signs of t o x i c i t y upon 
repeated ora l exposure. 
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Because the substance shows structural relationship with Clotrimazole (which 
is used medicinally against infections with Candida and fungi) the Committee 
discussed the possibility of resistance or cross-resistance to imidazole 
compounds. Available evidence suggests that secondary resistance and cross 
resistance of fungi to imidazole derivatives are rare and inconsistent. The 
Committee noted that the compound is used in certain cosmetics for purposes 
other than preservation at concentrations higher than 0.5%. 
The use of this substance as preservative in cosmetic products at a maximum 
level of 0.5% can be permitted. 
Information : - Colipa dossier 
- Data sheet National Institute of Public Health, 
the Netherlands 
116 -
N° 50 1 ,3-Bis(hydroxymethyl ) -5 ,5-dimethyl imidazol id ine-2,4-dione 
CH20H 
H3C, ^rv 
,V— < CH^ OH 
C7H12N2°4 C A S N° 6 4 4 0~ 5 8 _ 0 
MW : 188 
Synonyms : - Dimethylol dimethylhydantoin 
- GLydant 
Easily soluble in water. 
This substance is used in cosmetics up to a concentration of 0.2% expressed 
as formaldehyde. In the remaining of this report dose levels refer to the 
55% aqueous solution of the compound in question and not to formaldehyde. 
The oral LD_n in rats was between 3 and 5 g/kg b.w. for females and between 
2 and 3.65 g/kg b.w. for males. In a one hour inhalation toxicity test in 
male rats the LC,-n was > 204 mg/liter. A 4-hour inhalation study in rats 
of both sexes resulted in an LC_0 value of > 377 mg/liter. The acute 
dermal LDcn in rabbits was > 20 g/kg. 
In a skin irritation test in rabbits application of 0.5 ml of the test 
substance to the intact or abraded skin was not irritating. 
An eye irritation test in rabbits with 0.1 ml of the 55% aqueous solution 
was positive, but a 1% dilution of this material was not irritating. 
In a sensitization test in 50 humans, following repeated dermal applications 
of 0.5 ml of a 0.1% aqueous dilution of the test material for 24 hours (nine 
times in an induction period of 3 weeks), the challenge treatment, after a 
12 day rest period, did not induce irritation or sensitization. In a 
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similar test in 202 subjects treated 10 times with 0.2 ml of a 1.0% aqueous 
dilution, the challenge treatment induced signs of sensitization in 3 
subjects. 
A photosensitization test was conducted in 25 persons by dermal application 
of 0.3 ml of a 0.4% aqueous dilution in occluded patches on 10 days in 2 
successive weeks each time followed by UV irradiation at twice the minimal 
erythema dose. The challenge treatment, conducted after a 14-day rest 
period, did not provide indications of phototoxicity or photosensitization. 
In a sub-acute (28-day) dermal toxicity study (conducted by IBT - Chicago) 
rabbits received 20 daily applications of 0, 0.4 or 40% aqueous solutions; 
or 0, 8 or 800 mg/kg b.w. No changes attributed to treatment were reported 
with respect to body weight, haematology, clinical chemistry of blood or 
urine, or in the weight and pathology of the internal organs. Animals of 
the high dose group showed signs of mild to moderate irritation of the 
treated skin. Practically no irritation occurred in the low-dose group. 
In a short-term (21-week) oral rat study, dose levels of 0, 100, 200 and 400 
mg/kg were applied daily by gavage for 8 weeks, and at levels of 0, 100, 300 
and 600 mg/kg for the remaining 13 weeks of the study. No significant, 
dose-related changes were found. An increase in adrenal weight of the 
high-dose males was not attributed to treatment. The target organ was not 
established. 
Mutagenicity tests with S.typhimurium and Saccharomyces cerevisiae, with and 
without metabolic activation were negative. 
The Committee knows that the substance resembles Phenytoin and methoin 
hydantoin, which are known drugs with a narrow-therapeutic range. Due to 
the low toxicity of the compound, no further information is requested. 
The use of this substance as preservative in cosmetic products can be 
permitted at a maximum level of 0.2% expressed as formaldehyde. 
Information : - Colipa dossier 
- Data sheet National Institute of Public Health, 
the Netherlands 
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N° 51 Benzyl alcohol 
CH20H 
^ 
C7H8° 
MW : 108.13 
CAS N° 100-51-6 
Synonym : Phenyl carbinol. 
Soluble in water, easily soluble in ethanol and ether. 
Used in cosmetics at levels up to 1.0%. 
Oral LD_n values for rats were 3.1, 2.08 and 1.23 g/kg. For mice and 
rabbits the values were 1.58 and 1.94 g/kg respectively. The i.p. LD,-n in 
rats and guinea pigs was between 0.4 and 0.8 g/kg; the i.v. LD_n in rats was 
0.3 g/kg. In guinea pigs the dermal LD_n was <£. 5 ml/kg. 
Symptoms of intoxication included paralysis, convulsions and narcosis. 
The substance possesses local anaesthetic properties. 
Skin irritation was moderately strong in guinea pigs treated with the 
undiluted substance. 
A sensitization test in 25 volunteers with 10% in petrolatum was negative. 
Cross-sensitization with Peru balsam has been reported. 
Exposure to the vapour phase results in dermal absorption and 100 ppm in air 
may induce systemic effects. No fatalities or symptoms were produced in 
rats exposed to 61 ppm for 6 hours. 
The body readily oxidizes benzyl alcohol to benzoic acid which, after 
conjugating with glycine, is eliminated as hippuric acid in the urine. 
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A negative result of an Ames test has been reported. 
No information is available on concentrations which are non irritant to the 
skin. Information on systemic toxicity may become available from the oral 
studies in rats and mice on sub-chronic and chronic toxicity and on 
teratogenicity which are being conducted in the framework of the US National 
Toxicology Program. 
The Committee sees no objection to maintaining the use of this substance as 
preservative in cosmetic products. 
Information : - Colipa dossier 
- NTP FY 82 
- Opdyke Monographs, Fd. Cosmet. Tox ico l . 11 (1973) 1011-1013 
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N° 52 1-Dodecylguanidin ium aceta te (Dodine - ISO) 
NH 
n ~ C 1 2 H 2 5 ~ N H - C ~ N H 2 " C H 3 C 0 0 H 
C15H33N3°2 C A S N ° 2 4 3 9 - 1 0 " 3 
MW : 287 
Moderate ly so lub le i n a l coho l s (7-23%), poo r l y s o l u b l e i n water (0.063%), 
i n s o l u b l e i n most o ther s o l v e n t s . 
Used i n cosmetics at l e v e l s of 0.5% i n r i nsed o f f products and 0.1% i n o ther 
p r o d u c t s . 
The o r a l LD5Q va lues f o r r a t s and mice vary from 0.27 t o 1.72 g / k g ; f o r 
r a b b i t s and guinea p igs va lues of 0.535 and 0.176 g/kg were r e p o r t e d ; f o r 
q u a i l and pheasants 0.848 and 0.950 g /kg r e s p e c t i v e l y . Acute e f f e c t s i n 
r a t s are hypoglycaemia, increased ATP-ase i n b lood and decreased ATP-ase i n 
the L i v e r . Dermal LD_0 va lues f o r r a b b i t s are 2.1 and 1.5 g/kg ( 1 , 2 ) , f o r 
ra t s > 6 .0 g/kg (5) 
Considerable erythema and oedema developed i n r a b b i t sk in t r e a t e d w i t h an 
aqueous paste of dodine ( 2 ) . 
Very severe eye i r r i t a t i o n occur red i n r a b b i t s t r e a t e d w i t h 10 mg u n d i l u t e d 
subs tance, but 0 .1 ml of a 0.12% aqueous d i s p e r s i o n produced on ly weak 
changes ( 2 ) . 
In a sub-chron ic (14-week) r a t s tudy the feed ing of 3200 ppm i n the d i e t 
induced marked reduc t i on in growth ra te and food i n t a k e , and increased 
i r r i t a b i l i t y and spontaneous a c t i v i t y . However, no changes i n haematology 
or in gross and microscopic patho logy were found . Feeding l eve l s lower than 
3200 ppm were not examined i n t h i s study ( 2 ) ; 
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In a two-year rat feeding study with dietary Levels of 50, 200 and 800 ppm, 
growth rate and food intake were reduced in the top-dose group. 
Haematology, organ weights, or gross and microscopic pathology did not 
reveal compound-related changes. Clinical chemistry of blood was not 
reported (2). 
A one-year feeding study in dogs with dietary levels of 0, 50, 200 or 800 
ppm did not reveal changes in growth, behaviour, haematology or gross 
pathology. The weight of the thyroid was slightly increased at all dose 
Levels. Microscopically, an activated appearance of this organ was seen in 
1/4 dogs at 200 ppm and in 4/4 dogs at 800 ppm, but in none of the dogs at 
50 ppm (2). 
No significant increase in incidence of tumours was seen in mice treated 
orally with 21 mg/kg b.w./day from day 7 to day 28 after birth and then with 
82 ppm in the diet for 18 months (3). 
No detrimental effects on reproduction were found in a three-generation 
study in mice with dietary levels of 400 and 800 ppm. The lactation index 
was reduced in the top-dose group. Gross and microscopic examination was 
negative (1). 
In a two-generation study in rats, 800 ppm did not affect reproduction but 
litter size was slightly reduced (2). 
Mutagenicity tests in Salmonella typhimurium, Escherichia coli, Streptomyces 
coelicolor, and Saccharomyces cerevisiae were all negative. 
The N-nitroso derivative of dodine showed mutagenic activity with E. coli 
K 12, but not with S. typhimurium his G 46. 
Metabolism of dodine differs amongst different species. While elimination 
of the compound in rats is rapid, it accumulates in guinea pigs and mice 
(4). 
Occupational exposure of workers involved in the production of dodine 
produced minor effects (acute dermatitis, eye irritation) which were readily 
reversible (1). 
Because dodine is a severe irritant to the mucous membrane of the eye, it 
should not be used in eye cosmetics, and its use in intimate sprays should 
be called in question. 
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The no effect Level in dogs was relatively low (1.25 mg/kg b.w.) and the 
Joint WHO/FAO Expert Committee on Pesticides allocated a temporary ADI of 
0.01 mg/kg. 
More information on dermal absorption, preferably in man, is required. 
However, the Committee sees no objection to maintaining the use of this 
substance as preservative in cosmetic products. 
Information : (1) WHO Pesticide Residues Series, N° 4 (1975) 265-284 
(2) Levinskas et al. Toxicol, appi. Pharmacol. 3 (1961) 
127-142 
(3) Innés et al. J. Natn. Cancer Inst. 42 (1969) 1101-1114 
(4) Vettorazzi G. Intern. Regulatory Aspects for Pesticide 
Chemicals. Vol. I. Toxicity profiles, CRS Press Inc. 1979 
(5) Data sheet University of Pisa - Genetics Laboratory 
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N° 53 Benzethonium c h l o r i d e (INN) 
CH3 
CH3 - C - CH2 - C - V y- 0(CH2CH20)(CH2CH2) - N + - CH-rV 
Cri3 CH3 \ / CH3 
H20 
C-.-,H/oN0-,.CL CAS N° 121-54-0 
MW : 448 
Synonyms : - 4 ' - ( 1 , 1 , 3 , 3 - t e t r a m e t h y I b u t y U p h e n o x y - e t h o x y e t h y l e n e -
dimethyLbenzyL-ammonium chLor ide 
- Phemerol c h l o r i d e 
- Hyamine 1622 
Soluble i n wa te r , a l coho l s and o ther organic s o l v e n t s . 
Used i n cosmetics at l eve l s of 0 . 1 % . 
LD_n va lues f o r the r a t are : o r a l 420 mg/kg, i . p . 33 mg/kg, and i . v . 
19 mg/kg. I n t r a n a s a l a d m i n i s t r a t i o n of 0.06 ml of a s o l u t i o n of 0.25% or 
more was l e t h a l t o r a t s . 
Var ious d i l u t i o n s app l i ed to the eye of r a b b i t s produced ba re l y p e r c e p t i b l e 
i r r i t a t i o n at concen t ra t i ons of 0.01 and 0.03%. 
Skin i r r i t a t i o n i n r a b b i t s d i d not occur when 2 ml of a 0 .1% d i l u t i o n were 
app l i ed d a i l y 5 days a week f o r 4 weeks. In humans, 0.1 ml of a 5% aqueous 
s o l u t i o n app l i ed under patches f o r 48 hours , was i r r i t a t i n g . 
A s e n s i t i z a t i o n t e s t i n humans w i t h 0.12% i n f o r m u l a t i o n s app l i ed to the 
sk in under c losed patches was n e g a t i v e . 
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Upon sub-acute, dermal app l ica t ion of 2 ml 0.1% solut ion to the skin of 
rabbi ts d a i l y , 5 days/week for 4 weeks no systemic e f fec ts were observed. 
Sub-chronic (13-wk) dermal studies in rats and mice are being conducted by 
the NTP. 
In a one year feeding study in groups of 3 dogs fed 0, 5, 100 and 500 ppm in 
the d i e t , no changes were observed in growth ra te , haematology or in gross-
or microscopic pathology. 
A two year study has been conducted with groups of 5 ra ts /sex, fed d iets 
containing 0 , 50, 200, 1000, 2500 and 5000 ppm. The top dose induced 
mo r t a l i t y . With 2500 and 5000 ppm t e s t i c u l a r atrophy and caecal enlargement 
occurred. With 1000 ppm there was only caecal enlargement. 
Several subcutaneous i n jec t i on studies have been conducted in rats and mice. 
In one study in rats a dose-related increase in the incidence of 
granulomatous reactions (mainly fibrosarcomas) occurred at the in jec t ion 
s i t e . I t i s not clear whether t h i s resul t is an ind icat ion of carcinogenic 
propert ies of the test substance. 
Concentrations as low as 0.002% inh ib i ted the m o t i l i t y of the isolated ileum 
of rats and rabb i ts . Blood pressure measurements in the dog indicated 
nearly complete blockage of sympathetic ganglions at an i . v . dose of 
2 mg/kg. 
An ora l te ra togen ic i t y study in rabbi ts with 1 , 3 and 10 mg/kg/day revealed 
signs of maternal t o x i c i t y with 3 and 10 mg, increased mor ta l i ty of mothers 
and pups with 10 mg, and an increased incidence of supernumerary r ibs with 3 
and 10 mg. The l a t t e r f ind ing was a t t r i bu ted to s t ress. 
In a second te ra togen ic i t y study in rabbi ts with ora l dosing of 1.125, 3.558 
and 35.576 mg/kg/day, the high dose induced maternal and foe ta l mor ta l i t y . 
A dose re lated increase in foe ta l resorptions occurred in a l l treatment 
groups although the change was s t a t i s t i c a l l y s ign i f i can t only in the high 
dose group. The mid-dose was not c lear ly without e f f ec t . 
In a te ra togen ic i ty study in rats with o ra l dosing of 1.125, 3.558 and 
35.576 mg/kg/day the high dose group showed decreased maternal body weight 
and an increased number of smaller pups. An increased var ia t ion in 
oss i f i ca t i on occurred in a l l t reated groups. Skeletal malformation was 
increased in the high dose group. Sl ight hydrocephalus was seen in one pup 
of the mid-dose group and in 5 pups ( in 2 l i t t e r s ) of the high-dose group. 
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A second ora l rat te ra togen ic i ty study with 0.059, 1.125, 3.558 and 35.576 
mg/kg showed Lower maternal body weights, increased va r ia t ion of ske le ta l 
oss i f i ca t i on and increased incidence of skeleta l malformations (wavy r ibs) 
in the top-dose group only. The l a t t e r f ind ing was considered to be w i th in 
the l im i t s fo r h i s t o r i c a l cont ro ls . 
F e r t i l i t y and reproductive performance were examined in rats t reated o r a l l y 
with 1.125, 3.558 and 35.576 mg/kg/day p r io r to and during mating and during 
the gestat ion and lac ta t ion per iod. The high dose produced growth 
depression, increased i r r i t a b i l i t y , respiratory signs in the parents and 
decreased v i a b i l i t y and decreased body weight of pups at b i r t h . F e r t i l i t y 
and general reproductive performance were not a f fec ted . 
Per i - and postnatal e f fects were examined in rats doses o r a l l y with 1.125, 
3.558 and 35.576 mg/kg/day from day 15 of gestat ion through day 20 of 
l ac ta t i on . A s l i gh t decrease in f oe ta l v i a b i l i t y occurred in a l l dose 
groups and in postnatal surv iva l in the mid- and top-dose group. 
Dermal absorption was examined by applying 1.0 ml of a 10% aqueous so lu t ion 
of the 14C-labelled compound under occluded patches to the skin of two 
rabbi ts on 4 consecutive days. One rabbit had the skin abraded. Blood 
samples taken on each day, showed an average concentration of 0.2 ppm, which 
corresponds to 0.003% of the amount app l ied. No mention is made of analyses 
in u r ine , faeces or carcasses. 
Maternal and foe ta l absorption of the 14C-labelled compound was examined in 
pregnant rats t reated o ra l l y with 1.125 and 3.558 mg/kg/day on days 6 
through 15 of gestat ion. Average blood levels in the two groups were 1.5 
and 0.97 ng/g respect ive ly . In u r i ne , the maximum levels were 52 and 149 
ng/ml a f te r a single ora l dose. V i r t u a l l y a l l r ad ioac t i v i t y was recovered 
in the maternal faeces and carcass. Results of foe ta l analyses var ied 
between not-detectable and 6.8 ng/g foetus. 
An Ames test with up to 100 nmoles/plate was negative. Another Ames test 
with up to 7500 ja g Hyamine 1622/plate was l ikewise negative. 
The avai lable data indicated that the substance has s ign i f i can t tox ic 
propert ies including pharmacological a c t i v i t y , embryotoxic i ty , 
t e ra togen ic i t y , interference with reproductive performance and i n h i b i t i o n of 
ileum m o t i l i t y at lower than use leve ls . A clear no-ef fect level had not 
been demonstrated. The Committee notes that i n s u f f i c i e n t information had 
been provided on dermal absorpt ion, and on t'he mutagenic propert ies of the 
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substance. Because/ moreover, further studies are in progress and other 
studies are planned, the Committee decides to await the results before 
recommending any classification. 
Information : - Data sheet National Institute of Public Healt, 
the Netherlands 
- Colipa dossier, Submission I, April 1984 
- Colipa dossier. Submission II, September 1985 
- Cosmetic Ingredient Review (C.I.R.). Final report on the 
safety assessment of benzethonium chloride and methyl-
benzethonium chloride. J. Amer. College Toxicol. 4 (nr 5) 
65-106 (1985) 
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N° 54 Benzalkonium chloride (INN) 
—i + 
CH, 
CH- - N - R 2 I 
CH, CL 
C21H38N.CL 
MW : 339,99 
CAS N° 139-07-1 
Synonym : Alkyl(C0-C.,Q)-dimethyIbenzylammoniumchloride, -bromide and 
o lo 
-saccharinate 
Soluble in water and alcohols, poorly soluble in hydrocarbons, o i l s and 
f a t s . 
Used in cosmetics at levels of 0.5%. 
Oral LD50 values fo r rats and mice obtained for commercial products with 
d i f f e ren t a l ky l groups usually vary between 0.5 and 1.0 g/kg b.w. 
Intravenous LD™ values in mice of 12.8 - 26 mg/kg have been reported. 
Intranasal administrat ion of 0.06 ml of a 0.125% solut ion was le tha l for 
ra ts . 
Skin i r r i t a t i o n tests in rabbits with 0.1% so lu t ions , and in humans with 
1.0% solut ions were negative. With extended contact period in the rabb i t , 
or repeated appl icat ion in humans these concentrations produced d i s t i n c t 
i r r i t a t i o n . In rabb i t s , repeated appl icat ion of 0.3% induced only mild 
erythema. 
Eye i r r i t a t i o n in rabbi ts may occur upon a single appl icat ion of 0.01% 
solut ion and above and upon repeated appl icat ion of 0.004%. Concentrations 
of 0.01% and above caused eye i r r i t a t i o n in guinea pigs when applied 
repeatedly on the same day. Single treatment of human eyes with 0.1%, or 
da i l y treatment with 0.03 - 0.04% caused i r r i t a t i o n . 
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Soft contact Lenses d is in fec ted da i l y with 0.0025% benzalkoniumchloride + 
0.01% EDTA induced severe i r r i t a t i o n when brought in to contact with rabbi t 
eye for 6 hr/day. 
A sens i t i za t ion test in 100 male and 100 female volunteers with 0.1%, 
applied da i l y for 5 days, fol lowed by a challenge treatment with 1% a f te r 3 
weeks, was negative. In the l i t e r a t u r e only a few cases of sens i t i za t ion in 
humans have been reported. 
Short-term ora l administ rat ion to several animal species in the d ie t or the 
dr ink ing water containing concentrations of 0.02% or more induced tox ic 
e f f ec t s . 
Sub-chronic (13-wk) ora l studies in rats revealed t o x i c i t y and mor ta l i ty at 
dose levels of 25 mg/kg b.w. and above. With 25 mg/kg b.w., administered to 
dogs da i l y f o r 52 weeks, mor ta l i t y and gas t ro in tes t ina l damage was observed. 
In a 2 year rat study, 0.5% in the d ie t (250 mg/kg b.w.) caused mor ta l i t y 
and pathological changes in the gas t ro in tes t ina l t r a c t . Pathological 
changes were seen also in a 2-year study with a second commercial product at 
dose levels of 25 and 12.5 mg/kg, and in a 2-year study with a t h i r d product 
at a dose level of 30 mg/kg b.w. 
A dermal 90-day study was conducted in rats with a formulation containing 1% 
stearyldimethylbenzylammoniumchloride and 0.2% benzalkoniumchloride 50%. 
Once d a i l y , 5 days/week for 13 weeks the rats received top i ca l l y 2.4 ml/kg 
(2.4 mg benzalkoniumchloride/kg). I t is stated that no s ign i f i can t local or 
systemic e f fec ts occurred. However, the report is confusing and incomplete. 
Dermal l i f e - t i m e studies in mice and rabb i t s , t reated top ica l l y with 0.02 ml 
of 8.5 or 17.0% solut ions twice weekly showed local skin damage in both 
species, but no skin tumours. 
In an ora l te ra togen ic i t y study, groups of 15 pregnant rabbits were t reated 
by gavage with 0 , 10, 30 or 100 mg/kg/day from day 7 through day 19 of 
gesta t ion . A l l rabbi ts of the high dose group d ied. The intermediate dose 
caused maternal and embryotoxic i ty. Signs of maternal t o x i c i t y occurred 
also in the low-dose group. There were no indicat ions of teratogenic 
proper t ies . 
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A dermal teratogenicity study was conducted in rats treated topically with 
0.5 ml aqueous solutions of 1.6, 3.3 and 6.6%, (estimated to be about 30, 60 
and 120 mg/kg) once daily from day 6 to day 15 of pregnancy. No 
embryopathic effects were observed. 
Skin penetration tests in vitro with pieces of human skin were conducted in 
aqueous solutions of 0.005M to 0.1M benzalkoniumchloride. No penetration 
into the dermis was detected when the solution was unbuffered or acid. 
Measurable penetration occurred when the epidermal barrier was damaged or 
with intact skin in solutions of pH 11. 
No penetration was found in vitro with skin from hairless rats exposed to 
2.5% C-dimethylbenzylammoniumchloride for 4.5 hours. 
In a similar in vitro test with human epidermis the mean penetration was 
1.47% of the dose applied. 
The distribution of the compound was studied after oral, rectal and 
intramuscular administration of the 10-fold lethal dose to rabbits, dogs and 
cats. Most of the dose remained at the application site. After oral and 
rectal administration, small amounts were detected in blood and liver. Upon 
rectal administration a small amount was found also in the kidneys. 
A mutagenicity test with S. typhimurium His G 46-uvr B exposed to 
10-100 /jg/plate was negative. 
A micronucleus test in mice treated i.p. with 20 mg/kg b.w., twice, with an 
interval of 24 hours did not reveal increased numbers of micronuclei. 
The substance was found to induce repairable DNA damage in the E. coli DNA 
polymerase A assay, but no mutagenic properties were observed. No forward 
muations were induced in Schizosaccharomyces pombe P,. with or without 
metabolic activation. A chromosome aberration test with CHO-cells in vitro 
was negative. 
Benzalkoniumchloride possesses considerable irritative properties for the 
eye and the gastrointestinal tract, and was highly toxic under certain 
conditions of acute exposure. The oral no-toxic effect level in rats was 
less than 12.5 mg/kg/day, while mortality occurred in dogs and rats with 25 
mg/kg. The use of this preservative in all kinds of cosmetics could lead to 
a human exposure of c. 1 mg/kg b.w./day. Even if the use level is reduced 
from 0.5 to 0.25% the Committee is unwilling to make any evaluaton until a 
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no-effect level for systemic toxicity has been established, and more 
information is available on dermal absorption. In addition information 
should be made available on other uses than as a preservative. 
Information : - Data sheet National Institute of Public Health, 
the Netherlands 
- Colipa dossier. - Partial submission (I), September 1983 
- Submission II, September 1985 
- Submission III, October 1985 
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N° 55 Alkyl(Cl2-C22) trimethylammonium bromide and chloride 
(including Cetrimonium bromide) (INN) 
CH, 
I 3 
R - N - CH, 
CH, 
Br 
R = alkyl 
C19H42NBr 
MW 364.48 
CAS N° 57-09-0 
Soluble in water and alcohols, insoluble in ether. 
Used in cosmetics up to 0.1%. 
LD5_ values reported (in mg/kg b.w.) are : oral for rats 1000; 
intraperitoneal for rats 56, for mice 39.8, for rabbits 125; subcutaneous 
for mice 75-80. 
Single intravenous administration of 4 mg/kg to dogs caused a fall in blood 
pressure, while 12 mg/kg i.v. in monkeys produced traces of haemoglobin in 
urine without severe effects. 
A primary skin irritation study in rabbits with a 1% solution did not 
produce any changes. With 5% there were mild effects (erythema, oedema, 
scab formation) lasting less than 48 h, with 25% there was mild to moderate 
erythema and oedema, while with 50% these changes were moderate to severe. 
Dermal application of 1% to humans produced reactions in 2.8% of the treated 
subjects. 
14 Cases of hypersensitivity to this substance have been reported when used 
in treatment of burns. In another study, skin sensitivity was confirmed by 
patch testing in 46 patients. 
Eye irritation occurred in the rabbit eye with concentrations of 0.1% and 
above. With 0.1% the changes disappeared in 24 hr. 
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In a sub-acute ora l study / groups of 6 mice fed a d ie t containing 0.1% or 
more showed growth depression; with 0.2% they died in 35-63 days, white with 
0.4% the surv iva l period was only 9-12 days. Mice fed 0.5% in the d ie t died 
between 3-12 days showing destruct ion of mucosal e p i t h e l i a l ce l l s and 
haemorrhages in the i n t e s t i n a l t r a c t ; with 0.05% marked hypertrophy and 
hyperplasia of the duodenal and je juna l mucosa occurred a f te r 3 months, but 
with 0.02% no changes were found a f te r 6 months. 
In a one-year o ra l study, rats received 0, 10, 20 or 45 mg/kg b.w. in the 
dr ink ing water. The top-dose group showed reduced weight gain and food 
conversion, we t t i ng , and brown d isco lourat ion of the fur over the anter ior 
vent ra l region and increased caecal weight. Caecal enlargement also 
occurred with 20 mg/kg. No changes were seen with 10 mg/kg. 
A te ra togen ic i t y study in mice, t reated once in t raper i tonea l l y with 10.5 or 
35.0 mg/kg b.w. on day 8, 10, 12 or 14 of ges ta t ion , revealed an increased 
incidence of c l e f t pa la te , and ske le ta l defects in sku l l and sternum in both 
treatment groups, and embryolethal i ty in the high-dose group. 
14 The percutaneous absorption of the C-labeled substance in the rat was 
3.15% from a 3% aqueous so lut ion which was not r insed, 0.093% from a 0.5% 
concentration in a hair r inse formulat ion (r insed a f te r 5 min.) and 0.59% 
from a 1% aqueous so lu t ion (r insed a f te r 15 min . ) . 
14 Upon o ra l administ rat ion of the C-labeled compound to r a t s , 80% of the 
dose was s t i l l present in the gas t ro in tes t ina l t rac t a f te r 8 hours, and 20% 
was excreted in the b i l e during the f i r s t 12 hours. These resul ts indicate 
poor i n t e s t i n a l absorpt ion. Only small amounts were found in the organs, 
which disappeared largely w i th in 4 days. Excretion of rad ioac t i v i t y in the 
faeces and ur ine amounted to 92% and 1% respect ively w i th in 3 days. 
Examination of b i l e and urine by TLC indicated that some metabolism occurs 
in the r a t . No rad ioac t i v i t y was found in expired C0?. 
I t was observed that t h i s substance may be teratogenic under ordinary 
condit ions of use. 
The Committee recommended that information be requested as fol lows : 
1 . A no e f fec t level fo r te ra togen ic i t y on ora l and dermal admin is t ra t ion . 
2. Genotoxicity information by a gene mutation test and a chromosomal 
aberrat ion test on mammalian ce l l s in v i t r o . 
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No opinion can be expressed. 
Information : - Data sheet National Institute of Public Health, 
the Netherlands, September 1978 
- Colipa dossier, Submission I, April 1984 
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N° 56 1-Phenoxypropan-2-oL 
O - CH2 - CH2 - OH 
C 9H 1 20 2 CAS N° 770-35-4 
MW : 153.11 
Synonyms : - PhenoxypropanoL 
- Propylenephenoxyethol 
Soluble in water (1%), miscible with alcohol, ether and chloroform. 
Used up to 1.0% in cosmetics. 
Oral LD,-n values in rats are 2720 and 2544 mg/kg. 
A skin irritation test in rabbits with the undiluted substance produced only 
minimal irritation. 
In an eye irritation test in rabbits the undiluted substance elicited 
moderate to marked reactions of cornea, conjunctivae and iris. With 5% and 
2% aqueous dilutions there were no eye reactions attributable to the 
substance. 
A maximization test in guinea pigs with 0.5% in water for induction and 75% 
aqueous preparation for the challenge did not produce evidence of 
sensitization. 
In a 2-wk oral test in rats with 0, 200, 500 or 1250 mg/kg/day by gavage, 
the top-dose was lethal. The two lower dose levels induced clinical signs 
and gross pathological changes. 
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In a 4-wk oral study in rats with 0, 40, 120 and 400 mg/kg/day, the top-dose 
group showed clinical signs including sedation and abnormal gait, but no 
pathological changes. No abnormalities were seen with 120 mg/kg. 
A 2-wk oral test in rabbits with 0, 100 and 500 mg/kg/day showed paralysis 
and death in the top-dose group. No effects were noted with 100 mg/kg. 
In a 4-wk oral test in rabbits with 0, 50, 100 and 200 mg/kg/day, the top-
dose induced a general decline of condition, and increased liver weights. 
With 100 mg/kg growth rate and food intake were reduced. No changes 
occurred with 50 mg/kg. 
Dermal exposure of rabbits to 0, 20, 50 or 1000 mg/kg/day for 90 consecutive 
days induced transient signs of toxicity only in the top-dose group 
(peripheral hypothermia, paralysis). Gross and microscopic examination were 
negative. (In this study the stratum corneum was removed at the site of 
treatment to enhance penetration). 
In teratogenicity studies, rats and rabbits were treated orally during 
pregnancy with dose levels of 0, 80, 160 or 320 mg/kg/day for rats and 0, 
25, 50 or 100 mg/kg/day for rabbits. In neither of these two studies were 
there adverse effects on foetal development. 
A dermal dose of 2 ml of a 2% solution of the radioactively labelled 
compound, caused a maximum blood level in rabbits of 4-5 /ug/ml. An average 
of 54% of the applied radioactivity was excreted in the urine and an 
additional 23% was excreted in the faeces. Two radioactive compounds (a 
glucuronic acid conjugate and the aglycone) were identified in the urine, 
and an additional metabolite was extracted from the faeces. 
In view of the relatively low no-effect level, the relatively high use level 
and the considerable dermal absorption, the Committee cannot recommend the 
use of this substance at the proposed concentrations, even if its use is 
restricted to rinsed off products. The Committee is willing to reconsider 
its opinion, if further data become available. 
Information : - Colipa submission I, February 14, 1980 
- Colipa submission II, September 1985 
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N° 57 1-Hydroxy-4-methyl-6(2,4,4-trimethyLpentyL) 2-pyn'don and its 
monoethanolamine salt 
(¡H3 
CH3-C-CH2-CH2-CH2 
CH, 
C16H30N2°3 
MW 298.4 
CAS Nc 
Synonyms : - Octopyrox 
- Pyroctone olamine 
Poor ly s o l u b l e i n wa te r , w e l l so lub le i n e t h a n o l . 
Used up t o 0.5% i n cosmet ics , but up to 1.0% i n r i nsed o f f p roduc ts . 
Ora l LD,-n va lues are 8100 mg/kg i n r a t s , > 1000 mg/kg i n mice , and 
> 4000 mg/kg i n dogs. 
Dermal LD_n va lues i n r a t s are > . 2000 mg/kg, and .>.750 mg/kg. 
I n s k i n i r r i t a t i o n t e s t s w i t h two s t r a i n s of r a b b i t s 1% i n aqueous PEG (75%) 
was found t o be s l i g h t l y i r r i t a t i n g . A 1% s o l u t i o n i n 1,2-propylene g l y c o l 
was l i kew i se s l i g h t l y i r r i t a t i n g i n two s t r a i n s of r a b b i t s . A f o r m u l a t i o n 
w i t h the t e s t substance was not more i r r i t a t i n g than the same f o r m u l a t i o n 
w i t hou t the t e s t substance. 
Eye i r r i t a t i o n t e s t s w i t h a f o r m u l a t i o n w i t h and w i thou t octopyrox showed a 
s i m i l a r degree of i r r i t a t i o n . With 50% aqueous isopropano l the degree of 
eye i r r i t a t i o n was t he same as w i t h 0.2% octopyrox i n 50% aqueous 
i s o p r o p a n o l . A shampoo w i t h 0.5% octopyrox was not more i r r i t a t i n g than the 
same shampoo w i thou t oc topy rox . 
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In a sensitization test in guinea pigs by the Buehler method, 9 epicutaneous 
applications of a 40% aqueous concentration in 3 weeks, followed after 14 
days by a challenge of the same concentration with a closed patch, did not 
induce signs of sensitization. 
A maximization test in guinea pigs fusing as induction treatment 0.05% in 
propyleneglycol (PG) for injection, and 5% in PG on a patch, and as 
challenge treatment (after 2 weeks rest) 0.4 ml, 0.05 and 0.1% in PG on a 
patch during 48 hours], did not result in signs of sensitization. 
In a photosensitization test, guinea pigs were treated topically 10 times in 
2 weeks with 0.05 ml 5.0% in PG followed by irradiation for 2 hours. After 
2 weeks rest, 0.2 ml of 0.03% up to 1.0% were applied topically. No dermal 
changes occurred either at the irradiated sites or at the non-irradiated 
sites. 
In a repeated insult patch test with 50 humans, 0.5% in a vehicle containing 
20% disodium laurylalcohol polyglycol ether sulfosuccinate did not induce 
skin irritation, skin fatigue or sensitization. 
In a use test in more than 300 volunteers, 0.2 to 1.0% in shampoos applied 
seven times in 4 weeks provided no evidence of adverse reactions. 
A phototoxicity test in humans treated topically with a 0.1% aqueous 
solution in isopropanol was negative both with UV-A and UV-B. 
Short-term (30-day) oral treatment of rats with 0, 4, 15, 55, 210 or 800 
mg/kg b.w./day in the diet induced growth retardation with 210 and 800 mg, 
mortality (2/20 rats), and signs of anaemia with 800 mg. No changes were 
detected at lower levels. 
A 90-day oral rat study with 0, 40, 100 and 250 mg/kg b.w. by stomach 
intubation on 5 days/week showed growth depression and decreased haemoglobin 
levels in the top-dose group. Clinical chemistry, urine composition and 
microscopy of c. 20 organs examined did not reveal treatment-related 
changes. 
Short-term (30-day) diet administration to dogs of 0, 16, 40 or 100 mg/kg 
b.w./day did not induce any adverse effects. 
The feeding of the same dietary levels to dogs for 90 days likewise failed 
to induce any abnormalities. 
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Dermal treatment of rabbits with 0.5 mg/day in shampoo, or with 0.1 mg/day 
in hair Lotion 30 times in 36 days or 30 times in 64 days respectively did 
not induce any dermal or systemic effect. 
A 5-week subcutaneous injection study was conducted in rats with 0, 100, 500 
or 2000 mg/kg b.w./day in 0.5% aqueous carboxymethyIcellulose. The two 
higher dose levels caused haematological and clinical chemical changes and 
inflammation at the injection site. The no-toxic effect level was 100 mg/kg 
(Summary only). 
In a 6 months dermal study, rats were treated topically with 0, 1 or 2 
mg/rat/day administered in 0.2 ml, 0.05 and 1.0% in PG 6 times weekly [for 4 
weeks ij. The only change was thickening of the epidermis which was 
attributed to the vehicle. 
A similar study was conducted [with 4 weeks treatment ij for one year. The 
treated skin sites showed thickening and necrosis. 
(The English version of the reports on the latter two Japanese dermal 
studies do not contain a description of the study design). 
An Ames test with up to 500 /jg/plate was negative. Another Ames test with 
up to 200 jug/plate (which also included a test with E.coli) was likewise 
negative. A micronucleus test in mice treated orally with 125, 250 or 500 
mg/kg, and a second micronucleus test in mice with up to 125 mg/kg (given 
intraperitoneally once, or once daily for 4 days) were negative. 
No increase in chromosomal aberrations was seen in bone narrow-cells of 
Chinese hamsters upon single oral treatment with 3.5 g/kg b.w. 
14 Subcutaneous administration of the 6- C-labelled compound to rat« 
level of 35 mg/kg b.w. did not reveal any measurable DNA binding. 
No indications of teratogenic properties were obtained in a study in rabbits 
treated with 0, 16, 32 or 63 mg/kg b.w./day by stomach intubation from day 
7 - 19 of gestation. 
In a rat teratogenicity study, with subcutaneous injection of 100, 500 or 
2000 mg/kg b.w./day on days 7 through 17 of gestation, growth depression 
occurred in the top-dose group. No treatment-related increase in foetal 
abnormalities (external, visceral or skeletal) was observed. 
In another rat teratogenicity study 2000 mg/kg was administered 
subcutaneously on days 6 through 20, 7 through 17, or 9 through 17. The 
type and incidence of foetal abnormalities were not affected by treatment. 
No evidence of teratogenic potential was observed in a hen's egg test by 
single injection of 0.93 mg/egg. 
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The kinetics were studies in dogs and rats. Dogs received a single oral 
dose of 50 or 100 mg/kg b.w. Maximum blood levels were respectively 22.9 
and 33.0 /jg/ml. The elimination occurred with a half-life of 2.7 hours. 
Upon single oral treatment of rats with the compound as the monoethanolamine 
salt (100 mg/kg), the sodium salt (87.2 mg/kg) or the free acid (79.9 mg/kg) 
no noticeable differences in serum levels were observed. Maximum levels 
were 12.3 ;ug/ml, which were reached after 1.2 hours. The elimination 
occurred in 2 phases with half lives of 0.5 hour and 4.5 hours. 
Dermal absorption was examined in rats treated topically with 2 mg of the 
14 2 
C-labelled compound on 4 cm , and rubbed in for one minute. Then the 
treated site was cleaned with wet cotton wool pads, which removed 43.1% of 
the dose applied. During the next 7 days 1.4% of the dose was excreted in 
the urine and 3.1% in the faeces. 
After oral administration of 0.24 mg/kg, maximum blood levels were between 
0.006 and 0.014 ^ig/ml between 3 and 8 hours after treatment. 
Skin penetration in rats of 1% in a shampoo, applied without rinsing, was 
2 2 
65.1 jug/cm under occlusion, and 38.2 jug/cm without occlusion. When rinsed 
after 109 minutes of contact, penetration was reduced to 3.4/jg/cm under 
2 occlusion and 2.0/jg/cm without occlusion. 
Skin penetration increased with increasing concentration and also with 
increasing duration of contact up to 10 minutes. 
Topical application under occlusion without rinsing resulted in tissue 
levels similar to those after oral intubation. 
This compound has been well examined, and showed only moderate toxicity. 
From adequate short-term (90-day) studies in rats and dogs, 100 mg/kg b.w. 
was found to be a no-toxic effect Level. No indications of mutagenic or 
teratogenic properties were obtained in appropriate tests. Dermal 
absorption is not considerable ( -<.10%). A dermal dose is rapidly 
eliminated, partly with the urine and partly with the faeces. 
The use of this substance as preservative in cosmetic products can be 
permitted. 
Information : - Colipa dossier, Submission I, December 1979 
Submission II, January 1985 
- Data Sheet National Institute of Public Health, 
the Netherlands, October 1980 
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N° 58 3-Heptyl-2-(3-heptyl-4-methyl-4-thiozolin-2-ylidenemethyl)-4-
methyLthiazoLinium iodide 
CH 
C23 H39 N2 S2 I 
m 534.61 
CAS Nc 
Synonym : Kankohso 201 
Poor ly s o l u b l e i n water and e t h a n o l . Replacing the i od i ne i on of Kankohso 
201 by an o r o t a t e i on (Kankohso 201-OA) improves the s o l u b i l i t y i n water 
w i t h a f a c t o r 1 0 , and i n e thano l w i t h a f a c t o r 28 . 
Used at Levels up t o 0.002%. 
In m ice , t he o r a l LD_n of the i od ide was 1.1 g/kg i n males and 1.7 g/kg i n 
f ema les ; t he i n t rade rma l LD_Q of t he i od ide was > 40 mg/kg. An 
i n t r a p e r i t o n e a l L D ^ of 110 mg/kg f o r mice was ob ta ined w i t h the o r o t a t e . 
A s k i n i r r i t a t i o n t e s t i n r a b b i t s w i t h 0.3 ml of a 0.3% s o l u t i o n of the 
i od ide i n po l ye thy lene g l y c o l a p p l i e d t o i n t a c t and abraded sk i n r esu l t ed i n 
s l i g h t oedema i n 1 out of 4 animals t r e a t e d on the abraded s k i n , and i n none 
out of 4 t r e a t e d on t he i n t a c t s k i n . 
Closed patch t e s t s i n 10 humans w i t h 20 - 200 ¿ig of the iod ide i n 0.1 g of a 
hyd rophy l i c o i n t m e n t , or w i t h 0.05 ml of 0.03% i n po lye thy lene g l y c o l , were 
n e g a t i v e . 
An eye i r r i t a t i o n t e s t i n r a b b i t s w i t h 0.00075% of the iod ide i n s a l i n e was 
n e g a t i v e . With 0.1 ml of a 0.02% or a 0.05% d i l u t i o n of the o r o t a t e 
( d i l u e n t not mentioned) in t he r a b b i t eye , no i r r i t a t i o n was produced w i t h 
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0.02% while with 0.05% minimal changes were observed. The undi luted iodide 
der ivat ive produced considerable changes, but with 0.3% in polyethylene 
g lycol only s l i gh t signs of i r r i t a t i o n were observed. 
In a maximization tes t in guinea pigs t reated top i ca l l y and by intradermal 
i n j ec t i on with a 1% solut ion in the induct ion per iod , the challenge 
treatment with 0.3% produced a s l i g h t response in 1 out of 10 animals, 
whereas none of the animals showed a response with lower concentrations. 
(The document concerned, does not mention the compound or the sa l t with 
which th is test was conducted). 
Several photo tox ic i ty tests were conducted with the iod ide. In a rabbit 
tes t 0.02 ml of 0.3% in polyethylene g lyco l or 0.3% in ethanol was negative. 
Negative resul ts were obtained also in a photo tox ic i ty test in 10 humans 
treated with 0.1 g ointment containing 20 or 200 / jg . A photopatch test in 
18 humans treated with 20 or 100 jug in water-soluble ointment was also 
negative. 
In a 90-day dermal study in rabbi ts da i l y appl icat ion of 0.5 ml , of a 0.05% 
solut ion of the orotate in a glycer ine/alcohol /water mixture to the ear skin 
d id not induce any changes other than a yellow d iscolourat ion and 
keratolyses of the appl icat ion s i t e (summary report on l y ) . In another 
dermal rabbit study (only 2 rabbi ts per group) 0.5 ml of a 0.01% or a 0.1% 
solut ion of the iodide in glycer in-ethanol-water mix applied da i ly to the 
ear, 6 days a week, fo r 13 or 26 weeks, no changes in growth ra te , 
haematology, biochemistry, or histopathology were observed. Only very 
s l i gh t changes occurred at the appl icat ion s i t e (e .g . thickening and 
desquamation of horny layer ) . Only a summary report is ava i lab le . 
In a 15 wk ora l study (with only 5 ra ts /group) , administrat ion of the iodide 
by gavage of 4 or 40 mg/kg b.w./day, 6 days a week, induced growth 
depression and decreased weight and pathological changes of the l i ve r and 
spleen. The l i ve r was the organ most markedly a f fec ted . (The report shows 
many def ic ienc ies in the conduct of the study) . 
An Ames test with the iodide at a maximum level of only 10 /ug/plate was 
negative. 
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It was noted that Kankohso 201 is the iodide. 
A short-term oral study in rats is requested with the iodide to establish 
the highest dose that does not induce growth depression or Liver damage. 
Depending on the results, information on dermal absorption, teratogenicity 
and further mutagenicity tests may be desirable. 
No opinion can be expressed. 
Information : Colipa dossier, Submission I, March 1984 
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N° 59 1,2-Dibromo-2,4-dicyanobutane 
H Br H H 
l i l i 
Br — C — C — C — C — H 
l i l i 
H CN H CN 
MW : 265.9 
Synonym : Tektamer 38 
Soluble in water 0.27% at 0 °C; eas i ly soluble in organic solvents. 
Used in cosmetics up to 0.1%. 
Oral LD,-n values in rats were 720 mg/kg, and 541 mg/kg. The dermal LD,-n in 
rabbits was > 5000 mg/kg. The LC,-n in rats (exposed to the powder for one 
hour) was > 200 mg/liter air. 
A skin irritation test in rabbits with 0.5 g of undiluted powder produced 
erythema and oedema. The substance was classified as a moderate irritant. 
A 0.3% aqueous solution was not irritaing to the rabbit skin. A 0.3% 
dilution in oil was neither irritating nor sensitizing when applied to the 
skin of humans. 
The undiluted substance was found to be a severe irritant to the eye of 
rabbits, but when applied as a 0.1% aqueous solution no irritation was 
noticed. 
In a 90-day study in rats with 0, 83.5, 500 or 3000 ppm in the diet (given 
to the offspring of rats which had already been fed these diets through the 
periods of mating, pregnancy and lactation) an increased weight of the 
thyroid was observed in the top-dose group and growth rate was decreased in 
males fed 500 or 3000 ppm. Increased haematopoiesis was observed 
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microscopical Ly in the spleen of the top-dose females. No diseased or 
malformed pups were seen in the l i t t e r s of the parent r a t s , which suggests 
absence of teratogenic proper t ies . 
In a 90-day study in dogs with feeding levels of 0, 167, 1000 or 4000 ppm, 
the top-dose group showed growth re ta rda t ion , d iarrhoea, changes in 
haematology and blood biochemistry, enlarged thyroids (hyperplasia) and 
increased haematopoiesis in the l i v e r and spleen. 
The lowest feeding level (4.2 mg/kg b.w./day) was a no-effect level in the 
rat and possibly also in the dog. 
A second 90-day dog study with feeding levels of 0 and 167 ppm, and designed 
to examine thyro id f unc t i on , showed increased thyro id weights in t reated 
females. These changes were not accompanied, however, by changes in T, or 
T, values or in the microscopy of the t h y r o i d . 
An o ra l dose (50 mg/kg) given to r a t s , was mainly excreted in the urine 
(84 - 91%). A small part (6 - 10%) was excreted in the faeces, and a very 
small part (0.5%) in the resp i ra t ion a i r . Seven days a f te r a single 
i n t ragas t r i c dose 0.4% remained in the organs, 0.3% of the dose was in the 
l i v e r . 
The Ames test (wi th and without ac t i va t ion) and a dominant le tha l assay in 
male mice were negative. 
Although there is adequate information fo r accepting the use of the 
substance in cosmetics in general , information on dermal absorption and 
pharmacokinetics is needed to j u s t i f y i t s use in sunscreening agents. 
The use of t h i s substance as preservat ive in cosmetic products can be 
permi t ted, except for sunscreening agents. 
Information : Colipa dossier , March 4 , 1981 
Submission I I , Sept. 1984 
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N° 60 4,4-Dimethyl-1,3-oxazol.idine 
See report EUR 8634. 
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PART 2 
LIST OF PRESERVATIVES PROVISIONALLY ALLOWED 
Reference 
□umber 
a 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Substance 
b 
2,6-Dimethyl-1,3-dioxan-4-yl 
acetate (Dimethoxane) 
Boric acid (*) 
Chlorphenesin (INN) (*) 
3-Acetyl-6-methyIpyran-2,4(3H)-
dione (Dehydroacetic acid) and its salts 
Fonnic acid (*) 
4-Hydroxybenzoic acid benzyl ester 
Hexamidine (INN) and its salts 
(including isethionate (INN) and 4-
hydroxybenzoate) (*) 
3,3' Dibromo-4,4'-hexamethylene-
dioxydibenzamidine (Dibromohexa-
midine) and its salts (including 
isethionate) 
Dibromopropamidine (INN) and its 
salts (including isethionate (INN) 
Maximum authorized concentration 
c 
0 - 2 % 
(a) 0 - 5 % 
(b) 3 % 
0 - 5 % 
0 - 6 % (acid) 
0 - 5 % (acid) 
0-1 % (acid) 
0-1 % 
0-1 % 
0 - 1 % 
Limitations and requirements 
d 
(a) Products for oral hygiene 
(b) Other products 
Conditions of use and warnings 
which must be printed on the label 
e 
z 
o 
ON 
N> 
Q. 
O 
c 
m 
c 
3 
T3 n a 
3 
■n 
o 3 3 
c 
3 
5; 
O l 
ON 
co 
Reference 
number 
a 
10 
11 
12 
13 
14 
15 
16 
17 
18 
Substance 
b 
Thiomersal (INN) 
Phenylmercuric salts (including 
borate) 
Esters of sorbic acid 
(Hexa-2,4-dienoic acid) (*) 
Undec-10-enoic acids: salts, esters, 
the amide, the mono- and 
bis(2-hydroxethyl) amides and their 
sulphosuccinates (*) 
2,6-Diacetyl-l ,2,3,9b-tetrahydro-
7,9-dihydroxy-8,9b-dimethyldiben-
zolfuran-l,3-dione (usnic acid) and 
its salts (including the copper salt (*) 
Hexatidine (INN) (*) 
Benzylformal (a 1:1 mixture of 
benzyloxymethanol and (benzyloxy-
methoxy) methanol) 
Clorofene (INN) 
5-Bromo-5-nitro-l,3 dioxane (*) 
Maximum authorized concentration 
c 
0 - 0 0 7 % (of Hg) 
If mixed with other mercurial 
compounds authorized by this 
Directive, the maximum 
concentration of Hg remains fixed at 
0 - 0 0 7 % 
Ditto 
0 - 6 % (acid) 
If mixed with sorbic acid and/or its 
salts, the maximum total 
concentration of the acids, salts and 
esters remains fixed at 0-6 % (acid) 
0 - 2 % (acid) 
0 - 2 % 
0 - 2 % 
0 - 2 % 
0 - 2 % 
0-1 % 
Limitations and requirements 
d 
For eye make-up and eye make-up 
remover only 
Ditto 
Only for. products rinsed off after 
use 
Conditions of use and warnings 
which must be printed on the label 
e 
Contains thiomersal 
Contains phenylmercuric 
compounds 
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Reference 
number 
a 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
Substance 
b 
Bronopol (INN) (») 
6,6-Dibromo-4,4-dichloro-2,2'-me-
thylene-diphenol (Bromochlorophen). 
C) 
Tetrabromo-ó-cresol (*) 
2-Chloroacetamide 
3,4-Dichlorobenzyl alcohol (*) 
2,4-DichIorobenzyl alcohol (*) 
Triclocarban (INN) (*) 
4-Chloro-a-cresol (*) 
Halocarban (INN) (*) 
Triclosan (INN) (») 
Dichlorophen (INN) 
N-(Trichloromethylthio)cydohex-4-
ene-1,2-dicarboximide (Captan — 
(ISO)) (•) 
Maximum authorized concentration 
c 
0-1 % 
0 - 1 % 
0 - 3 % 
0 - 3 % 
0-15% 
0-15% 
0 - 2 % 
0 - 2 % 
0 - 3 % 
0 - 3 % 
0 - 2 % 
0 - 5 % 
Limitations and requirements 
d 
Maximum concentration in 
aerosols: 0 • 2 % 
Conditions of use and warnings 
which must be printed on the label 
e 
Contains chloroacetamide 
Contains dichlorophen 
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Reference 
number 
a 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
Substance 
b 
Chlorhexidine (INN) and its 
digluconate, diacetate and 
dihydrochloride (*) 
4-Chloro-3,5-xylenol (*) 
2,4-Dichloro-3,5-xylenol (*) 
Quinolin-8-ol and its salts (*) 
1,3,5-Tris (2-hydroxyethyl)hexa-
hydro-l,3,5-triasine 
3,3'-Bis (l-hydroxymethyl-2.5-di-
oxoimidazolidin-4-yl)-l ,1 ' -methyl-
enediurea ("Imidazolidinyl urea") (*) 
4-Isopropyl-m-cresol 
2-Chloro-N-(hydroxymethyl) 
acetamide 
l-Hydroxymethyl-5,5-dimethyl-
hydantoin (*) 
Pyrithione sodium (INM) (*) 
Maximum authorized concentration 
c 
0 - 3 % 
0 - 5 % 
0-1 % 
0 - 3 % 
0 - 3 % 
0 - 6 % 
0-1 % 
0-3 % for the chloracetamide 
0 • 2 % expressed as free 
formaldehyde or theoretically 
available formaldehyde 
0 - 5 % 
Limitations and requirements 
d 
Not to be used in products applied 
after sunbathing, or in talcum 
powders for children under three 
years of age 
For products rinsed off after use 
For products rinsed off after use 
Conditions of use and warnings 
which must be printed on the label 
e 
Not to be used for children under 
three years of age 
Contains 1,3,5-Tris (2-hydroxyethyl) 
hexahydro-1,3,5-triazine 
Contains formaldehyde (') 
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(') Only if the concentration is greater than 0-05 %. 
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Reference 
number 
a 
41 
42 
43 
44 
45 
46 
47 
48 
Substance 
b 
2,2'-Dithiobis(pyridine 1-oxide), 
addition product with magnesium 
sulphate trihydrate (*) 
Poly(l-hexamethylenebigu anide 
hydrochloride) (*) 
2-Phenoxyethanol (*) 
Hexamethylenetetramine (*) 
(methenamine) (INN) 
Mixture of 
5-Chloro-2-methyl-isothiasol-
3(2H)one and 2-methylisothiazol-
3(2H)-one with magnesium chloride 
and magnesium nitrate 
Pyridin-2-ol 1-oxide (*) 
Pyrithione aluminium camsilate 
(INNM) 
Methanamine 3-chloroallyIochloride 
(INNM) 
Maximum authorized concentration 
c 
0 - 5 % 
0 - 3 % 
1 % 
0 - 2 % 
expressed as free formaldehyde or 
theoretically available formaldehyde 
0-005 % (of a mixture in the ratio 
3:1 of 5-chloro-2-methylisothiazol 
3(2H)one and 2-methylisothiazol-3 
(2H)-one 
0 - 5 % 
0 - 2 % 
0 - 2 % 
Limitations and requirements 
d 
Only for products rinsed off after 
use 
Conditions of use and warnings 
which must be printed on the Label 
e 
Contains formaldehyde (') 
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(') Only if the concentration is greater than 0 05 ' 
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Reference 
number 
a 
49 
50 
51 
52 
53 
54 
55 
56 
Substance 
b 
l-(4-Chlorophenoxy)-l-(imidazol-l-
yl)-3,3-dirnethylbutan-2-one (*) 
l,3-Bis(hydroxymethyl)-5,5-dime-
thylimidazolidine-2,4-dione (*) 
Benzyl alcohol (*) 
1-Dodecylguanidinium acetate 
(Dodine — ISO) (*) 
Benzethonium chloride (INN) (*) 
Benzalkonium chloride (INN), 
l-2-Benzisothiazol-3-(2H)-one 1,1 
dioxide) (*), its bromide and 
saccharinate 
Alkyl (C12-C22) trimethylammo-
nium bromide and chloride 
(including Cetrimonium bromide 
(INN) H 
1 -Phenoxypropan-2-ol 
Maximum authorized concentration 
c 
0 - 5 % 
0 - 2 % 
expressed as free formaldehyde or 
theoretically available formaldehyde 
1 % 
0 - 5 % 
0 - 1 % 
0-1 % 
0-5% 
0-1 % 
1 % 
Limitations and requirements 
d 
For products rinsed off after use 
For other uses 
Conditions of use and warnings 
which must be printed on the label 
e 
Contains formaldehyde (' ) 
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(l) Only if the concentration is greater than 005 %. 
z 
o 
os 
Reference 
number 
a 
57 
58 
Substance 
b 
l-hydroxy-4-methyl-6(2,4,4-
trimethylpentyl) 2-pyridon and its 
monoethanolamine salt 
3-HeptyI-2-(3-heptyl-4-methyl-4 
thiozolin-2-ylidenemethyl)-4-methyl-
thiazolinium iodide 
Maximum authorized concentration 
c 
1-0% 
0 - 5 % 
0 - 0 0 2 % 
Limitations and requirements 
d 
For products rinsed off after use 
For other uses 
Creams, toilet lotions, shampoos' 
Conditions of use and warnings 
which must be printed on the label 
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